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Abstract 
 
 
Nature has evolved proteins that can spontaneously self-assemble to create 
complex structures such as virus particles and molecular motors. The fields of 
bionanoscience and synthetic biology are based on the concept that by combining 
biological building blocks with synthetic molecules it will be possible to construct 
novel nanoarchitectures and machines that can do useful work. This thesis 
describes strategies that have been developed using protein-ligand interactions to 
construct nanoscale assemblies.  
 
The B-subunit of cholera toxin (CTB) has been site-specifically modified at the 
N-teminus, by oxime ligation, with carbohydrate ligands and the assembly of these 
modified proteins was observed. A W88E non-binding mutant of CTB was made 
and modified with GM1os ligands. The interaction of this pentavalent protein-based 
ligand with wild-type CTB has been investigated and showed the formation of a 
protein heterodimer. 
 
The CTA2-subunit of the cholera toxin AB5 complex was also modified at the 
N-terminus enzymatically with depsipeptides via sortase ligation and by oxime 
ligation. Biotin ligands have been covalently attached and the formation of a 2:1 
complex with streptavidin was observed. 
 
The structures and assemblies demonstrated herein have been analysed and 
characterised by a range of analytical and biophysical techniques including dynamic 
light scattering, analytical ultracentrifugation and isothermal titration calorimetry.  
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1 An introduction 
 
 
 
 
Part I:  
From the wilds of Nature to the confines of the lab 
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In this introduction, the broad discipline of self-assembling structures will be outlined 
with particular focus on protein assemblies mediated by protein-ligand interactions. 
The discussion will range from the wonders of the natural world to the humble ideas 
and designs created by man.  
1.1 Nature the great architect 
Taking a minute to think about the great variety of life on this planet can only leave 
you with a feeling of awe. The multitude of complex and beautiful forms that have 
covered our world seem to be innumerable in their differences. On the nanoscale 
these differences can become even more apparent. Even within a single species 
many different tissues are present and each may comprise many different types of 
cell. 
 
There is structure to everything. On every scale a new level of appreciation can be 
found, from the straight, solid trunks of huge redwood trees, to the flexible muscle 
tissue allowing our movement and to the delicate, helical DNA that encodes all 
existence. The huge variety of natural structures is easy to see around us and on 
the nanoscale bioarchitecture can be just as impressive. 
 
It took billions of years for the natural universe to be shaped around us, yet it is only 
in the last hundred years or so that humans have truly began to understand the 
fundamental principles that hold this world together. We are starting to better 
understand the complex mechanisms that govern how all these systems interact 
and scientists can now use this information to change and add to what nature has 
already created. 
 
A central goal of synthetic biology is to learn from nature and take inspiration. This 
knowledge can then be used to create bioinspired and novel artificial architectures 
and systems that meet our needs, demands and are limited only by our own 
imagination.[2] 
1.2 The rise of synthetic biology 
Synthetic biology is an emerging field of science that focuses on the design and 
construction of biological materials and re-design of natural biological systems for 
purposes useful to us.[3] Whether this involves redesigning proteins, building novel 
biological networks or creating new life, synthetic biology combines ideas from a 
range of disciplines such as engineering, chemistry, biology and computing.  
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The term synthetic biology was first coined in 1912 by Stéphane Leduc with the 
publication of ‘La Biologie Synthétique’.[4] It has been redefined over the years; from 
the production of synthetic life forms, to a more recent definition of the design, 
construction and re-design of biological systems.[3] One thing that is clear is the 
overall goal of a greater understanding of nature and how this knowledge can be 
used to help us. By mimicking nature and gaining more information on the 
associations between different natural systems, it will become possible to assemble 
our own new programmed semi-biological systems. 
 
The standardisation of biological parts is a major aim of synthetic biology. As has 
been done with electronics and building circuit boards, it is hoped that the building 
blocks of biological systems can be standardised to allow ‘plug and play’ design for 
non-natural functionality from a combination of natural and synthetic components. 
The Registry of Standard Biological Parts has already started along this path and 
hopes to provide a resource to make biology simpler to engineer.[5] An annual 
challenge to students is The International Genetically Engineered Machines 
competition (iGEM) where a kit of standard parts is used, to design and create new 
living biological systems.[6] Other sources such as the well established Protein Data 
Bank also add to this collective knowledge of standard parts.[7] 
 
There has been a recent increase in attention from the media concerning synthetic 
biology. A BBC Horizon episode broadcast in January 2012 provocatively titled 
‘Playing God’ was one of many programs and articles hoping to inform the public of 
this new branch of science.[8] As this area gains more interest, more people see the 
benefits and ethical questions start to be raised. Many organisations are working 
towards a better public understanding through outreach programmes, conferences 
and a wealth of internet based information.[3, 9-12] 
 
Richard Feynman’s frequently quoted statement that, “What I cannot create, I do 
not understand”, holds true in synthetic biology and nanotechnology. Nature has 
achieved a remarkable array of different structures and the goal of scientists 
working in this area is to mimic and ultimately improve biological systems by 
combining genetically and structurally altered natural molecules.[13] A whole range 
of new materials could be constructed which would be used to solve problems in 
areas such as drug delivery and tissue engineering.[14] 
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The diverse creations that come from synthetic biology all have one thing in 
common, and that is self-assembly.[15] Whether new genes are being read, or 
artificial proteins are folding up, these processes happen spontaneously without 
human input. When creating new systems we must take advantage of the strategies 
already in place, one of the most powerful being self-assembly.  
1.3 A lot of recognition for self-assembly 
The key concept in both natural and synthetic multi-component systems is the 
ability of the materials to self-assemble into larger, more useful structures. For this 
result to occur, the components involved must have the ability to recognise each 
other and then stick together. The principles of self-assembly are often 
anthropomorphised through the use of terms such as “intelligent molecules” that 
“recognise” one another, which can easily distract the reader from the true wonder 
of these systems that have no intelligence at all. All processes are driven by 
diffusion and Brownian motion, and simply happen without choice. Nevertheless 
with a little external design and a push in the right direction, using self-assembly 
could trivialise the creation of large complicated structures.  
 
There are many examples of self-assembly in nature, many of which are essential 
for life, including protein folding, the formation of cell membranes and DNA double 
helix formation. The human body is essentially a self-assembled system, with each 
cell constructing itself to enable life to exist. This ability to spontaneously organise 
also provides us with the tools to construct novel nanoscale materials. 
 
 
Fig 1.1 The concept of Emil Fischer’s ‘lock and key’ model with common supramolecular forces. 
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Scientists that boast the most well understood hold over self-assembly work in 
supramolecular chemistry as this field is reliant on this concept when creating 
structures. Supramolecular chemistry focuses on the use of non-covalent bonds 
including hydrogen bonds, hydrophobic interactions, and electrostatic interactions 
including metal binding and π-π stacking. With only a few simple recognition motifs, 
elaborate constructions can be created. The concept of molecular recognition has 
come a long way since Emil Fischer proposed a lock and key model for an enzyme 
reaction in 1890 (Fig 1.1). In 1987, Cram, Lehn and Pedersen shared the Nobel 
Prize for chemistry for their work on host-guest interactions and properly 
established the field of supramolecular chemistry.[16] It is beyond the scope of this 
introduction to discuss all the possibilities supramolecular chemistry affords and the 
area has been extensively reviewed.[17-20]  
 
Nature has evolved using these weak interactions to induce the spontaneous 
organisation of many complex biological creations. For example, the cell membrane 
is formed by lipids clustering their hydrophobic tails; actin proteins polymerise into 
filaments to stabilise the structure of cells; and histones interact with DNA, winding 
it up into chromatin in the cell nucleus. Looking at the elegance of the interactions 
employed by biological systems, with a knowledge of the forces involved, has 
allowed scientists to explore the use of biomolecules as supramolecular building 
blocks.[21] So far, the manipulation of DNA and proteins has been the main focus of 
research in this area. 
1.3.1 DNA: Boxes full of origami 
The DNA double helix comprises only four different nucleotides (adenosine, 
thymidine, cytidine and guanosine) and stores all the information needed for life. 
This simplicity makes it an alluring material for the scientist interested in 
self-assembly. The double helix structure is held together via hydrogen bonds 
between each base pair and this complementarity allows DNA to be easily 
manipulated. The helix of DNA naturally forms with a right-hand rotation but it has 
been seen that under high salt conditions certain sequences can exist as left-
handed. Recent research has also shown that pH can influence the handedness of 
DNA with guest molecules bound and so great control over these self-assembling 
superstructures can be achieved.[22] 
 
Ned Seeman first showed the possibilities of what could be achieved using DNA [23] 
by constructing the first example of a polyhedron made from DNA. Here a cube was 
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created with each face of the object being a single-stranded cyclic piece of DNA, 
which was doubly catenated to four other strands and therefore holding the cube 
together (Fig 1.2). This groundbreaking work was performed to create structures 
that could be used to template larger assemblies, however it also opened up the 
potential for DNA to be used to create designed self-assembled structures for a 
variety of other uses.[24] 
 
Fig 1.2 Ned Seeman’s design of DNA catenated and ligated to form a cube.
[23]
 
 
Since then so-called DNA origami has led to the creation of intricate two-
dimensional assemblies and then more complicated three-dimensional structures. 
Here a long strand of DNA is used as a scaffold whilst smaller staple strands bind 
and fix the complete assembly into the desired shape. DNA origami has seen the 
construction of a vast array of structures from a 100 nm smiley face[25] to a 
megadalton-sized DNA box with an interior large enough to hold a ribosome[26] (Fig 
1.3). This box even had a lid that could be ‘unlocked’ by the addition of ‘key’ 
oligonucleotides. 
 
 
Fig 1.3 From (A) the DNA origami design of a smiley face, to (B) the AFM image of the assembled 
structure.
[25]
 (C) A lockable box from DNA origami.
[26]
 
 
Furthermore, DNA polyhedra have been produced that use a smaller number of 
different DNA strands so as to simplify the synthesis.[27] These strands then form 
three-point motifs that join together to form symmetrical three-dimensional objects 
such as a tetrahedron, a dodecahedron and a buckyball (truncated icosahedron). 
The objects created were dependent on concentration and the number of bases in 
the central loop of the motif (Fig 1.4). Polyhedra have also been made from tRNA 
A B
 
 
 
 
 
 
 
 
  
C
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which takes advantage of the natural tRNA(Ser) structural motif which enables a 
rigid, stable nanostructure to be formed.[28] These structures are not only beautiful 
examples of the control that scientists can exert over biomolecules but they can 
also potentially be useful as scaffolds or nanoscale containers. Nucleotide 
manipulation has come so far now that almost any two or three dimensional 
architecture can be designed and constructed with extremely high precision.[29, 30]  
 
    
Fig 1.4 Self-assembling DNA stands into different three-dimensional structures.
[27]
 
 
1.3.2 From peptide filaments to protein cages 
Proteins represent a step up in complexity from DNA as we move to using a 
possible 20 natural amino acids in these biopolymers. Protein folding is a 
complicated phenomenon that is still not fully understood.[31] Hydrophobic 
interactions, polar contacts and salt bridges contribute to creating the stable, and 
often complicated, tertiary structures of proteins. 
 
Proteins can interact with one another to give rise to the formation of many elegant 
architectures in nature. Research into protein-protein interactions (PPIs) has tended 
to focus on the self-assembly of peptides as these components are easier to make 
chemically than full proteins.[32] Coiled coils are a natural assembly and have been 
researched extensively.[33] They exist when two or more peptide α-helices interact 
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to coil around each other. They have hydrophobic ‘knobs in holes’ interactions 
between the strands and salt bridges also help to hold the structures together. The 
Woolfson group is leading the way in this area and has designed and created some 
complex coiled-coil structures.[34, 35] A recent study by Gradišar et al. used coiled 
coils to create a self-assembling three-dimensional tetrahedron from a single 
polypeptide chain (Fig 1.5).[36] This work showed that the design and manipulation 
of coiled coils has the potential to become as standardised as DNA origami. 
 
 
Fig 1.5 Schematic representation of the polypeptide self-assembling tetrahedron.
[36]
 
 
Amyloid is another natural peptide supramolecular assembly. The development of 
this type of structure has been linked closely to Alzheimer’s disease and so these 
structures are the subject of much research.[37] Amyloids are created when proteins 
misfold into cross-β sheets which then form insoluble fibrous aggregates.[38] A 
further understanding of the formation of amyloids has been used as a guide to the 
design of β-sheet proteins. One example of recent work has seen an artificial β-
barrel created from peptides designed to self-assemble into β-sheets.[39] 
 
Viruses offer a plethora of self-assembled protein structures; from the simple 
icosohedral structure of the rhinovirus capsid, to the tubular arrangement of the 
Tobacco mosaic virus coat proteins and the almost alien appearance of 
bacteriophages. The viral proteins self-organise around nucleic acids to form 
symmetrical structures of varying shape and size ranging from a modest 30 nm for 
the rhinovirus up to a 440 nm diameter for the megavirus[40]. These constructions 
rely on the strength of many PPIs over large surface areas to give them great 
stability. 
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Building on this knowledge of control over peptides and PPIs there has been much 
research to manipulate these interactions. A non-natural peptide assembly has 
been created by Ghadiri and co-workers.[41] They used cyclic D,L-peptides that then 
self-organise to form nanotubes. Alternating D- and L-amino acids are used because 
in this configuration they can stack with backbone-backbone hydrogen bonds (Fig 
1.6). The internal diameter of the nanotubes can be controlled simply by altering the 
size of the peptide rings and these structures could be employed as ion channels or 
closed reaction chambers. 
 
 
Fig 1.6 Ghadiri’s cyclic structures of alternating D- and L-amino acids formed self-assembled 
nanotubes held together by hydrogen bonding.
[41]
 
 
Fusion proteins have been used by Padilla et al. in a new strategy for the design of 
large nanoscale assemblies.[42] Two different proteins that each want to naturally 
assemble into oligomers were used; a natural dimer and a natural trimer. The 
different protein monomers were fused together and then oligomerisation allowed 
for the self-assembly of a nanoscale cage or a flat array depending on the geometry 
of the fusion protein (Fig 1.7). This work was quite elegant in the way that prior 
design led to the desired supramolecular complexes. Tetrahedra, fibres and two-
dimensional lattices have also been made by similar techniques.[43, 44]  
 
Breakthrough work from the Baker group showed the design of a novel protein-
protein interface that facilitated the construction of a 24-subunit cage with 
octahedral symmetry.[45] In this study computational docking was used to predict 
which mutations in the proteins would lead to the desired interactions. Crystal 
structures of the protein constructions revealed atomic level accuracy to the original 
computational design. Many other structures that have been created through PPIs 
have been reviewed extensively.[46, 47]  
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Another characteristic of some proteins is their ability to bind small molecules. 
When this feature is exploited for initiating self-assembly, a whole new range of 
designs can be accessed. 
 
 
 
   
  
 
 
 
 
Fig 1.7 The strategy for creating flat networks as well as three-dimensional protein assemblies from 
fusion proteins of two natural oligomeric proteins.
[42]
 
 
1.4 Ligands take hold of assembly 
Just as DNA has its sequence recognition with base pairs and PPIs have evolved to 
specifically choose one interface out of a mixture, so too can protein-ligand 
interactions be precise and unambiguous. Protein-ligand interactions can thus be 
used as another means to create nanostructure assemblies. However, ligand 
mediated protein assembly is a concept that has been less widely researched and 
there are only a few examples of ligands being used to access large complexes. 
Here we define a ligand as a small molecule able to bind specifically to a larger 
protein. As with supramolecular chemistry, the same types of non-covalent 
interactions are relevant here, the ligand and protein binding site are now the 
recognition motifs. 
 
Bringing two proteins together to initiate or increase their activity has been achieved 
using chemical inducers of dimerisation (CIDs). This dimerisation technique has 
been shown to be a powerful tool when investigating cellular processes.[48] Recent 
work from the Bertozzi group provides a nice example of CIDs at work. In this study 
the catalytic (cat) and localisation (loc) domains of a glycosyltransferase were split 
and fused to two different binding proteins.[49] The binding proteins FKBP and a 
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bacterial dihydrofolate reductase were used and a heterodivalent ligand was 
developed that could dimerise these proteins. Without this CID the cat domain was 
secreted from the cell but when the CID was employed it brought both halves 
together and so activated the full protein (Fig 1.8). Bringing two proteins together 
that were previously far apart is known as chemically induced proximity and has 
been shown to be useful not just in the dimerisation of proteins, but also in the 
formation of larger structures.[50] 
 
 
 
 
Fig 1.8 Activation of a glycotransferase using a CID. A) Only in the presence of the CID do the two 
domains associate activating the enzyme and in B) the structure of the CID is shown.
[49]
 
 
To create larger assemblies different tactics must be used and there are several 
different strategies for using protein-ligand interactions to create larger assemblies. 
The use of non-covalent interactions gives reversibility to the system and the 
possibility of self-correction which can aid the build up of ordered structures.  
 
A homodimeric protein A-A with two binding sites could bind to a homodivalent 
ligand a-a which in turn would bind to another A-A and so on. Secondly 
homodimeric A-A could bind to B-B with a heterodivalent ligand a-b and a three 
membered system builds up (Scheme 1.1). 
 
 
 
A 
 
 
 
 
 
 
 
 
 
B 
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Scheme 1.1 Simple assembly systems of divalent ligands binding to proteins. 
 
A different method would involve a covalent bond between protein A and ligand a 
(Scheme 1.2). This A-a unit then binds to a similar one and continues. Using the 
same technique but with a different ligand b attached to protein A, a dimeric system 
will be created.  
 
 
   
 
   
Scheme 1.2 Assembly system for proteins with covalently attached ligands. 
 
Structures can become increasingly complex when the valency is increased or 
when the valency of each protein and ligand are mixed (Scheme 1.3). Branching 
points can be created giving rise to two- and three-dimensional structures. With the 
right ligand design, proteins can be brought together in a well ordered manner.[51] 
Depending on the flexibility and arrangement of the ligand, proteins could be held in 
a specific way predesigned in the system to create discrete structures. 
 
To covalently attach ligands to proteins many methods are available. Traditional 
methods such as targeting amine groups can modify multiple amino acid side 
chains and are thus not selective. Modifying cysteine residues can be a better 
strategy as it is more selective because cysteine is relatively rare in proteins. In 
recent years methods to specifically modify N- or C-termini have developed using 
native chemical ligation, sortase and oxime formation.[52, 53] Unnatural amino acids 
can also be introduced for modification with click chemistry.[54] 
 
A-A        a-a          
A-A        a-b         B-B  
    A-a        
     A-b                 B-a  
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Scheme 1.3 Assembly systems with an increased valency and a mixed valency between ligands and 
proteins resulting in more complex structures. 
 
1.4.1 Linear assemblies - it all starts to add up 
Linear protein assemblies have been prepared by a number of groups. One 
example used a calix[4]arene core with carbohydrate ligands to polymerise the 
lectin LecA.[55] Two galactose moieties from the ligand bound to two sites on one 
side of LecA with each tetravalent ligand bringing two proteins together. AFM was 
performed on the structures and showed very straight assemblies with rare 
branching points attributed to conformational changes in the calixarene based 
ligand (Fig 1.9). Another group took streptavidin which has four binding sites.[56] The 
proteins were linked by bis-biotinylated ligands that bound to two binding sites on 
one side of streptavidin. These ligands were attached to terpyridine organised 
around an iron ion and the structures were deemed metal-organic protein networks. 
 
       
Fig 1.9 A) Representation of the galactose ligand. .B) An AFM image of the assembled protein 
polymers showing straight lines with occasional branching points.
[55]
 
 
One of the first examples of controlled self-assembly by protein-ligand interactions 
of discrete nanostructures was by Carlson et al.[57] Building on their work with CIDs, 
A B 
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they expressed E. coli dihydrofolate reductase (DHFR) dimers connected by a 
flexible peptide linker with the aim of producing protein nanorings. Using a divalent 
methotrexate derivative (MTX2-C9) as a ligand to mediate the assembly, toroidal 
structures were created with diameters ranging from 8 to 20 nm depending on the 
length of the peptide linker (Fig 1.10).  
 
     
 
Fig 1.10 Representation of the cyclic structure created by DHFR dimer proteins linked with 
MTX2-C9.
[57]
 
 
Other protein nanorings have been produced by the Meijer group.[58] Ribonuclease 
A was digested with a protease to yield the S-protein and the much smaller 
S-peptide which have a nanomolar affinity for each other. These fragments were 
then chemically joined with a flexible linker to form an A-a type system. The 
structures were studied at varying concentrations and it was found that the protein-
peptide structures formed larger rings as the concentration was increased. The 
absence of linear constructs was attributed to the flexibility of the linkers and the 
propensity for cyclisation as the effective concentration of binding sites is increased 
when the proteins are brought together. 
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The Hayashi group have employed another type of ligand for their supramolecular 
protein polymers. Linear assemblies of a hemoprotein, cytochrome b562, 
conjugated to heme have been constructed.[59] A cysteine residue was introduced 
into the protein at a specific site, opposite to the heme binding pocket and then a 
heme modified with an iodoacetaamide group was attached. After acid denaturing 
and renaturing the protein to remove native heme, the protein-ligand interactions 
allowed polymerisation (Fig 1.11). Oligomers greater than 100-mers were observed 
using AFM, with lengths around 350 nm.  
 
 
Fig 1.11 Representation showing heme attached to a heme binding protein and the one and two-
dimensional hemoprotein networks that were formed.
[59]
 
 
The polymers were further characterised by SEC and CD and it was shown that the 
system was under thermodynamic control due to the reversible associations.[60] 
Again it was found that the length of the assemblies was concentration dependent. 
This work was then extended to a more complex hemoprotein, myoglobin, to 
assess its physiochemical properties in the polymerised state.[61] Most recently the 
same group have created polymers of alternating myoglobin and streptavidin 
proteins.[62] For this they had to dimerise myoglobin by using a disulfide bond at the 
opposite side of the protein to the heme binding pocket, which enabled the protein 
to bind two heme units. When a heme-bisbiotin ligand was used, polymerisation 
could then occur (Fig 1.12). This is one of the only examples of a heterotropic linear 
protein assembly being formed. 
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Fig 1.12 The assembly of the alternating copolymer made of streptavidin bound to dimerised 
myoglobin with heterovalent ligands.
[62]
 
 
1.4.2 Making more contacts and building networks 
There are relatively few examples in the literature of the use of protein-ligand 
interactions to create multi-dimensional nanoscale networks. The first such example 
was the production of a two-dimensional quadratic network by Ringler and 
Schulz.[63] A C4-aldolase tetramer and streptavidin were combined to make the 
cross-linked network. Streptavidin has two biotin binding sites on each of its long 
faces, therefore the aldolase was mutated at selected sites to allow two biotin 
ligands to be tethered to each side of the protein, such that they had the correct 
spacing allowing a divalent interaction with streptavidin (Fig 1.13). 
 
Fig 1.13 C4-aldolase tetramer (
b
R) with tethered biotin bound to streptavidin (S) which is then bound to 
another streptavidin (
bb
S) when a divalent biotin ligand is added. Point mutations that allowed the 
ligand to be bound are highlighted on one subunit.
[63]
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As expected the streptavidin bound to the biotin-labelled aldolase, thus allowing the 
blocks to self-assemble in solution. Divalent-biotin ligands were also used to induce 
connections between the streptavidin and so a combination of covalently attached 
ligands and free ligands was used. This research showed order could be achieved 
with protein-ligand interactions and defined structures could be made. The 
reversibility of the networks was limited by the exceptional strength of the 
biotin-streptavidin interaction. This is one of the strongest protein-ligand interactions 
known and therefore there was no propensity for self-healing of irregular points in 
the network. 
 
Other two-dimensional assemblies were created by Hayashi and co-workers using 
their hemoprotein polymers.[64] A trivalent heme ligand gave rise to branching points 
in the polymers and allowed the dimensionality of the networks to be controlled by 
altering the ratio of the heme-conjugated proteins to the branching molecules. 
Another two-dimensional network was produced by the same group using a 
combination of the same hemoproteins with gold nanoparticles as the branching 
points (Fig 1.14).[65] The heterotropic structures were visualised by TEM and AFM, 
which showed that the nanoparticles were assembled by the protein-ligand 
interactions. 
 
 
Fig 1.14 The assembly of hemoprotein-nanoparticle structures.
[65]
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1.4.3 To the third dimension and beyond 
Each increase in dimensionality brings new challenges and greater control is 
always needed. One study by Mori et al. found that their protein assemblies, formed 
from streptavidin binding to a biotin labelled phosphatise, created uncontrolled 
aggregates and precipitated. This was due to too many ligands per receptor being 
used and it was only when they had the correct ratio that discrete protein structures 
started to form.[66] Another investigation by Ma and Bong saw streptavidin proteins 
brought together by mixed bivalent ligands.[67] The ligands had a biotin moiety at 
one end for streptavidin binding and then either a Tris-functionalized cyanuric acid 
(TCA) or melamine (TM) group at the other end. These two groups have a strong 
affinity for each other and so when mixed together with streptavidin, protein-ligand 
and supramolecular interactions began to build up large aggregates (Fig 1.15). The 
hydrogen bonding motifs could be dissociated thermally, breaking up the 
aggregates. The system was then cooled before being allowed to form again. The 
size and shape of the networks was, however, uncontrolled.  
 
 
Fig 1.15 The structure of the complementary tris-functionalized cyanuric acid (TCA) and melamine 
(TM) ligands. When biotin was attached to the ligands, self-assembled aggregates with streptavidin 
were formed. 
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The first example of the controlled assembly of a predesigned three-dimensional 
lattice was shown by Dotan et al. with the cross-linking of the tetrameric lectin 
concanavalin A.[68] This work used molecular modelling to guide the design of the 
divalent ligands needed to create the self-assembling structures. When the divalent 
mannose ligand was added at 2:1 stoichiometry to the proteins, the tetrahedral 
lectins became non-covalently cross-linked into a diamond-like structure that 
crystallised out of solution (Fig 1.16). These protein crystals grew up to 100 nm in 
size, were highly stable to pH change across the range 4.5-8.0 and were not 
disassembled by addition of a competing mannose ligand, even up to a 
concentration of 1.5 M. This example provided the first demonstration of the great 
stability non-covalent protein assemblies can achieve and the assistance that 
computational design can offer. However, the lattices assembled were insoluble 
and their size could not be controlled with great precision. 
 
  
Fig 1.16 A) model of two tetrahedral lectins in a staggered orientation. B) Two views of the predicted 
diamond structured lattice. C) Structure of the divalent mannose ligand.
[68]
 
 
A discrete three-dimensional structure was realised by the Whitesides group. They 
presented work in which a trivalent hapten ligand bound divalent antibodies in a 
thermodynamically and kinetically stable aggregate.[69] The reversibility of 
non-covalent interactions meant that the initially disordered system could eventually 
rearrange into stable structures leading to three IgG proteins being bound to two 
trivalent ligands (Fig 1.17). These structures again showed the enhanced stability 
that can be achieved through multivalency, as the complex had a 225 fold increase 
in stability compared to a single bound ligand. 
 
Whilst there are a few examples of discrete three-dimensional structures formed by 
protein-ligand interactions, nobody has yet achieved the sophistication and 
A 
B C 
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standardisation that has been seen with DNA. Nevertheless, these studies 
demonstrate the intricacies that must be fully understood in the design process 
before being able to manipulate protein self-assembly into the exact, organised, 
unnatural configuration that is desired. Another important point shown here is the 
inherent stability that multivalent assemblies possess and this desirable property 
makes these types of assembly attractive for many applications in nanotechnology. 
 
 
 
Fig 1.17 A bivalent antibody (IgG) and a trivalent hapten ligand (1) form stable aggregates in a 3:2 
stoichiometry.
[69]
 
 
1.4.4 The promise of greater things 
Between the simple binding motifs of supramolecular chemistry and the complexity 
of biological systems, a common ground is being formed. The rise of synthetic 
biology has seen researchers playing with natural systems to bring their own ideas 
to life. By combining the strategies of supramolecular chemists with the building 
blocks supplied by nature we will create opportunities to shape new devices and 
structures inspired by nature but of our own design and for our own use. 
 
Self-assembly is an important concept to be used for the goal of creating large 
ordered structures. Using carefully designed small molecules as the mortar to hold 
natural protein bricks together, has the potential to yield limitless extraordinary 
architectures. Nature’s toolkit has been thoroughly ransacked by scientists looking 
to create more sophisticated structures with increasing precision and ease. Thanks 
to years of scientific advances there is plenty to build upon but more importantly 
there is still plenty to achieve. 
 
  
A 
B 
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A review based on the following section has been published: T. R. Branson and W. 
B. Turnbull, “Bacterial toxin inhibitors based on multivalent scaffolds, Chem. Soc. 
Rev., 2013, 42, 4613”.[70] 
1.5 The power of multivalency 
As seen with many of the assemblies discussed so far, it is often the combined 
effect of more than one interaction that gives strength and stability to the structures. 
This cooperative binding effect is known as multivalency.[71-73] Supramolecular 
chemistry takes full advantage of multivalency as individual non-covalent 
interactions can be quite weak but by combining many interactions, an overall more 
powerful force may be achieved. When ligands are arranged on a multivalent 
scaffold, their effective concentration increases and prearrangement can aid the 
interactions.[51] 
 
Noncovalent multivalent interactions are prevalent in many biological processes and 
lead to the formation of countless larger complex structures. Improving our 
understanding of multivalency can give us a better insight into natural processes.[74] 
Carbohydrate interactions throughout nature are typically weak and therefore many 
biological processes use multivalency to overcome this problem.[75] Bacterial toxins 
are a good example of where the weak carbohydrate interactions and binding 
efficiency are greatly enhanced with multivalency.[73, 76] Work undertaken to find 
inhibitors for the toxins has tended to focus on multivalent binding. Some 
multivalent ligands have even led to the creation of protein assemblies which, whilst 
not being the ultimate goal of the projects, opened up other interesting possibilities. 
1.5.1 Bacterial toxin inhibition with multivalent scaffolds 
A significant portion of diarrhoeal diseases can be attributed to bacteria that 
produce protein toxins. These cases continue to pose a serious threat to human 
health, with an estimated two million deaths per annum, most of which are in 
children under five years old.[77] The most widely studied of these toxins are cholera 
toxin (CT), the closely related E. coli heat-labile toxin (LT)[78, 79] and shiga-like toxin 
(Stx; also known as verotoxin, VT).[80] Together, they belong to a family of AB5 
toxins that are comprised of a single toxic A-subunit associated with a non-toxic 
B-pentamer. The B-pentamer is a carbohydrate-binding protein enabling the toxin to 
enter cells (Fig 1.18).[81] 
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Fig 1.18 Cartoon and surface representations of bacterial toxins. (A) Cholera toxin AB5 protein with 
CTA1 (blue), CTA2 (green) and CTB (red) (1S5F.pdb). (B) Cholera toxin B-pentamer (CTB) with GM1 
ligand 1 depicted as a stick structure (3CHB.pdb); (C) Shiga-like toxin B-pentamer (VTB/StxB) with 
Gb3 ligand 2 depicted as a stick structure (1BOS.pdb). 
 
Following initial adhesion of the B-pentamer to specific glycolipids that are present 
on the surface of epithelial cells that line the intestine, the toxins enter the cells by 
endocytosis. They are then transported through the cell to the endoplasmic 
reticulum where the toxic A-subunit is released into the cytosol where it has its 
cytotoxic effect.[78, 82] In the case of CT and LT, the toxin ADP-ribosylates the Gsα 
protein which leads to a rise in cAMP concentration in the cell leading to a complex 
series of events that result in release of water into the intestine. In the case of Stx, 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
C 
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the toxic A-subunit is an N-glycosidase that removes purine bases from ribosomal 
RNA, thus inhibiting protein synthesis and causing cell death.[83] 
 
 
Fig 1.19 GM1 ligand 1 for CTB and Gb3 ligand 2 for StxB. 
 
The B-subunits of cholera and heat-labile toxins (CTB and LTB) are 80% identical, 
but share essentially no sequence homology with the shiga-like toxin B-subunit 
(StxB).[81] This observation is surprising as all three toxins have the same protein 
fold and have evolved to perform the same function, i.e., to enable toxin 
endocytosis by binding to cell surface glycolipids. This function is facilitated by 
having their glycolipid binding sites arranged on the same face of the protein so that 
they can engage multiple copies of the carbohydrate ligands at the same time.  
 
The similarities and differences in protein sequences of CTB, LTB and StxB are 
reflected in their carbohydrate-binding specificities. CTB and LTB both recognise 
ganglioside GM1 1,[84] while StxB binds to globotriaosyl ceramide (Gb3) 2 (Fig 
1.19).[85] However, CTB and LTB are not identical, and certain variants of these 
proteins can differentiate between blood group oligosaccharides in a secondary 
binding site on the circumference of the pentamer.[86-88] The most striking difference 
between CTB/LTB and StxB lies in the affinities for their glycolipid ligands. The 
CTB/LTB-GM1 interaction is among the highest affinity protein-carbohydrate 
interactions known (Kd = 10-40 nM for a monovalent interaction),
[89] whereas StxB 
binds only weakly to individual Gb3 oligosaccharides (Kd = 1 mM).
[90] Therefore, 
StxB relies on multivalency (i.e., simultaneous binding to multiple copies of its 
ligand) to achieve a functionally useful interaction with a cell surface. Up to 15 
copies of the Gb3 ligand can bind simultaneously to a StxB pentamer leading to a 
sub-nM dissociation constant.[85] Although CTB/LTB can bind tightly to an individual 
GM1 molecule, multivalent interactions are still important in facilitating 
endocytosis.[91] 
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1.5.2 Bacterial toxin inhibitors 
As protein-carbohydrate interactions are an essential prerequisite for cell entry and 
toxin activity, the development of inhibitors for these interactions has attracted much 
interest over recent years. In general it is very challenging to make low weight 
inhibitors of carbohydrate-binding proteins as the binding sites are typically shallow 
and highly solvated. In the case of CTB/LTB, substantial changes to the GM1 
structure usually result in a loss of affinity (Fig 1.20).[92] For example, methyl 
β-galactoside 3 has a 15 mM dissociation constant;[89] GM1 mimic 4 has a Kd value 
of 10 mM;[93] and aromatic α-galactosides 5 and 6 have Kd values of 125 and 12 
mM, respectively.[94] As even the best of these compounds still bind around 1000 
times more weakly than GM1 1, researchers have instead focussed their attention 
on multivalent inhibitors that can engage multiple carbohydrate binding sites 
simultaneously.[95]  
 
 
Fig 1.20 Monovalent galactoside inhibitors for CTB/LTB 
 
Multivalent binding can be accomplished in many ways and so there are a wide 
range of designs employed as inhibitors. Glycopolymers, glycodendrimers, tailored 
glycoclusters and inhibitors exploiting templated assembly have all been developed 
to bind the bacterial toxins (Fig 1.21). 
 
    
Fig 1.21 Multivalent bacterial toxin inhibitor designs. (A) glycopolymer, (B) glycodendrimer and 
(C) glycocluster. 
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1.5.3 Stringing together the inhibitors 
To take advantage of the benefits of multivalency, a suitable method must be found 
to connect multiple ligands together. The most simple way to organise multiple 
copies of a ligand is to string them out along a chain. Polymers can be used to 
achieve this arrangement; their relative ease of synthesis and variability of structure 
and length make them ideal for use as a general architecture for multivalent 
presentation. 
 
The benefits of using multivalent inhibitors for bacterial toxins were shown in an 
early example by Schengrund and Ringler.[96] In this study, reductive amination of 
the GM1 oligosaccharide (GM1os) to the free amino groups on the polylysine 
scaffold resulted in polymer 7 (Fig 1.22) with an average of eight oligosaccharides. 
It was found that this polymer was 1000-fold more effective than GM1os for 
inhibiting cholera toxin from adhering to GM1 coated plates.  
 
Gb3-polyacrylamide conjugates have been used to neutralise Stx-1 in human ACHN 
cells by Dohi et al.[97] They concluded that the clustering effect of multiple ligands 
presented on polymer 8 must be the reason for successful inhibition as the 
individual affinity of one copy of the Gb3 ligand was too low to have any effect in 
cells. Analogous polyacrylamide glycopolymers having varying degrees of 
substitution with the Gb3 trisaccharide were reported by Gargano et al.
[98] They 
found that polymer 9 gave 5000 times enhancement of the inhibition of Stx-1 over 
the monomeric carbohydrate. The degree of ligand substitution (between 10% and 
30%) did not have a substantial effect on inhibition. In contrast, other studies with 
similar polymers have shown that the density of the carbohydrate ligands on the 
polymer chain can affect the binding affinity to the Stx-2 isoform of the toxin, as can 
the length of spacer from the backbone chain.[99, 100] For example, a higher density 
of Gb3 along polymer chain 10 provided higher affinity binding to Stx-2 but had little 
effect on binding to Stx-1.[99] The density-dependence of binding to Stx-2 is 
significant as the Stx-2 isoform of the toxin is considered to have greater clinical 
importance than Stx-1. 
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Fig 1.22 Glycopolymer inhibitors of bacterial toxins. 
 
The Kiick group have extensively investigated the effect on inhibition of 
carbohydrate density; the specific distance between carbohydrates on a polypeptide 
chain; and the spacer length from the polypeptide backbone. Using galactosyl 
polymers 11 and 12 as inhibitors for CTB, it was found that as the density of ligands 
increases, so the inhibitory effect decreases.[101] These results are in contrast to the 
previous findings by Watanabe et al. with Stx-2.[99] Kiick and co-workers concluded 
that the best inhibition was achieved when the spacing between ligands on the 
polymer chain was matched to the distance between binding pockets of the toxin; 
this distance being 35 Å for CTB. When the density was sufficiently high that 
spacing between carbohydrates was smaller than the distance between binding 
sites, steric hindrance created by unbound ligands decreased overall binding. The 
spacer length from the polymer backbone chain told a similar story.[101] Inhibition 
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was greater when the spacer matched the natural ligand length of GM1 (16 Å). The 
longer ligand 12 could therefore fully penetrate the binding site as opposed to a 
reduced accessibility when a shorter spacer 11 was used. Matching the ligand 
spacing to the binding site dimensions improves the effectiveness of the ligands, 
giving rise to high inhibition with these well designed polymers. 
 
Richards et al. had similar findings with their polymethacrylamide polymers 13 
presenting galactosyl ligands for CTB binding.[102] This study went further to suggest 
that there is a varying relationship between ligand density and inhibition. At a high 
density of carbohydrates along the polymer chain, a high rate of statistical rebinding 
is achieved giving good inhibition. At only 10% density there is lower steric 
hindrance and a better fit to the binding site. Similar inhibition results were found 
per galactose moiety for polymers substituted 100% and 10% with ligand groups. 
Between these values, inhibition decreases as the balance between the competing 
effects worsens. 
 
Further studies were performed by the Kiick group on the composition of 
polypeptide backbones. They found that random coil backbones were better suited 
than those with restricted alpha helical conformations, as flexibility of the polymers 
allows more accessible ligand groups.[103] They showed that electrostatic repulsion 
gave a larger hydrodynamic radius for a polymer with negatively charged residues 
than for a neutral chain.[104] The resulting larger chain dimensions led to better 
inhibition, again due to the accessibility of the ligands. The charge of the peptide 
backbone was also shown to be of importance as negative glutamic acid residues 
aided inhibition, neutral glycine residues were acceptable, but positively charged 
lysine residues were detrimental to the inhibitory properties of the 
glycopolymers.[105] There are positively charged residues present on the surface of 
CTB around the binding pocket and so complementing these charges should 
improve binding. A negatively charged backbone gave an IC50 value almost three 
times better than that for a neutral backbone, whereas introducing positive charges 
led to an IC50 value four times worse than a neutral backbone. 
 
Bundle and co-workers have reported a strategy to identify optimal ligand groups for 
multivalent display by synthesising libraries of glycomimetics on polyacrylamide or 
aminated dextran backbones.[106] They found that screening ligand groups for CTB 
inhibition in a multivalent format made it easier to identify optimal ligands than if 
they had studied the analogous low affinity monovalent compounds. 
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Without prior knowledge of the valency or structure of the target protein, polymers 
are a good starting point for building multivalent inhibitors. However, defining the 
distance between ligand groups and the length of the spacer to the polymer 
backbone can result in much improved binding when these parameters can be 
matched with the dimensions of the protein binding sites. While linear polymers with 
pendant carbohydrate groups are relatively easy to make, they are also frequently 
heterogeneous in their distribution of the ligand groups. Therefore only a subset of 
ligand groups will be in the optimal arrangement to bind to the target protein. 
Multivalent scaffolds that provide greater homogeneity or restrict the ligand groups 
into a favourable orientation for binding could potentially provide improved 
inhibition. 
1.5.4 Branching out into glycodendrimers 
Glycodendrimers are monodisperse, branched tree-like structures that, in principle, 
combine the advantages of homogeneous small molecular inhibitors with the 
dimensions and high valencies of glycopolymers.[107, 108] Schengrund’s group was 
the first to use PAMAM 14 and poly(propylene imine) 15 dendrimers for CT 
inhibition, building on their knowledge of multivalent polymers.[109, 110] These 
dendrimers (Fig 1.23), with an average of seven GM1 ligands attached, provided 
inhibition against CT binding to cell surfaces. The results were found to be similar to 
those for their polymers and provided 1000-fold increased inhibition relative to GM1 
oligosaccharide.  
 
The Pieters group have created a set of dendrimers, synthesised by a convergent 
approach, with a variety of carbohydrate end groups as CTB inhibitors (Fig 
1.24).[111] Their first scaffolds were prepared with two, four and eight arms 
terminating in lactose sugars (16a-c).[112] As expected, it was found that the 
multivalent dendrimers gave an increase in inhibition with the octavalent ligand 
having the strongest binding with a Kd of 33 µM as measured by a fluorescence 
titration assay. More surprisingly however, were the results for the monovalent and 
divalent ligands. The monovalent lactosyl head group had a Kd of 248 µM, 73 times 
more potent than simple lactose. This increase in affinity could partially be 
explained by additional interactions being created between the aglycone and the 
protein. The divalent ligand 16a gave an affinity only slightly stronger and it was 
proposed that this was because the linker length was not sufficient to allow both 
carbohydrates to bind simultaneously to adjacent subunits. It is therefore important 
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to note that binding site spacing needs to be taken into account when designing 
dendrimers for multivalent inhibition, as with glycopolymers. 
 
A more systematic study then followed from the same group using the same 
dendrimer scaffold as before, but with increased linker lengths to improve the reach 
of their ligands. SPR binding studies demonstrated that dendrimers 17a-c bearing 
an (R)-lactic GM1 mimic all achieved improved binding.[113] The monovalent ligand 
had an IC50 value of 97 µM, while that for divalent compound 17a was 13 µM. The 
tetra- and octavalent inhibitors 17b and 17c both gave IC50 = 0.5 µM, however, the 
detection limit for the assay had been reached. An ELISA assay confirmed the 
octavalent dendrimer to be the most potent. 
 
 
Fig 1.23 PAMAM and poly(propylene imine) glycodendrimers. 
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Fig 1.24 Glycodendrimer inhibitors synthesised by Pieters and co-workers. 
 
Galactose ligands on a long PEG spacer were also studied.[114] The PEG spacer 
was introduced to mimic the hydrophilicity and lipophilicity of GM1 and was 
introduced onto the dendrimers via “click” chemistry. Divalent compound 18a had 
an IC50 value of 130 µM in an ELISA assay, compared to 80 mM for the monovalent 
ligand. The best dendrimer was found to give similar activity to the natural GM1 
oligosaccharide ligand (GM1os). This was octavalent ligand 18c which had an IC50 
of 12µM, i.e., 2500 times more potent per sugar group than the monovalent 
galactosyl compound. The strongest inhibitory potency was found when GM1 
oligosaccharides were attached to dendritic scaffolds a-c.[115] Octavalent ligand 19c 
was found to have an IC50 of 50 pM, almost 50,000 times stronger per carbohydrate 
group than the GM1 oligosaccharide. 
 
Sisu et al. used a combination of analytical ultracentrifugation, dynamic light 
scattering and atomic force spectroscopy to show that Pieters’ di- and tetravalent 
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dendrimers (19a and 19b) inhibited toxin adhesion through an aggregation 
mechanism.[116] Some dimerisation of LTB was shown to be induced by the divalent 
compounds but this was not seen for the tetravalent compound. While the 
multivalent ligands could have potentially formed discrete protein assemblies, in this 
case uncontrolled aggregation was observed. It was proposed that the random 
aggregation occurred as a consequence of a mismatch between the valencies of 
the ligands and the toxin. 
 
The best glycodendrimers are better than the best of the linear polymers. However, 
the preference for having long flexible linkers to the ligand groups indicates that the 
densely packed globular shape of higher generation dendrimers is not desirable for 
inhibition. The glycodendrimers synthesised to date do not take advantage of the 5-
fold symmetry of bacterial toxins, which suggests that further advantage could be 
gained through the design of tailor-made inhibitors.  
1.5.5 Reaching for the stars 
Concurrent independent studies by Bundle[117] and Fan[118] led to the creation of 
star-shaped inhibitors that take advantage of the pentagonal symmetry of bacterial 
toxins. Theoretically, a five armed star could sit on a toxin pentamer with each arm 
reaching out to a separate binding site. While the Bundle group focussed on 
inhibitors of Stx, Fan, Hol and co-workers designed inhibitors for LT and CT.  
 
The Fan group attached galactose onto the arms of a scaffold radiating from a 
pentacyclen core (Fig 1.25).[118] A modular approach was adopted to the design and 
synthesis of the linker arms so that they could be varied in length. The use of 
squaric acid diesters as linking agents allowed two different amines to be coupled 
consecutively in an efficient manner. The effective length of long flexible linkers is 
actually much shorter than the extended conformation and it was found that the 
inhibitor was most potent when the linkers were of a size that presented the 
carbohydrate ligands efficiently at the binding sites. This finding confirmed the 
concept proposed previously by Kramer and Karpen that matching the effective 
dimensions of a ligand with flexible linkers and the binding site distribution, gives 
the greatest binding affinity.[119] The multivalent effect of the optimal pentavalent 
scaffold 20 (n = 4) gave a 100,000-fold enhancement in the IC50 value over a 
monovalent galactoside. It was also found that the pentavalent ligands formed 1:1 
complexes with the toxins and no large scale aggregates were observed. 
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Higher affinity inhibitors were produced by incorporating m-nitrophenyl 
α-galactoside as the ligand group, and introducing a guanidine-bridged water 
soluble linker. The resulting compound 21 had an IC50 of 6 nM, which was about 3 
times more potent than the GM1 oligosaccharide.[120]  
 
Fig 1.25 Star-shaped LT/CT inhibitors reported by Fan, Hol and co-workers.  
 
Recently a study produced pentavalent ligands for CTB based on a calix[5]arene 
core.[121] GM1os and galactosyl ligands attached to the core structure were 
analysed by ELISA experiments which showed 450 pM and >1 mM IC50 values for 
the respective pentavalent ligands. The result for the galactosyl ligand was 
surprising compared to the similar Fan structures that showed strong inhibition with 
galactosyl ligands. This discrepancy may have been due to the lower flexibility of 
the calixarene or some supramolecular aggregation of the core structure. The 
pentavalent GM1os ligand showed an impressive 20,000 fold increase in inhibitory 
potency per arm compared to the monovalent GM1os ligand. The limit of detection 
for the ELISA may, however, have been reached. The assay went down to where 
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the concentration of inhibitor was lower than that of the CTB. If 1:1 binding was 
achieved, then at these lower concentrations it would not be possible to detect 
inhibition. 
 
A concurrent study produced star-shaped inhibitors based on a corannulene 
core.[122] GM1os ligands were attached to the pentavalent core using microwave 
assisted CuAAC, “click”, chemistry and ELISA experiments were performed. The 
corannulene core structure exhibited an IC50 value of 5 nM after optimisation of the 
PEG chain arms. However, structures modified with simple galactose ligands failed 
to show any inhibition, which was thought to be due to the supramolecular 
aggregation of the corannulene core. This supramolecular assembly may also have 
contributed to the IC50 value being lower than what might have been expected from 
similar pentameric structures. Despite the tailor-made nature of the pentavalent 
structures, they are yet to reach the inhibitory power of the dendrimer structures 
with a higher valency. Octavalent dendrimer 19c remains the most potent CTB 
inhibitor which may in part be simply due to unoptimised assay results. 
1.5.6 Targeting multiple copies of the toxins 
When using multivalent ligands to inhibit protein binding it has been seen that 
tailoring the design of the ligand can greatly improve its binding strength. However, 
it could prove more efficient to be able to complex more than one toxin protein with 
each inhibitor. Targeting multiple proteins at once can be achieved by using 
chemical-inducers of dimerisation (CIDs).[48] If the multivalency strategy were to be 
combined with CIDs then self-templating, self-assembled structures could 
potentially produce better inhibition of the toxins. 
 
The Bundle group was the first to make a large step towards this goal with their 
Starfish ligand 23 (Fig 1.26).[117] Two carbohydrate ligands were arranged at the 
end of each arm of a pentavalent glucose core. Starfish 23 gave over a million fold 
increase in inhibition relative to the monovalent Gb3 ligand. The decavalent 
structure was originally designed to bind to two separate binding sites on each sub-
unit of the shiga-like toxin. However, a crystal structure of the complex revealed that 
Starfish bound only to one carbohydrate site in each of the toxin subunits, while 
using the remaining five Gb3 groups to complex binding sites on a second StxB 
pentamer, thus holding two pentamers together. These unexpected dimeric 
structures were proposed to be thermodynamically favourable and were thought to 
avoid potential strain that would arise if the ligands were to chelate two binding sites 
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within a single StxB protomer. A later study indicated that divalent binding to a 
single StxB protomer was accompanied by a significant entropic penalty for 
restricting the dynamics of the protein.[123] Improving on Starfish, was another 
inhibitor from the same group nicknamed Daisy 24.[124] This decavalent structure 
used the same Gb3 trisaccharide but linked through the reducing terminus rather 
than two position of the central sugar of Gb3. The new ligand with slightly longer 
linker spacing between the oligosaccharide groups was found to better protect mice 
against Stx-1 and Stx-2.  
 
 
Fig 1.26 Star-shaped Stx inhibitors reported by Bundle and co-workers. 
 
Fan’s group also incorporated divalent ligands into their pentameric scaffolds to 
make the inhibitors decavalent (Fig 1.25).[125] These, as with the Bundle ligands, 
bound to two toxin pentamers in a face to face dimer. Decavalent ligand 22 with 
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optimised linker lengths gave a one million-fold decrease in the IC50 value 
compared to the simple monovalent ligand, again showing the power of 
multivalency in these carefully designed structures. Importantly, decavalent ligand 
22 was over 10 times more potent than the equivalent pentavalent structure 20 
(where n = 4). 
1.5.7 Inhibitors using templated assembly 
Templated assembly is another strategy for inducing protein dimerisation that was 
pioneered by Pepys et al. in their work on serum amyloid P component (SAP).[126] 
SAP is a pentameric protein in the pentraxin family that plays a role in the human 
innate immune system. Pepys et al. found that simple divalent proline derivatives, 
26, are able to bring two SAP pentamers together to form a face-to-face dimer (Fig 
1.27) (Scheme 1.4 A). 
 
   
Fig 1.27 Homodimeric ligands for SAP 
 
SAP shares the pentameric structure that is common to the bacterial toxins and 
their binding sites are conveniently spaced for a simple divalent ligand to bridge the 
binding sites in both proteins (Fig 1.28). Fan and co-workers made heterodivalent 
ligand 29, which combines a proline derivative with a nitrophenyl galactoside, and 
showed that it could complex SAP with CTB.[127] Dynamic light scattering 
measurements confirmed the formation of the two protein complex and no 
significant higher aggregates were observed. Inhibition studies on CTB showed the 
divalent ligand to have an IC50 of 620 µM, but when SAP was included this value 
was reduced to 0.98 µM. The templating effect of the SAP protein thus provided a 
great enhancement in inhibition.  
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In a similar way, the Bundle group have used homodivalent, and heterodivalent 
ligands to create dimers of SAP[128] and to form complexes with StxB[129]. In this 
case they employed a cyclic ketal of pyruvate and glycerol as the SAP ligand. The 
flexible short ligand 27 had an IC50 value of 3.8 µM but a more rigid linker 28 gave a 
greater potency with an IC50 of 0.12 µM. The rigid unit was thought to minimise the 
loss of conformational entropy upon binding. Complexes of SAP with StxB were 
also formed by use of heterodivalent ligands comprising a pyruvate acetal and the 
Gb3 oligosaccharide (Scheme 1.4 B).
[129] As before, flexibility in the linker was 
detrimental to its inhibitory potency; rigid ligand 30 was about 50-fold better than the 
more flexible ligand 31. They found that these smaller ligands were just as potent 
as the Starfish ligand in a cytotoxity assay. However, in vivo trials showed a poor 
performance for the heterodivalent inhibitors as a consequence of their rapid 
clearance when compared to the much larger Starfish compound 23. 
 
   
Fig 1.28 Heterodimeric ligands for SAP and CTB/LTB/StxB 
 
Heterodivalent ligands comprising a cyclic pyruvate ketal of glycerol and the Gb3 
oligosaccharide were also incorporated onto modified a Starfish scaffold.
[130] Ligand 
25 (Fig 1.26), now bifunctional, was able to bring together the two different proteins 
as expected (Scheme 1.4 C). The inhibitor had an IC50 value of 140 µM but in the 
presence of SAP this value was improved by a factor of 35. A combination of ligand 
prearrangement and templating was also demonstrated using the same 
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heterodivalent ligands on a polymer backbone.[131] The polymers themselves had 
modest inhibitory power against Stx, similar to other polymeric inhibitors. But when 
combined with SAP, the protein templating effect for the ligand resulted in a 
100,000 fold improvement on the IC50 value. These multimeric inhibitors performed 
much better than Starfish 23 in a cytotoxicity assay and trials in vivo. 
 
 
Scheme 1.4 Templated assembly of protein dimerisation using (A) homodimeric ligands for SAP, (B) 
heterodimeric ligands for SAP and CTB/LTB/StxB and (C) heterodimeric ligands on a pentameric 
scaffold (e.g. compound 25, Fig 1.26) 
 
1.5.8 Conclusions 
The studies outlined in this review show us that weak interactions can be greatly 
enhanced through multivalency. A wide variety of different structures have been 
created for use as multivalent inhibitors. This review is not intended to be a 
comprehensive review of all scaffolds investigated to date and other scaffolds, e.g., 
calixarenes and glyconanoparticles have been discussed elsewhere.[132, 133] Instead 
the aim has been to highlight some of the general principles of multivalent inhibitor 
design for the bacterial toxins by considering some of the major classes of 
multivalent scaffolds. Investigations using glycopolymers and glycodendrimers have 
led to the realisation that multivalent ligands that have been designed to have an 
improved fit to the carbohydrate binding sites can display a significant increase in 
affinity. The ligand spacing and length of spacer connecting the sugar to the 
scaffold are important to achieve optimal binding. However, better inhibition is not 
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necessarily achieved by maximising the number of ligand groups as increased 
steric crowding can prevent efficient interactions from forming. 
 
An understanding of the structure of the bacterial toxins has led researchers to 
move away from simple polymeric inhibitors to more sophisticated constructions. 
Having a prior knowledge of the target protein is advantageous in aiding the design 
of the most suitable ligands and it has been seen that prearrangement of ligands to 
precisely fit the binding sites increases their inhibitory potential. The five-fold 
symmetry of the toxins has directed work towards star shaped inhibitors that 
present their carbohydrate ligands at precise positions for binding. Matching the 
valency of the inhibitor to that of the target protein can prevent unwanted 
aggregation. These designs can be further improved by creating self-assembling 
complexes of proteins. The templating effect created by the first protein can pre-
organise the ligand for engaging with a second protein molecule. Templating can 
also have a powerful effect when used with simple small divalent ligands. Binding 
interactions that individually have unimpressive affinities, can still give rise to strong 
inhibition when assembling proteins.  
 
In the search for higher affinity ligands and the improved inhibition of bacterial 
toxins, there are many different multivalent scaffolds to choose from. The smartest 
designs, including a combination of templating and pre-organisation of ligand 
groups, have the potential to produce the most potent inhibitors. Future studies 
should aim to combine these principles to develop scalable, economically viable 
multivalent materials that can ultimately be applied in the clinic.  
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1.6 Outline of the project 
The project was an investigation to develop general strategies for the construction 
of nanoarchitecture by exploiting protein-ligand interactions. As seen in the previous 
section, the use of protein-ligand interactions can bring about new and complex 
nanoarchitecture, and this area of research is still young and expanding. Protein-
carbohydrate interactions are generally weak and so could be used to create a 
self-correcting, reversible system. CTB has five carbohydrate binding sites and 
there are a range of ligands with varying affinities to choose from.  
 
The main aim of the project was to create a nanoscale virus-like particle from CTB 
protein building blocks that do not naturally have any affinity for forming such a 
structure. Pentagons do not tessellate flat but instead may fold round to form a 
dodecahedron. If twelve of the CTB pentamers could be brought together they may 
form a three-dimensional dodecahedral structure, held together via protein-
carbohydrate interactions (Fig 1.29). Three main strategies were investigated 
towards this goal. The developments, pitfalls and other structures created on the 
path to this goal are discussed in the work presented here. 
 
 
Fig 1.29 (A) Dodecahedron structure and the proposed arrangement of CTB proteins (red) to form 
such a structure either with (B) trivalent ligands (blue) or (C) divalent ligands (blue).  
 
Site-specific modification of the CTB or AB5 protein was also studied. Methods for 
covalent attachment of small molecules, such as carbohydrate ligands, at either the 
CTB or CTA2 N-terminus were investigated (Scheme 1.5).  
 
 
Scheme 1.5 Potential covalent modification of CTB (red) or CTA2 (light green) with ligands (blue). 
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The first strategy for protein assembly involved direct covalent modification of the 
CTB pentamers with carbohydrate ligands. The aim was that the modifications 
would allow the self-assembly of the proteins into discrete dodecahedral structures 
(Scheme 1.6). Each pentamer would be held to another via two complementary 
noncovalent interactions, with the N-terminus attached ligand of one pentamer 
linking to the carbohydrate binding site of another pentamer.  
 
 
Scheme 1.6 Strategy for the self-assembly of CTB (red) pentamers via covalent attachment of 
carbohydrate ligands (blue). Pentamers are brought together via carbohydrate binding and arrange 
into discrete dodecahedral particles. 
 
The second strategy was to use a separate template to preorganise the CTB 
proteins into the desired conformation (Scheme 1.7). A micelle template modified 
with carbohydrate ligands was used for this goal. Once assembled, the aim was 
that the protein units could be linked together through direct modification of the CTB 
pentamers with carbohydrate ligands or by the introduction of multivalent ligands.  
 
 
Scheme 1.7 Strategy using a micelle template (green) to first preorganise the CTB pentamers (red). 
Multivalent ligands (blue) are then introduced to cross-link the proteins. 
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Finally the AB5 structure of cholera toxin could be used. The CTA2 peptide could be 
covalently modified with a metal binding group for coordination of three AB5 proteins 
(Scheme 1.8). This protein cluster could then be cross-linked with multivalent 
ligands which may also bring together multiple clusters forming larger species. 
 
 
Scheme 1.8 Using the AB5 protein. Modification of the CTA2 peptide (light green) with metal binding 
ligands (purple) to cluster the proteins before cross-linking with multivalent ligands (blue). 
 
To investigate other protein-ligand interactions, the CTA2 peptide could also be 
modified with a protein binding ligand. If this ligand could bind to a separate protein 
with multiple binding sites, such as biotin with streptavidin, then protein clusters 
could be formed through the interaction of this protein with modified AB5 (Scheme 
1.9). This small cluster could again then be cross-linked with multivalent ligands. 
 
 
Scheme 1.9 Using the AB5 protein, modification of the CTA2 peptide with biotin (brown) for binding to 
streptavidin (pink). 
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2 Building blocks 
 
 
 
 
 
The analysis and characterisation of CTB 
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The cholera toxin B-subunit pentamer (CTB) has been identified as a potential 
building block for creating nanoscale assemblies using protein-carbohydrate 
interactions. To investigate the nanoscale structures, a range of analytical and 
biophysical techniques are at our disposal. This chapter outlines the complementary 
use of a number of these techniques to analyse the CTB protein and its interactions 
with carbohydrate ligands.  
2.1 CTB expression and purification 
To use CTB as a protein building block, the protein itself first needed to be made. 
CTB was expressed in a high salt growth medium using a Vibrio sp.60 clone 
containing the pATA13 plasmid[134] (see appendices for protein and gene 
sequences). This marine vibrio species, which requires extra salt for optimal growth, 
was used because it directly exports the protein of interest out of the cells, thus 
simplifying purification. The protein can be purified from the media by precipitation. 
Initial studies were performed to optimise the procedure. 
 
Initially the method of Fontana et al. was employed.[135] This method involved 
adjusting the pH to 3.5, adding sodium hexametaphosphate and storing at 4 °C. As 
CTB is known to dissociate into monomers below pH 3.9[136], precipitation was also 
tested at pH 4.5. The addition of ammonium sulfate is another common method for 
precipitating proteins. Stirring for 1 hour in 60% w/v ammonium sulfate was 
investigated. 
 
In all cases, the precipitated protein was resuspended in phosphate buffer and 
purified on a lactosyl affinity column. CTB binds to lactosyl groups on the resin and 
so can be separated from any other material present. The CTB protein was eluted 
with a high concentration of lactose (300 mM). SDS-PAGE was used to determine 
the purity and size of CTB isolated from the affinity column (Fig 2.1). Comparison 
with the protein standards showed CTB had an apparent mass of around 40 kDa. 
This value is lower than that expected for the CTB pentamer (58 kDa) and is due to 
the compact, folded shape of the protein causing it act on the gel as if it is a smaller 
protein. Many proteins denature under the conditions of electrophoresis but CTB is 
stable enough as a pentamer that it mostly retains its tertiary structure on the gel 
with some dissociating into monomers. When boiled, the pentamer fully dissociates 
into monomers which then migrate on the gel at their expected mass of around 
12 kDa. 
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Fig 2.1 SDS-PAGE showing that CTB mostly migrates as a stable pentamer on the gel, with an 
apparent mass of around 40 kDa. When boiled, the protein dissociates into the monomers which 
migrate to the bottom of the gel. 
 
The yield of each different purification method was calculated (Table 2.1). It was 
found that precipitation by ammonium sulfate followed by purification on a lactose 
affinity column produced a high yield of 30 mg L-1. The yield was reduced by a third 
when sodium hexametaphosphate was used at pH 3.5 and when the pH was raised 
to 4.5 a further decrease in yield was found. 
 
Table 2.1 Yields of CTB from various precipitation methods. 
Precipitation method Yield / mg L-1 
Sodium hexametaphosphate pH 3.5 10 
Sodium hexametaphosphate pH 4.5 2 
Ammonium sulfate 60% w/v 30 
 
Mass spectrometry (MS) was used to confirm that it was indeed CTB being 
produced from the bacteria. The pentamer did not survive intact in the mass 
spectrometer due to the denaturing conditions of the solvents used in the 
electrospray process and so the spectrum showed only peaks for the individual 
monomeric B-subunits. A range of ions were observed for different charge states of 
the monomer and these could be deconvoluted to calculate the molecular weight. 
The mass measured by ESMS for CTB was 11642.9 Da (calculated 11642.9 Da) 
(Fig 2.2 A). 
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Fig 2.2 (A) Mass spectrum of the monomeric B-subunit showing a range of charge states and (B) the 
deconvoluted high resolution spectrum. 
2.2 CTB analysis 
The MS method used here does not give information on protein oligomerisation and 
SDS-PAGE can overestimate the amount of monomer present due the denaturing 
conditions. Therefore other techniques are needed to confirm the size of the 
proteins and any assemblies that will be made. 
2.2.1 Size exclusion chromatography (SEC) 
SEC can be used to separate proteins of different masses and thus reveal how 
many different species are present in a mixture. The components are separated 
based on their size and shape by using a bed of porous beads. The stationary 
phase contains tunnels of different sizes that will allow the passage of different 
sized molecules. Therefore samples with a smaller size than the pore size will have 
a longer path and retention volume, than larger particles that cannot enter all the 
pores. However, samples that are too large to enter any pores will elute at the void 
volume and cannot be analysed by SEC. 
 
To calibrate the SEC column (superdex™ 200 using a Pharmacia ÄKTA FPLC 
system) a number of calibrants of different masses were first passed through the 
column (Fig 2.3 A). The known mass of each calibrant was plotted against the ratio 
of its retention volume (Ve) to the void volume (Vo) of the column and an exponential 
function was fitted to the data (Fig 2.3 B). The void volume was calculated as the 
retention volume for Blue Dextran which has a molecular weight of 2000 kDa and is 
unretained by the column. The R2 value for the trend line of the graph was 0.98 and 
therefore shows a good correlation between the masses and their retention 
volumes. Subsequent analysis of proteins or their assemblies during SEC 
purification allowed estimation of the mass of the assembly. The CTB pentamer 
was found to have a SEC retention volume of 17.4 mL (Fig 2.3 C). When placed on 
(A)                                                    (B) 
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the calibration graph, the actual retention volume for CTB compares well to the 
expected value. 
 
 
 
 
Fig 2.3 (A) Traces for each calibrant for SEC. (B) A calibration graph for the SEC column showing the 
molecular weights of the calibrants plotted against the ratio of retention volume (Ve) to void 
volume (Vo). (C) Chromatogram for CTB showing a retention volume of 17.4 mL for the pentamer. 
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2.2.2 Analytical Ultracentrifugation (AUC) 
Sedimentation velocity AUC experiments were conducted to obtain mass 
information and assess the oligomerisation state of CTB.  
 
 
 
 
Fig 2.4 AUC sedimentation coefficient distribution of CTB performed at a rotor speed of 35,000 rpm, 
rotor temperature of 20 °C and scanned at 280 nm. (A) The absorbance data measured across the cell 
length. Measurements taken over time, from blue to red, show the gradual sedimentation of the 
absorbing species. (B) The c (s) plot shows a single species at 4.1 S which corresponds to a mass of 
50 kDa for the CTB pentamer. 
 
AUC measures the absorbance, and thus protein concentration, across the sample 
cell as it is centrifuged. Early in the experiment the protein sample is evenly 
distributed across the cell but as the experiment progresses a concentration 
gradient is built up from the sedimentation and diffusion of the particles (Fig 2.4 A). 
The position of the concentration boundary is monitored as a function of time, as 
the sample becomes sedimented. The rate of sedimentation gives information on 
the mass and the absorbance gradient gives information on particle shape. The 
Svedberg equation can be used to calculate size and shape information of the 
particles (Equation 2.1). The Lamm equation describes the sedimentation and 
diffusion of a particle under ultracentrifugation (Equation 2.2). 
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Equation 2.1     
       
   
 
        
  
 
 
   
 
 
Equation 2.2   
  
  
 
 
 
  
  
   
  
  
         
 
where s is the sedimentation coefficient, M is the mass of the molecule, v is the partial specific volume 
(buoyancy), ρ is the density of the solution, NA is Avogadro’s number, f is the frictional coefficient, D is 
the diffusion coefficient, T is the temperature, R is the gas constant, u is the radial velocity of the 
particle, r is the radius, w is the angular velocity, c is the particle concentration and t is the time. 
 
The Sedfit software[137] fits the parameters from the Svedberg and Lamm equations 
to create a c (s) plot (Fig 2.4 B) which shows the relative concentration of species 
with a given sedimentation coefficient, and from this calculates the mass of the 
particles. A sample of CTB was analysed at a monomer concentration of 800 µM 
and a single species was seen with a sedimentation coefficient of 4.1 S which 
corresponds to a mass of 50 kDa (Fig 2.4). 
2.2.3 Dynamic light scattering (DLS) 
DLS allows the hydrodynamic diameter to be calculated to give another 
measurement for the size of the protein. In a DLS experiment the sample is 
illuminated by a laser and the intensity of the scattered light fluctuations is detected 
at a given angle. Light scattered by different particles can be in phase or out of 
phase leading to higher or lower intensity. Particles diffuse in a liquid due to 
Brownian motion and the rate at which the scattering intensity fluctuates is related 
to the speed of motion and therefore the size of the particles (Fig 2.5). 
 
 
Fig 2.5 The different fluctuations in DLS scattering intensities over time for large, slow moving particles 
or small, fast moving particles. 
 
The hydrodynamic diameter is calculated from the velocity of the Brownian motion 
for the particle defined by its translational diffusion coefficient, D. The hydrodynamic 
diameter can be calculated using the Stokes-Einstein equation (Equation 2.3). The 
51 
 
measurement obtained is for the diameter of a sphere that has the same 
translational diffusion coefficient as the particle and so may lead to inaccuracies for 
non-spherical particles and proteins. 
 
Equation 2.3        
  
    
 
 
where d(H) is the hydrodynamic diameter, k is the Boltzmann constant, T is the temperature,   is the 
viscosity of the medium and D is the translational diffusion coefficient. 
 
An auto correlator measures intensity fluctuations. The signal is compared with 
itself at varying time intervals to construct the correlation function, G(τ) (Fig 2.6). 
This function can be described as an exponential decay function dependent on the 
translational diffusion coefficient of the particle in solution (Equation 2.4). As the 
signal changes more slowly the correlation persists for longer with large particles 
compared to small particles. 
 
 
Fig 2.6 The difference in correlation decay for large and small particles over time. 
 
Equation 2.4                    
 
where A is the baseline of the function, B is the intercept, τ is the time difference of the correlator and 
   is the decay rate (Equation 2.5). 
 
Equation 2.5         
 
where q is the wave vector (Equation 2.6).  
 
Equation 2.6     
   
 
   
 
 
 
 
where n is the refractive index of the dispersant, λ is the wavelength of the laser and θ is the scattering 
angle. 
 
A sample of pure CTB at a concentration of 100 µM was filtered (400 nm filter) and 
analysed by DLS. The result showed a single peak corresponding to a particle with 
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a diameter of 5.6 nm (Fig 2.7). As CTB is not completely spherical this 
measurement compares well with the known dimensions of CTB of roughly 6.5 × 
3.5 nm determined by x-ray crystallography.[138]  
 
 
Fig 2.7 DLS measurement for CTB showing a single peak of diameter 5.6 nm. 
 
2.2.4 Atomic Force Microscopy (AFM) 
Whilst the biophysical techniques discussed above can give a good estimate of the 
size of particles in solution, being able to visualise the proteins directly would be 
much preferable.  
 
In an AFM tapping mode experiment, a cantilever is made to vibrate at a resonant 
frequency and the amplitude of the vibration is measured via a laser (Fig 2.8). As 
the cantilever moves over the surface and encounters bumps, the amplitude of 
oscillation decreases and a feedback system adjusts the height of the cantilever to 
maintain a constant amplitude. This feedback allows a height representation of the 
surface to be constructed. Details of the size and shape of particles on a surface 
can be seen down to the low nanometre scale. Measuring the size of proteins 
pushes AFM to its detection limits, but it should be possible to resolve larger protein 
assemblies and structures. 
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Fig 2.8 The AFM set-up showing the feedback system from a laser reflecting off the cantilever.
[139]
  
 
It has been shown previously that CTB will spontaneously adhere to a mica surface 
under aqueous conditions which allowed AFM experiments to be conducted to 
image the protein.[140] CTB protein in a citrate phosphate buffer (pH 5.0) was 
incubated for 60 min and imaged. Scanning at pH 5 meant that the sample was two 
pH units away from the isoelectric point of CTB, so the protein would have a net 
positive charge and therefore interact more strongly with the negatively charged 
mica surface. Closely packed proteins were seen at a reasonable resolution (Fig 
2.9 A). Expanding the image revealed the round shape of the CTB pentamer with 
some particles exhibiting a small hole at the centre (Fig 2.9 B & C).  
 
Bilayers can be laid down on a mica surface for AFM imaging. GM1 glycolipids 
were incorporated into bilayers and used to bind CTB to the surface. This different 
way of capturing CTB on a surface would guarantee all the proteins were of the 
same orientation and could also show any assemblies formed by interactions with 
the top or sides of the proteins. Flat networks or vertical constructions could 
potentially be visualised by anchoring a CTB unit to the surface in this way. These 
networks could even be manipulated on the surface and imaged as the structures 
are assembled and disassembled. 
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Fig 2.9 AFM image of CTB in citrate-phosphate buffer, pH 5, on a mica surface. (A) The pentamers 
are closely packed and reasonably resolved. (B) An expanded region of the image reveals the round 
shapes more clearly. (C) The expanded image cross section allows the depth of the structures to be 
seen (boxed) with a small recess in the centre and of appropriate size for a CTB pentamer (~6.5 nm). 
 
 
Fig 2.10 Structure of the DOPC phospholipid. 
 
A lipid bilayer of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) (Fig 2.10) was 
prepared in PBS buffer, applied to a mica surface and imaged in tapping mode. A 
smooth single bilayer was observed with few defects (Fig 2.11 A). 
 
50 nm 200 nm 
A B 
C
A 
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Fig 2.11 AFM images of (A) a flat lipid bilayer of DOPC and (B) a bilayer containing GM1, with CTB 
bound to the surface. A region had been cleared of CTB by applying force to the surface (boxed 
region). (C) Height profile for line across the scan in B. The height difference between the points 
marked with red triangles is 3.04 nm, which corresponds to the height of a CTB protein flat on the 
surface. 
 
Another lipid bilayer of DOPC was prepared on a mica surface again in PBS buffer 
but with 1% GM1 incorporated. CTB was applied to the surface in PBS buffer and 
bound to the GM1 on the surface. A surface was observed with some areas ~3 nm 
higher. The higher areas could be moved by zooming in and applying force in an 
area. After zooming out, a square shaped region of the lower surface could be 
seen, where the excessive force had been applied (Fig 2.11 B). The height profile 
analysis showed a height difference of 3.04 nm between the points marked. The 
higher layer was consistent with CTB bound on the surface, but the resolution was 
not sufficient for the individual pentamers to be observed clearly. Although the 
individual protein pentamers could not be imaged clearly by this method, larger 
structures should prove easier to visualise with AFM. 
 
2.2.5 Characterisation of protein assemblies 
SEC can separate a mixture and give a rough estimate of the size of proteins. AUC 
gives more accurate mass information and can show the number of different size 
species in solution. The size of particles can also be found using DLS which is a 
2 µm 
A B 
250 nm 
C  
56 
 
faster analysis and uses a smaller sample than the other techniques. These three 
techniques are complementary and a powerful array of techniques for analysing 
individual protein structures and higher assemblies in solution. 
 
MS is vital to obtain a quick and accurate mass for CTB, to show modifications 
made and to what extent these reactions have proceeded. From SDS-PAGE the 
size of the structures can be seen and can also provide an indication of whether the 
protein has denatured or whether larger aggregates are beginning to form. SEC 
also gives another measure of the size of structures present and can be used to 
purify CTB or larger supramolecular particles. Finally, AFM allows imaging of the 
protein structures and so should present ultimate proof of the size and shape of the 
nanoscale protein assemblies. 
2.3 Binding site studies with isothermal titration calorimetry (ITC) 
CTB has 10 natural carbohydrate binding sites. If we wish to take advantage of this 
ligand binding ability then these sites need to be fully understood. Five blood group 
oligosaccharides bind to the top-side face of CTB and five GM1os groups bind to 
the bottom face (Fig 2.12). Both sets of carbohydrates are equally spaced around 
the five-fold symmetry axis of the protein (Fig 2.13). 
 
 
Fig 2.12 CTB binding ligands. The ganglioside GM1 1 and the GM1os 32 bind to the bottom face of 
CTB whereas blood group O (lewis y) 33 binds to the top-side of CTB. 
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Fig 2.13 (A) Bottom, (B) Top and (C) side view of CTB with carbohydrates bound. Five GM1 
oligosaccharides 32 (blue) bind to the bottom face and five blood group O structures 33 (yellow) bind 
the the top side evenly distributed around the five-fold symmetry of the protein. 
 
Isothermal titration calorimetry (ITC) can be used to measure the affinity of the 
carbohydrate interactions. From a single titration a binding affinity, Kd, the enthalpy 
change, ΔH°, the entropy change, ΔS°, and the stoichiometry of a binding 
interaction can be found. The calorimeter has two cells, a reference cell and a 
sample cell. The cells are controlled by independent heaters and when samples are 
mixed during the titration heat is released for which the heaters compensate by 
supplying less power to the sample. The raw data shown is the difference in power 
between the heaters which is then integrated to give the Wiseman binding isotherm.  
 
The shape of the curve describes the change in enthalpy per mole of ligand titrated 
into the protein and from this the binding affinity can be found. For a simple single-
site model (Equation 2.7) the fitting parameters are varied in the Wiseman isotherm 
to find the best fit for the curve (Equation 2.8).[141] The equation relates the stepwise 
change in heat of the system for a given change in ligand concentration to the ratio 
of ligand to protein concentration. The shape of the curve depends upon the c value 
which is a ratio of protein concentration to the Kd (Equation 2.9). Low c value curves 
possess a hyperbolic curve and high c value curves show a sigmoidal shape (Fig 
2.14). 
 
Equation 2.7  
 
 
Equation 2.8 
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Equation 2.9 
  
 
       
 
    
  
        
 
where Q is the heat of the system, [X]t is the concentration of ligand after injection t and [M]t is the 
protein concentration after injection t. ΔH° is the enthalpy change, V0 is the effective volume of the cell, 
Kd is the dissociation constant and c is a ratio of the protein concentration to the dissociation constant. 
 
 
 
Fig 2.14 (A) The shape of the titration curve varies with the c value. (B) If the isotherm is depicted as a 
ratio of ligand concentration and dissociation constant then the hyperbolical curve for low c value 
systems is shown more clearly. The red and blue curves are magnified to highlight the similarity in 
curve shapes.
[141]
  
 
2.3.1 GM1os derivatives 
GM1 adhesion is the mechanism by which CTB binds to cells in the body. The five 
binding sites are evenly spaced around one face of the protein and a single GM1os 
interaction has been shown to have a high affinity with a Kd of 43 nM.
[89] Such a 
high affinity would provide an excellent basis for the binding of other units or 
multivalent ligands to CTB. 
 
To confirm the affinity of GM1os for CTB, the oligosaccharide first had to be 
purified. Ceramide glycanase (Takara Bio Inc) was used to cleave the ceramide 
chain from GM1 1 enzymatically resulting in the GM1os 32. The oligosaccharide 
was then separated from the ceramide lipid by reverse phase chromatography. 
Analysis by LC-MS showed the pure GM1os product 32 to have a mass of 997.6 Da 
(calculated 997.3 Da). 
 
(A)       (B) 
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Isothermal titration calorimetry (ITC) was used to check the CTB protein was 
functional. The GM1os (50 µM) ligand was titrated into a solution of CTB (5 µM) in 
the cell (Fig 2.16). The binding affinity was calculated and the interaction was found 
to have a Kd of 22 nM which agreed well with the literature value of 43 nM
[89] (Table 
2.2). The GM1os binds with a very high affinity for a protein-carbohydrate 
interaction, but fragments of GM1os are known to bind with a much reduced affinity, 
with the terminal galactose found to be the most important moiety in the GM1os 
interaction[89] and so ITC was performed with α-methyl galactoside 34 (200 mM) 
titrated into CTB (350 µM). This monosaccharide gave a much reduced affinity with 
a Kd of only 12 mM, again in close agreement with the millimolar affinity reported 
previously.[89]  
 
 
Fig 2.15 Galactose derivatives for ITC analysis. 
 
Another galactose derivative, meta-nitrophenyl α-D-galactopyranoside (MNPG) 5 
(15 mM), was titrated into CTB (170 µM) and a Kd of 550 µM was found (Fig 2.16) 
showing a 20 times increase in affinity from the simple galactoside 34. This result 
for MNPG 5 was within the same order of magnitude as the Kd of 175 µM, which 
was found by ITC for 5 binding to LTB.[94] 
 
Table 2.2 ITC data for GM1os and galactose derivatives binding to CTB. 
a
Stoichiometry was set at 
1.00 as it could not be varied in the fitting model.
[141]
 
ligand Kd / nM ΔH° / kcal mol
-1 n 
GM1os 32 22.0 ± 2.61 -18.20 ± 0.13 1.01 
34 (12.2 ± 0.69) × 106 -15.39 ± 1.71 1.00
a 
5 (550 ± 10.0) × 103 -7.12 ± 0.06 1.00a 
 
The galactose ligands tested here, along with GM1os, showed a wide range of 
possible affinities that can be achieved by ligands for CTB. In this project we will 
take advantage of the variation in the binding affinities to design ligands with 
different properties. Lower affinity ligands will give a greater potential for reversibility 
and self-correction in the self-assembling systems. Furthermore, it may be possible 
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to use lower affinity ligands to assemble structures initially and displace them with 
higher affinity ligands to induce a change or reorganisation of the assembly. 
 
 
Fig 2.16 ITC titrations of CTB binding ligands. (A) The weak interaction of α-methyl galactoside 34 
(200 mM) titrated into CTB (350 µM), (B) the stronger interaction of MNPG 5 (15 mM) titrated into CTB 
(170 µM) and (C) the very strong interaction of GM1os 32 (50 µM) titrated into CTB (5 µM).  
 
 
 
 
(A)           (B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(C) 
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2.3.2 Blood group oligosaccharides 
A manuscript based on the following section has been published: P. K. Mandal, 
T. R. Branson, E. D. Hayes, J. F. Ross, J. A. Gavín, A. H. Daranas and W. B. 
Turnbull, “Towards a Structural Basis for the Relationship Between Blood Group 
and the Severity of El Tor Cholera, Angew. Chem. Int. Ed., 2012, 51, 5143-5146”.[88] 
 
It is known that the severity of cholera caused by the El Tor biotype of V. cholerae is 
blood group dependent, but the reason for this observation is unknown.[142] Those 
with blood group O are affected more severely than those in A or B. However, there 
is no clear dependence for the O1 classical biotype of V. cholerae.[143] Krengel and 
co-workers published a crystal structure showing LTB in complex with a blood 
group A-Lewis-y oligosaccharide[144] and predictions were made that O- and B-
blood group derivatives of the Lewis-y oligosaccharide would not bind to LTB.[145] 
Two oligosaccharides were synthesised to test this hypothesis, the O- and B-blood 
group derivatives 35 and 36 respectively (Fig 2.17) (synthesised by Dr Pintu 
Mandal). The B-blood group was chosen as it had been suggested that this 
oligosaccharide has a more pronounced affect on the severity of El Tor Cholera 
than the A-blood group. 
 
 
Fig 2.17 Blood group tetrasaccharide derivative O 35 and pentasaccharide B 36. 
 
A combination of ITC and saturation transfer difference (STD) NMR was used to 
confirm the binding of each carbohydrate structure with LTB. Similar affinities of 7.5 
mM and 5.0 mM were found for 35 and 36 respectively (ITC performed by Dr Pintu 
Mandal and STD-NMR performed by Dr Antonio Daranas). It was found that El Tor 
CTB bound to blood group O 35 but not to blood group B 36. STD-NMR was used 
to confirm which ligands were binding (Fig 2.21). The technique involves irradiating 
the nuclei on the protein and observing the magnetisation transferred to the ligand. 
The technique is particularly good for weakly binding ligands that are in fast 
exchange on the NMR timescale.  
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There are differences in the amino acid sequence, found in the carbohydrate 
binding pocket, between LTB and El Tor CTB. There are four differences between 
LTB and El Tor CTB in this region; S44N, N94H, S4N and T47I (Fig 2.18). It was 
proposed that the T47I difference was responsible for the lack of binding to blood 
group B with El Tor CTB. This change would result in the loss of a hydrogen bond 
from the threonine hydroxyl group to the 2-NHAc/OH group of carbohydrate residue 
E (Fig 2.18) and introduce a potential steric clash with the ethyl group of the 
isoleucine. 
 
Fig 2.18 Overlay of LTB structure (light blue; 2O2L.pdb) and a model of El Tor CTB (yellow) 
constructed using the structure of classical biotype CTB mutant (3CHB.pdb) by introducing appropriate 
mutations at positions 18, 47 and 94 (model realised using pymol). The position of blood group B 
(green) is based on the coordinates of analogue 3b bound to LTB (2O2L.pdb). Q3’ and N/S4’ are 
residues in the neighbouring B-subunit.
[88]
 
 
My role in the project was to test the key hypothesis that the T47I mutation was 
responsible for determining if the oligosaccharides bound to El Tor CTB. Plasmid 
pSAB2.2T (see appendix) contains the CTB gene for expression in E. coli. Site-
directed mutagenesis was performed on this plasmid to introduce a threonine 
residue at position 47, creating plasmid pTRB-I47T. The binding of the CTB mutant 
produced from this plasmid could be compared to the wild-type El Tor CTB. E. coli 
XL10 competent cells were transformed with the new plasmid, a plasmid prep was 
then performed to purify the DNA for sequencing and for transformation into E. coli 
C41 cells for over-expression. The new protein was expressed by induction with 
IPTG and growth at 30 °C for 24 h. After purification by ammonium sulfate 
precipitation of the media, a nickel affinity column and then SEC, a yield of 2.9 mg 
L-1 was obtained. SDS-PAGE was performed to check the protein expression and 
purification (Fig 2.19). 
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Fig 2.19 SDS-PAGE showing the expression of CTB I47T and purification by Ni affinity 
chromatography and SEC. 
 
ITC titrations were performed with oligosaccharide 35 or 36 (32 mM) titrated into the 
I47T CTB mutant (120 µM) (Fig 2.20). The expected binding with 35 was found to 
have a Kd of 1.0 mM and an enthalpy change of -2.3 kcal mol
-1, similar to the 
interaction with wild-type CTB (Table 2.3). A slight buffer mismatch was seen in the 
titration due to the presence of D2O from lyophilising the compound from an NMR 
sample, therefore a control titration was performed with the corresponding amount 
of D2O which accounted for the large heat of dilution in the data. The binding of 
pentasaccharide 36 was inconclusive with direct titrations, possibly due to a low 
enthalpy for the interaction. Therefore a competition titration was performed with 
pentasaccharide 36 premixed with CTB I47T. Tetrasaccharide 35 was titrated into 
the mixture and a binding interaction was observed with a decreased enthalpy 
change indicative of competitive binding. 
 
Table 2.3 ITC results for oligosaccharides 35 and 36 binding to LTB, El Tor CTB and CTB I47T. 
Protein Ligand Kd / mM ΔH° / kcal mol
-1 
LTB O 35 7.5 ± 1.9 -5.8 ± 0.5 
CTB I47T O 35 1.0 ± 0.3 -2.3 ± 0.8 
El Tor CTB O 35 1.8 ± 0.2 -1.3 ± 0.2 
LTB B 36 5.0 ± 0.5 -8.5 ± 0.9 
El Tor CTB B 36 ẋ ẋ 
CTB I47T B 36 Binding detected Binding detected 
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Fig 2.20 ITC titrations with I47T CTB mutant. (A) titration of tetrasaccharide 35 into CTB I47T (black) 
with corresponding dilution experiment (red) and control titration of 180 mM D2O into water (blue). (B) 
Titration of tetrasaccharide 35 into CTB I47T (black) overlaid with a competition titration experiment in 
which tetrasaccharide 35 was titrated into a mixture of I47T CTB premixed with 5.5 mM 
pentasaccharide 36 (green).
[88] 
 
Although it was not possible to obtain a binding affinity for the interaction of the I47T 
mutant with oligosaccharide 36 by ITC, STD-NMR analysis (performed by Dr 
Antonio Daranas) confirmed that the I47T mutant could bind to both tetrasaccharide 
35 and pentasaccharide 36 (Fig 2.21). It was concluded that the structural basis for 
the selective binding by El Tor CTB was due to the isoleucine residue at position 
47. This mutation prevents binding of the protein to blood group B, whereas with 
blood group O the toxins could be concentrated on the cell surface by blood group 
binding, which may act as a precursor to endocytosis via GM1os binding. Whilst 
these individual interactions are quite weak, multivalent presentation may give rise 
to a strong and important binding, which leads to the difference in the severity of 
cholera, from the El Tor biotype. 
 
A          B 
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Fig 2.21 STD-NMR data showing the binding of O-blood group 35 to (A) LTB, (C) CTB and (E) CTB 
I47T. The binding of B-blood group 36 was seen with (B) LTB and (F) CTB I47T but not with (D) CTB. 
 
2.4 Conclusions 
The CTB protein can be expressed in a high yield and its size can be analysed by a 
variety of biophysical techniques. The carbohydrate binding sites have been well 
studied and the GM1os site was found to be especially suitable for potential ligand 
binding due to its location on the protein and high affinity interaction. 
 
A combination of MS, SDS-PAGE, SEC, AUC, DLS, AFM and ITC can be used to 
characterise the size and shape of protein structures and ligand interactions.  
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3 Connecting the parts 
 
 
 
 
 
CTB modification with carbohydrate ligands 
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The first strategy for assembling the proteins was to attach a self-complementary 
ligand at a suitable position on CTB. The ligands could cross-link adjacent 
pentamers via non-covalent interactions, with the ligand group attached to one 
pentamer binding to the carbohydrate binding site of another pentamer which in turn 
could provide another ligand to bind back (Scheme 3.1). Each of these divalent 
interactions should provide a constraint on the assembly process which could direct 
the assembly into the desired structure. 
 
 
Scheme 3.1 Formation of a dodecahdron via protein-ligand interactions with modified CTB. 
 
3.1 Protein modification 
The N-terminus of CTB is situated on the protein surface towards the bottom of the 
side and almost directly between two of the GM1 binding sites (Fig 3.1). It has been 
shown that modifications at this position on CTB do not affect ligand binding to the 
protein.[146] It was therefore decided that this position would be perfect for 
modification as it provides five identical sites, equally spaced around the edge of 
CTB. If a galactose or larger GM1 oligosaccharide was attached at this position it 
could bind to another CTB unit and bring multiple copies together to form a larger 
protein complex. The N-terminal amino acid in CTB is a threonine residue which 
bears a unique amino alcohol group. Vicinal diols and, even more so, amino 
alcohols are easily oxidised with periodate to give an aldehyde.[147, 148] This strategy 
was previously applied by Chen et al. for the N-terminal modification of CTB.[146] 
The resultant aldehyde could then be reacted with an aminooxy functional group 
forming an oxime bond. Therefore any ligand of interest could be synthesised with 
an aminooxy group to be attached to the N-terminus of CTB. 
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Fig 3.1 A surface representation of CTB with the position of the N-termini (yellow) on CTB seen 
between the binding sites with GM1os (blue). 
 
3.1.1 Oxidation of the N-terminus 
The oxidation reaction was performed on CTB at a concentration of 200 µM using 
NaIO4. The reaction was found to proceed to completion after only 5 minutes with 5 
equivalents of NaIO4. The oxidised CTB protein (CTBox) was then purified on a 
PD10 G-25 minitrap column. 
 
MS was used to confirm the successful reaction. The product was found to have a 
mass of was 11616.8 Da (calculated 11616.2 Da) indicating a mass loss of 27 Da 
which corresponded to the hydrated form of the CTBox product (Fig 3.2) (Scheme 
3.2). The aldehyde was prone to hydration in aqueous solution due to the 
neighbouring carbonyl group which makes the aldehyde carbon more electrophilic. 
Fortunately, hydration is an equilibrium process and therefore reversible so that the 
aldehyde was still accessible for further reactions. 
 
   
Fig 3.2 Mass spectrum of CTB and CTBox in the hydrated form showing a small change for each 
charge state observed by ESMS. 
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Scheme 3.2 Oxidation reaction on the N-terminus of CTB and the hydration of the aldehyde group. For 
simplicity only one subunit is shown in the reaction, whereas in reality all five subunits react. 
 
It has been reported that once the N-terminus of CTB has been oxidised to an 
aldehyde group, a slow cyclisation process can lead to the formation of an 
unreactive hemiaminal.[149] The proline residue at position two in the protein adopts 
a conformation that brings the aldehyde back into close proximity with the amide 
nitrogen of the third residue (Scheme 3.3). The cyclised form has an identical mass 
to the oxidised protein and so it is impossible to differentiate between these two 
species by MS. But this problem can be avoided if further reactions are performed 
immediately. 
 
 
Scheme 3.3 The cyclisation of the N-terminus of CTBox. 
 
3.1.2 Oxime formation on the N-terminus 
An aldehyde functional group on the N-terminus of CTBox can react with an 
aminooxy containing molecule to form an oxime group which is hydrolytically 
stable.[150] A simple aminooxy compound was synthesised to test this reaction on 
the protein. N-hydroxysuccinimide ester 37 was reacted with methyl amine to give 
amide 38 which was deprotected using trifluoroacetic acid (TFA) to yield oxyamine 
38a (Scheme 3.4). The compound is labelled with an a, after removal of the Boc 
group, to represent the deprotected version. This nomenclature will be used for all 
subsequent oxyamine compounds. 
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Scheme 3.4 Synthesis of amide 8. 
 
CTB was oxidised as before and then immediately in the same reaction vessel 
without any further purification, amide 38a (15 equivalents to B-subunit) was added 
to the solution of CTBox at 200 µM and the pH was lowered to 2.5 by the addition of 
acetic acid (Scheme 3.5). After 30 min a sample was analysed by ESMS which 
gave a mass of 11684.5 Da (calculated 11684.3 Da). No oxidised protein was 
observed by ESMS and therefore the reaction was taken to have gone to 
completion with the successful attachment of the small amide to form protein 
CTB(38) (Fig 3.3). This reaction was simple, quick and the oxidation and oxime 
formation could be done consecutively without intermediate purification.  
 
 
Scheme 3.5 The modification of CTBox with ligand 38a to form an oxime bond 
 
 
 
Fig 3.3 Mass spectrum of the new modified protein CTB(38) compared to CTBox. 
 
SDS-PAGE was performed to determine the size of the modified protein (Fig 3.4). 
The gel showed that the protein had fully denatured into monomers rather than the 
usual pentamer due to the acidic conditions of the reaction. SDS-PAGE is 
performed under slightly denaturing conditions and so the result of only monomers 
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being observed may not be wholly representative of the sample in solution. 
However, it has been seen that CTB denatures into monomers below pH 4.[136] 
There are known methods for renaturing the protein from acidic conditions including 
a quick buffer change to a neutral pH and incubation at this new pH[151]. The original 
study by the Rose group to modify CTB with an oxime bond used SEC to purify 
their modified proteins.[146] Before purification, guanidinium hydrochloride was 
added, which denatures and solubilises the proteins. This study showed that it was 
possible to recover the pentamers with SEC even after deliberately denaturing 
them. However, it would be preferable to keep the pentamers intact as without 
stable modified pentamers there could be no interaction available with the GM1os 
binding sites and no formation of larger protein assemblies. Hirst and co-workers 
showed that denaturing CTB for any significant amount of time had a detrimental 
effect on the pentamer yield after renaturing.[152] This is due to a proline residue at 
the protomer interface that can isomerise when CTB is in the monomeric form and 
then prevents the pentamer reforming. 
 
With the introduction of carbohydrate ligands, protein-ligand interactions should 
occur as soon as they are attached. However, if the proteins are in a denatured 
state they will be unable to bind ligands, thus preventing any possible interactions 
and assemblies. The stability of the pentamers was paramount to the project goal; 
without stable modified pentamers there could be no interactions possible with the 
GM1os binding sites and therefore no formation of larger protein assemblies. 
 
  
Fig 3.4 SDS-PAGE of the modified protein showing that following the acidic reaction conditions the 
protein was no longer stable as a pentamer on the gel. 
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To keep the CTB pentamer intact, the pH of the oximation reaction was raised to 
pH 4. CTB was oxidised as before at pH 7 and then transferred into a sodium 
acetate buffer at pH 4 via a centrifugal concentrator. Amide 38a (15 equivalents) 
was added to this solution and the reaction was monitored by ESMS. After 4 hours 
it was found that the reaction had progressed only minimally and so it was 
concluded that the conditions were not acidic enough for the reaction to proceed 
successfully. 
 
The modification needed to be performed at a more neutral pH to be sure that CTB 
did not denature, but another procedure had to be found. Oxime bond formation can 
be enhanced by the addition of aniline, which has been shown to catalyse the 
reaction.[52] Dirksen et al. demonstrated that in aqueous solution at pH 4.5 the rate 
of ligation of two peptides increased 400-fold when aniline was present and at pH 7 
a moderate increase of 40-fold could be achieved. Under acidic conditions the 
oxime reaction progresses by nucleophilic attack by the aminooxy group on the 
protonated carbonyl followed by dehydration. The concentration of the protonated 
carbonyl is however extremely low at neutral pH due to its low pKa in the range -4 to 
-10. An aminooxy amine has a pKa, of 4.6 due to the α-effect, which is similar to 
aniline. The pKa of the Schiff base formed by the aniline is only 2 units lower 
whereas that of the imine formed by an aminooxy is 5-6 units lower. This means 
that the aniline Schiff base is more significantly protonated at a given pH and can 
provide a more reactive intermediate for the oxyamine to attack. This reaction leads 
to an unprotonated oxime which is unreactive to hydrolysis above pH 2 (Scheme 
3.6). 
 
 
Scheme 3.6 Aniline catalysis of the oxime bond formation on the N-terminus of CTB. 
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The oxime reaction was performed at pH 7 with amide ligand 38a. CTB was 
oxidised as before and amide ligand 38a was added (15 equivalents). The sample 
was split in two and aniline was added to one batch to a final concentration of 100 
mM. After 3 h in the aniline solution, ESMS showed a mass of 11684.0 Da 
(calculated 11684.3 Da) for CTB(38) and so the protein had fully reacted. The 
sample at pH 7 with no aniline present showed only a mass of 11616.6 Da 
(calculated 11616.2 Da) for CTBox indicating that it had not reacted at all. Although 
the reaction was a little slower, oxime formation could be achieved effectively at pH 
7 with the aniline catalyst present. 
 
The reaction was analysed by SEC (Fig 3.5) and the fractions collected were 
submitted to analysis by SDS-PAGE to confirm their size (Fig 3.6). Electrophoresis 
confirmed that CTB stayed mostly as a pentamer during the reaction and SEC 
showed the pentamer could be isolated. The protein was also separated from any 
unreacted ligand by SEC, which meant this method could be used not only for 
analysis but also purification of the modified proteins. 
 
 
Fig 3.5 Chromatogram showing CTB(38). The protein appears to remain as a stable pentamer under 
the new conditions. 
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Fig 3.6 SDS-PAGE showing CTB(38), modified at pH 7 with aniline as a catalyst, remained mostly as 
pentamer during the reaction and after SEC purification the pentamer was isolated. 
 
3.1.3 Introducing carbohydrate ligands 
A carbohydrate ligand was synthesised for attaching to the protein N-terminus. For 
the initial studies a galactose moiety was chosen as this has a low affinity for CTB 
and therefore could provide a reversible interaction. Low affinity ligands should be 
less prone to inducing protein dimerisation and should allow reversible self-
correction of undesirable interactions that could lead to aggregation. Galactose 
ligands could also be displaced from CTB by monovalent GM1os and so the 
disassembly of any structures formed should be possible in this way. With five 
carbohydrate groups attached to CTB, these ligands would be able to make five 
interactions with other proteins whilst the binding sites would accept another five 
ligands from other proteins. Many simultaneous interactions would take place 
forming a strong protein complex. The individual components would be both 
pentavalent acceptors and donors (Scheme 3.7). 
 
 
Scheme 3.7 Modified CTB with five carbohydrate groups. 
 
A chromophore was included in the initial ligand design allowing the attachment of 
the ligand to be monitored by UV spectroscopy and as an extra tag to allow 
detection of only the components containing this label (Fig 3.7). A dansyl group was 
chosen that absorbed at 330 nm, different to the 280 nm absorption of the protein. 
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An amino acid linker section was included which could be altered in a modular 
fashion to create longer or shorter ligands. 
  
 
Fig 3.7 Structure of galactose ligand 39. 
 
Ligand 39 was constructed by solid phase peptide synthesis (SPPS) (synthesised 
by Dr Martin Fascione). Following removal of the Boc group, galactose ligand 39a 
was then reacted with CTB to see if the carbohydrate groups could encourage 
assembly of the proteins into larger structures. The reaction conditions at neutral pH 
(100 mM aniline at pH 7) were used to react galactose ligand 39a (10 equivalents) 
with CTBox at 200 µM monomer concentration. The oxime formation was monitored 
by ESMS and appeared to proceed more slowly, but after 24 h ESMS showed a 
mass of 12593.4 Da (calculated 12593.2 Da) indicating a complete reaction to form 
CTB(39) (Fig 3.8 B). The reaction solution had however turned slightly cloudy with 
some precipitation and so the mixture was centrifuged at 13,000 rpm for 1 min to 
remove the insoluble fraction. SDS-PAGE was then performed on the remaining 
solution (Fig 3.8 A) which showed the modified protein was still mostly in its 
pentameric form. 
 
 A sample of the soluble fraction was also was taken for analysis by SEC (Fig 3.9) 
and the trace showed pentameric modified protein. The dansyl group on the ligand 
absorbs at 330 nm and so this wavelength was also monitored by SEC. A peak with 
an absorbance at 330 nm was seen that coincided with the 280 nm peak confirming 
attachment of the ligand. A peak with a high absorbance at 330 nm was also seen 
in the SEC trace around a 30 mL retention volume, which was attributed to the 
excess unreacted ligand.  
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Fig 3.8 (A) SDS-PAGE showing that CTB modified with galactose ligand 39a remained as a pentamer 
during the reaction. (B) Mass spectrum of CTB modified with galactose ligand 39a. 
 
 
Fig 3.9 Chromatogram showing CTB modified with galactose ligand 39, UV absorbance measured at 
280 nm (blue) and 330 nm (green). The purified protein appeared as a pentamer with a strong 
absorbance from the dansyl group at 330 nm confirming ligand attachment. There are also peaks from 
the excess unreacted ligand giving a strong absorbance at 330 nm due to the dansyl group. 
 
AUC was also used to evaluate the size of the modified protein CTB(39) and to 
check for larger assemblies. The pentamer fraction from SEC was concentrated to 
10 µM and subjected to AUC analysis (Fig 3.10). The AUC results showed a peak 
at 4.2 S confirming the protein to be a pentamer but showed no formation of any 
larger structures. 
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Fig 3.10 AUC sedimentation coefficient distribution of CTB(39) showing a species at 4.2 S which 
corresponds to a mass of 68 kDa for the modified protein pentamer. 
 
3.1.4 The effects of concentration on protein assembly 
Galactose ligand 39a had been successfully attached to CTB but no protein 
assemblies had been observed in solution. To investigate whether the formation of 
larger complexes was concentration dependent, the CTB concentration was 
increased in the oximation reaction. CTB was oxidised as before but now at a 
higher protein concentration of 600 µM subunit concentration. Again, galactose 
ligand 39a was attached via an oxime bond at pH 7 in phosphate buffer with 100 
mM aniline present. This time the reaction progressed more quickly, as expected, 
and after only 1 h ESMS gave a mass of 12593.7 Da (calculated 12593.2 Da) 
indicating a complete reaction. During this reaction, a much larger amount of 
precipitation was observed than before when the CTB concentration was 200 µM. 
The reaction solution was analysed by SDS-PAGE (Fig 3.11) and most of the 
protein appeared as pentamer but a number of higher mass bands were also 
observed. SDS-PAGE is, however, not necessarily representative of what protein 
structures are present in solution. The intensity of the pentamer band on the gel 
does not imply that this is the dominant species in solution as other larger stable 
structures may have partially dissociated on the gel. But the gel does show that 
there are larger assemblies being formed and the precipitation observed was 
possibly from these larger insoluble protein aggregates (Scheme 3.8).  
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Fig 3.11 SDS-PAGE showing CTB(39) forming larger structures during the oximation reaction. After 
centrifugation these larger aggregates were removed and only pentamer and a small amount of dimer 
were observed in the supernatent. After purification by SEC only pentamer was seen. 
 
 
Fig 3.12 Chromatogram showing CTB modified with galactose ligand 39a, after centrifugation of a 
sample to remove the insoluble precipitate. The UV absorbances were measured at 280 nm (blue) and 
330 nm (green) showing minimal protein was soluble in the supernatant (“sup”) and much more 
protein was recovered from the insoluble pellet (“pel”).  
 
The sample was centrifuged at 13 krpm for 1 min to remove the insoluble 
precipitate. The supernatant was analysed by SEC to find what remained in solution 
and phosphate buffer with 6 M guanidine hydrochloride was added to the pellet to 
redissolve the insoluble fraction before analysis by SEC (Fig 3.12). The SEC trace 
for the supernatant showed only a very small amount of protein pentamer and a 
large amount of the excess ligand. But much more protein was recovered from the 
pellet and much less excess ligand was observed. It was concluded that the 
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precipitate from the reaction did indeed contain the larger protein aggregates that 
were previously seen by SDS-PAGE and only minimal pentamer was stable in 
solution. Attempts were made to visualise the aggregates by using electron 
microscopy (EM), but no structures were observed. 
3.2 Introduction of a competing ligand 
The modified proteins were assembling into larger structures but this was 
uncontrolled leading to insoluble aggregates. At 200 µM CTB concentration there 
was minimal aggregation or precipitation but when this was increased to 600 µM 
most of the protein was seen to aggregate. It was of course necessary to gain a 
better control on the assembly process if the desired structures were to be 
achieved. A method was proposed to prevent all interactions with the introduction of 
a competing ligand (Scheme 3.8). If this ligand was present from the start at a high 
concentration it should bind to the CTB proteins and thus prevent the modified 
proteins from interacting.  
 
 
 
Scheme 3.8 Uncontrolled aggregation of the modified proteins and the introduction of a competing 
ligand to prevent protein assembly. 
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The modification of CTB was again performed with galactose ligand 39a, with CTB 
at a concentration of 600 µM which had previously led the proteins to precipitate. 
This time α-methyl galactoside 34 was included at 200 mM as a competing ligand to 
block the CTB carbohydrate binding sites. This simple galactoside has a Kd of 12 
mM and so its concentration needed to be greater than the Kd to ensure complete 
binding. After 1.5 h ESMS showed the reaction to be complete and the mixture was 
analysed once again by SDS-PAGE (Fig 3.13). This time the analysis showed a 
band for the pentamer, a very light band for a larger structure that could have been 
a dimer of pentamers and another small band for monomers. Therefore, the gel 
indicated that the presence of the competing ligand prevented the protein from 
aggregating and had instead remained mainly as the pentamer. 
 
 
Fig 3.13 SDS-PAGE showing the modification of CTB with ligand 39a remaining as a pentamer due to 
the presence of a competing ligand. 
 
The concentration of the competing ligand was varied in an attempt to find a 
minimal concentration needed to prevent aggregation. The modification reaction 
was carried out at the protein concentration known to cause aggregation (600 µM) 
and the competing ligand concentration was varied from 0 to 200 mM in parallel 
reactions.  
 
After completion of the reaction, samples were centrifuged at 13 krpm for 1 min and 
large pellets from the precipitated protein could be seen in the samples with 10 mM 
or less ligand and a very small pellet was observed in the other samples. The 
precipitate could not be analysed further but again showed how the concentration of 
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competing ligand was important for the proteins to remain in solution. After the 
samples were centrifuged, SDS-PAGE was performed to assess what remained in 
solution (Fig 3.14). The gel could also be visualised under a UV lamp which would 
highlight the dansyl groups of the ligand. This UV analysis of the gel was more 
revealing as it was more sensitive. It could be seen that with no competing ligand 
present most of the protein had precipitated and there was very little protein left. 
The amount of soluble protein increased with the concentration of competing ligand 
but small amounts of higher aggregates still showed. This observation confirmed 
that the competing ligand was necessary to keep the modified proteins in solution at 
a high protein concentration and inhibit the large scale aggregation. However, even 
with a competing ligand above 50 mM, some aggregation did still occur which was 
uncontrolled and tended to precipitate. The complementary nature of the binding 
sites and ligands was so strong that it was possible to overcome the great excess of 
free competing ligand. 
 
 
Fig 3.14 SDS-PAGE of the supernatants after centrifugation of the reactions. More protein is seen to 
remain in solution with more competing ligand but some larger assemblies are also still seen. Ligand 
alone in the absence of protein was seen to run at the same high position as shown above. 
82 
 
 
As it was shown that a competing ligand could inhibit most of the aggregation, it 
should also be possible to initiate the interactions between proteins by removing 
this competing factor. CTB was again modified at 600 µM, with the competing 
ligand 34 at 200 mM and no precipitation was observed. The sample was then 
dialysed extensively with four buffer changes over four days to completely remove 
competing ligand 34 and excess reacting ligand 39a. It was found that much of the 
protein had precipitated during the dialysis and the concentration of soluble protein 
had reduced from 600 µM to 112 µM which was a loss of 81% of the total protein 
due to precipitation.  
 
Fig 3.15 SDS-PAGE of CTB(39) modified with competing ligand and then dialysed extensively to 
remove the competing ligand and excess ligand 39a. The protein was seen to aggregate after the 
removal of the ligand. 
 
The sample was analysed by SDS-PAGE after the dialysis which now showed the 
modified protein pentamer, a number of larger complexes and minimal excess 
ligand remaining (Fig 3.15). Over the time course of the dialysis the CTB(39) 
proteins had been able to interact more and more resulting in the aggregation. It is 
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likely that this aggregation continued until the protein concentration was sufficiently 
low that the galactose binding interactions were no longer able to bring the separate 
pentamers together. 
 
It was postulated that ligand 39a might be long and flexible enough to reach round 
and bind back on the CTB protein it originated from. This self-binding may have 
been an entropically favourable interaction that would have had the consequence of 
preventing some aggregation of the pentamers (Fig 3.16). This binding may also 
explain why not all of the protein precipitated from solution when no competing 
ligand was present. The effective concentration of the attached ligands would be 
much higher than the overall protein concentration and so they may self-bind and 
when bound act themselves as competing ligands. ITC was performed with the 
sample of CTB(39) after extensive dialysis to see if any intra pentamer interactions 
could be detected. GM1os was titrated into the modified protein and any inter- or 
intra-ligand interactions would have competed with the GM1os. 
 
 
Fig 3.16 Model of CTB(39) with attached ligand 1(cyan) adopting a possible conformation to self-bind 
to the nearest binding site on the same CTB pentamer (red) that it originates from. GM1os (blue) is 
also shown in the binding site for clarity. 
 
The ITC titration showed little difference from the titration with wild-type CTB, with a 
Kd of 87.8 nM and Δ°H of -16.9 kcal mol
-1, and so no competition with the GM1os 
binding was observed (Fig 3.17). The titration was performed at a concentration of 
3.5 µM for CTB(39) and therefore at this low protein concentration it could be 
concluded that the ligands did not have a high enough affinity to form inter-protein 
interactions. The result also showed that no intra-protein interactions were taking 
place as this would be independent of the overall protein concentration. Self-binding 
N-terminus 
GM1os 
binding site 
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interactions do not occur and the precipitation, or lack of, is due solely to the affinity 
of the galactose ligands for other CTB units and the self-complementary 
cross-linking ability of CTB(39) at the higher concentrations. 
 
  
Fig 3.17 (A) ITC titration of GM1os (50 µM) into CTB(39) (3.5 µM). The Kd of 87.8 nM and Δ°H of -16.9 
kcal mol
-1
 were similar to the wild-type CTB and GM1os interaction indicating that no intra- or 
inter-protein interactions were being made by the attached ligands. (B) The wild-tye CTB titration 
shown for comparrison. 
 
3.3 The importance of ligand length 
The length of the ligand may be important in determining how the proteins can 
interact. A range of ligands were synthesised to assess how the ligand length might 
be affecting the aggregation (Fig 3.18). With a longer flexible ligand, the CTB 
pentamers could come together in many different orientations giving rise to an 
unrestricted, uncontrolled aggregation as seen with ligand 39a. However, if the 
ligands were too short then there may not be enough room for the proteins to 
interact in the desired arrangement. To achieve the goal of creating a 
dodecahedron from CTB proteins, there has to be some constraint in how the 
ligands are presented to bind proteins, resulting in only the desired complex 
structure. 
(A)         (B) 
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Fig 3.18 Different length galactose ligands. 
 
The shortest ligand investigated comprised of the amino oxy group attached via an 
amide bond to a galactose sugar. Acetylated galactosyl azide (provided by Dr. 
Martin Fascione) was hydrogenated using Pd/C and H2 (g), in the presence of 
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N-hydroxysuccinimide ester 37 and DMAP (Scheme 3.1). The resulting galactosyl 
amide was then deacetylated under Zemplén conditions to yield the short galactose 
ligand 40.  
 
 
Scheme 3.1 synthesis of ligand 40 
 
A step up in length was achieved by using a lactose unit contributing an extra 
monosaccharide to the length. Acetylated lactose was reacted with TMS azide in 
DCM using SnCl4 as a lewis acid to activate the anomeric acetate and produce 
lactosyl azide 45. This was then hydrogenated using Pd/C and H2 (g), in the 
presence of N-hydroxysuccinimide ester 37 and DMAP. Zemplén conditions were 
used for deacetylation to yield lactose ligand 41 (Scheme 3.2).  
 
 
Scheme 3.2 Synthesis of ligand 41. 
 
Peptide ligand 43 was constructed as a short peptide using SPPS on 2-chlorotrityl 
resin preloaded with glycine for ease of synthesis. The resin was chosen as it is 
very acid labile and so the peptide ligand could be selectively cleaved without losing 
the Boc group from the oxyamine. Firstly Dde-protected lysine 46 was attached to 
the glycinyl resin and the Fmoc protecting group was removed with piperidine/DMF. 
Next dansyl lysine 47 was attached and again the Fmoc protection for the terminal 
amine was removed using piperidine/DMF. Succinic anhydride was then added to 
the linker followed by galactosylamine 48. The Dde protecting group was removed 
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selectively with NH2NH2/DMF before the N-hydroxysuccinimide ester 37 was 
attached to the lysine side chain. Finally the ligand was cleaved from the resin using 
HFIP/DCM, before purification by SEC resulting in galactose ligand 43. 
 
 
Fig 3.19 Synthesis of galactose ligand 43 by SPPS. 
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Ligands 42 and 44 (synthesised by Dr. Martin Fascione) were constructed using 
SPPS in the same way used for ligand 43. The change in length from ligand 42 to 
ligand 43 involved a switch in the order of the dansyl lysine and lysine Dde amino 
acids to give an extra amide bond between the galactose moiety and the aminooxy 
group. Two glycine residues were then included for ligand 39 and a further two 
glycine residues for ligand 44. 
3.3.1 Varying the ligand length 
Short galactosyl ligand 40a was successfully attached to CTB at pH 7 with aniline 
catalysis at 600 µM protein concentration without a competing ligand present. 
ESMS analysis showed a mass of 11829.7 Da (calculated 11832.4 Da) which was 
within the error for the ESMS, for the completed reaction yielding CTB(40) (Fig 3.20 
A).  
 
          
Fig 3.20 (A) Mass spectrum showing CTB modified with short galactose ligand 40a. (B) SDS-PAGE of 
CTB(40) showing no aggregation with the short galactose ligand. 
 
The reaction solution was analysed by SDS-PAGE and most of the protein 
appeared as pentamers (Fig 3.20 B). At the high CTB concentration where 
previously aggregation had been seen, only pentamer was visible with this ligand. 
To confirm that no larger species were being formed, AUC was performed on 
CTB(40) and showed the protein to be a pentamer with a mass of 54 kDa (Fig 
3.21). As CTB(40) remained as pentamer it was concluded that the ligand was too 
short for the proteins to interact effectively and so did not form larger structures. 
(A)           (B) 
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Fig 3.21 AUC sedimentation coefficient distribution of CTB(40). The plot shows a species at 3.9 S 
which corresponds to a mass of 54 kDa for the modified CTB pentamer. 
 
The next step up in length was to lactose ligand 41. This ligand was attached to 
CTB at 600 µM with and without competing ligand. ESMS analysis gave a mass of 
11992.1 Da (calculated 11994.5 Da) for the modified protein CTB(41) (Fig 3.22). 
The samples were analysed by SDS-PAGE which showed mostly CTB pentamer 
and analysis of a centrifuged sample showed that the protein did not precipitate and 
stayed in solution as stable pentamers (Fig 3.23). Again it was concluded that the 
ligand was not long enough to make substantial interactions and so no larger 
complexes were formed. 
 
 
Fig 3.22 Mass spectrum showing CTB modified with lactose ligand 41a.  
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Fig 3.23 SDS-PAGE of modified CTB(41) modified with and without a competing ligand showing that 
all the protein stayed in solution and therefore did not aggregate. 
  
The longer peptide based galactose ligand 42a was attached to CTB. ESMS 
analysis showed the formation of CTB(42) with the mass of 12477.0 Da (calculated 
12479.1 Da) for the modified protein (Fig 3.24). The reaction was performed at high 
(600 µM) and low (200 µM) protein concentrations to assess if this ligand would act 
in a similar way to ligand 39 at different concentrations. The reactions were also 
performed with and without competing ligand α-methyl galactoside at 200 mM. 
 
 
Fig 3.24 Mass spectrum showing CTB modified with longer galactose ligand 42a. 
 
The reaction samples were analysed by SDS-PAGE and samples were also 
centrifuged for 1 min at 13 krpm to assess the stability of the species in solution (Fig 
3.25). It was seen that at 200 µM CTB monomer concentration with competing 
ligand, all protein was kept in solution as stable pentamers. When the competing 
ligand was not present at the lower protein concentration then a small amount 
91 
 
precipitated and was seen on the gel as monomers. Increasing the protein 
concentration to 600 µM increased the interactions between proteins and even with 
competing ligand present a small amount of the protein still precipitated and was 
seen in the pellet fraction on the gel. When the competing ligand was not present at 
600 µM protein concentration, the majority of protein precipitated and was seen on 
the gel as monomers from the pellet. The gel showed how much protein was 
present in solution but did not give an accurate representation of the size of 
particles in solution and did not show any larger aggregates for the precipitated 
samples although this may have been due to only a small amount of sample loaded 
on the gel. 
 
 
Fig 3.25 SDS-PAGE of CTB modified with ligand 42a. Removing the competing ligand was shown to 
result in more precipitate in the pellet fraction especially at 600 µM protein. 
 
The pellets from the different concentration and competing ligand conditions were 
again analysed by SDS-PAGE, only that this time a larger sample was applied to 
the gel in an attempt to get stronger bands (Fig 3.26). Electrophoresis now showed 
much more aggregation for the high concentration of CTB(42) without competing 
ligand similar to that seen by CTB(39). A fair amount of protein had aggregated in 
the high protein concentration sample even with competing ligand and a similar 
situation was seen at the lower concentration with no competing ligand leading to 
more precipitation although not as much as at the higher concentration. 
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Fig 3.26 SDS-PAGE of pellets from CTB(42). At the lower protein concentratio not much precipitated 
even without a competing ligand but at the higher protein concentration many larger complexes were 
seen on the gel. 
 
Investigations were also performed with ligands 43 and 44, but no differences were 
seen in the ability of the modified proteins to assemble compared to with ligand 42. 
It appeared that with ligands as long or longer than ligand 42, assembly of the 
proteins occurred but tended to form insoluble aggregates. 
 
3.4 Conclusions 
CTB can be site-specifically modified at the N-terminus first by oxidation and then 
by the formation of a stable oxime bond under acidic conditions or at pH 7 with an 
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aniline catalyst. CTB is stable at the neutral pH and so this improvement in the 
reaction allows for the attachment of carbohydrate ligands. 
 
Protein assembly was shown via the attachment of a galactose ligand to CTB. This 
assembly is dependent somewhat on the concentration of the protein and can be 
mostly prevented with the introduction of a competing ligand. The length of the 
ligand was also found to be important as when it was too short, there was not 
enough space or flexibility for the interactions to take place. Unfortunately the 
structures formed have been uncontrolled aggregates that precipitated from 
solution. Any structural analysis of the larger structures proved difficult as only the 
stable pentamer at low concentration could be isolated from solution.  
 
The initial strategy of creating a building block that has both multiple ligands and 
multiple binding sites may be too complicated to control. To form stable discrete 
particles, a “Goldilocks” set of conditions may need to be found. The correct 
concentration, the precise length of ligand and a suitable amount of competing 
ligand may all need to be varied systematically for the modified proteins to be 
controlled. The proteins were certainly assembling, but there was no control in this 
system and no constraints on what structures could form. 
 
If the system could be created from two components, each with either the ligands or 
the binding sites, then this may be easier to control. Each component could be 
created individually before being combined in a specific way. Attempts to control the 
system are discussed in chapter 4. 
 
Another method for encouraging the proteins to assemble into the desired structure 
would be to introduce a template. The proteins could then be prearranged before 
the ligands are added to crosslink the structure. This strategy should potentially give 
much more control over the size of the structures formed and prevent unwanted 
aggregation. Investigations into templating the system are discussed in chapter 5. 
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4 Controlling the system 
 
 
 
 
 
The creation of a binding site mutant, its 
modification, characterisation and interactions with 
wild-type CTB 
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Creating a system that combined binding sites and complementary ligands resulted 
in uncontrolled aggregation. A new strategy needed to be devised to introduce an 
element of control into the system. The separation of ligands and binding sites into 
separate building blocks could provide this control. To achieve this goal, a mutant 
CTB protein had to be created that could not bind the carbohydrate ligands (Fig 
4.1).  
 
 
Fig 4.1 Representation of a mutant non-binding CTB protein. 
 
This mutant CTB could then be modified with ligands in the same way as before 
(see chapter 3) resulting in a pentavalent protein based ligand. This ligand would 
not be able to bind to itself or others at the time of attachment but could still 
potentially interact with wild-type CTB (Scheme 4.1 A). Introduction of the wild-type 
protein with binding sites still intact, would then initiate the formation of larger 
protein complexes. 
 
The creation of the mutant pentavalent ligand allows the possibility for controlling 
assembly when wild-type CTB is added. If an excess of the binding component was 
added to the ligand then it might be expected that five CTB units could bind around 
a single pentavalent ligand (Scheme 4.1 B). Or if an equal ratio of the ligand and 
receptor were used then one-to-one binding might be achieved (Scheme 4.1 C). 
The binding strength of the ligand groups could be varied to provide a more or less 
reversible system. The length of the linkers could also be altered to constrain the 
orientation in which the proteins interact and so favour one type of complex 
formation. 
  
This chapter outlines the creation of a non-binding CTB mutant, its modification with 
a range of carbohydrate ligands and their interactions with wild-type CTB. 
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Scheme 4.1 (A) The non-binding mutant protein modified with ligands cannot form interactions by 
itself. (B) The assembly of five wild-type CTB proteins around a modified non-binding mutant protein. 
(C) The assembly of a 1:1 protein heterodimer. 
 
4.1 Removing the binding capacity of CTB 
Jobling and Holmes previously identified a number of mutations that change the 
binding properties of CTB.[153] A tryptophan residue (W88) sits in the GM1 binding 
pocket and forms a stacking interaction with the terminal galactose residue of GM1 
(Fig 4.2). It was found that if this residue was mutated to a lysine or a glutamic acid 
residue then CTB no longer bound to GM1. Both these mutations introduce a 
(A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
(C) 
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charged residue into the binding site and disrupt the stacking of the carbohydrate 
with CTB. It was therefore decided that these mutations would be introduced into 
CTB to create a non-binding protein. 
 
 
 
Fig 4.2 The carbohydrate binding site of CTB (red) shown with GM1os (blue) bound (A) with the 
surface representation and (B) without the surface and with W88 shown. 
 
4.1.1 Making the mutants 
The standard method for expressing wild-type CTB in the Turnbull lab used Vibrio 
sp.60 bacteria with the gene encoded in the plasmid pATA13.[134] It was difficult to 
use this plasmid for introducing a mutation due to its large size and low copy 
number and so an E. coli system was used.  
 
A pMAL-p5X plasmid was originally obtained from Genscript before an MBP-CTA2 
fusion was introduced along with the gene for CTB, to produce plasmid pSAB2.1A. 
The MBP-CTA2 gene was then removed to produce plasmid pSAB2.2A containing 
only the CTB gene for expression in E. coli. A W88K mutation was then introduced 
to remove the carbohydrate binding capacity of the protein. However, the 
N-terminus of this CTB protein was an alanine residue. This CTB protein was 
encoded in plasmid pSAB2.2-T1AW88K (DNA manipulation performed by Mr 
James Ross).  
 
Site-directed mutagenesis was performed on plasmid pSAB21.2-T1AW88K so that 
a threonine residue would be at position one of the protein and be suitable for 
N-terminal modification. This mutation produced plasmid pTRB-W88K. The binding 
site is in close proximity to the N-terminus and it was thought that a positive charge 
may affect reactions on the N-terminus. Therefore, a glutamic acid residue was also 
introduced at another position (Q61E), at the edge of the binding site, with the 
original W88K mutation still present to neutralise the overall charge and stabilise the 
protein (Fig 4.3). Plasmid pTRB-W88KQ61E encoded this new mutant protein. The 
(A)              (B) 
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second mutation would only be a small structural change but should neutralise the 
overall charge, thus stabilising the mutant protein. A final mutation was introduced, 
into pTRB-W88K, to alter residue 88 and create a different mutant protein with a 
glutamic acid residue (W88E), producing plasmid pTRB-W88E. This change yielded 
a mutant protein with a negative charge instead of the positive charge from the 
lysine mutant. 
 
 
Fig 4.3 Representation of the CTB (red) binding site with GM1os (blue) bound. The tryptophan residue 
at position 88 in the wild-type is shown with the mutations W88K (light blue) and W88E (orange) 
superimposed. Mutation Q61E (green) is shown in close proximity in the binding site. 
 
The amino acid sequences are shown below for all the CTB wild-type protein and 
the mutants described. Mutations from the wild-type sequence are underlined and 
highlighted in red: 
 
  1          11         21         31              
wild-type TPQNITDLCA EYHNTQIYTL NDKIFSYTES LAGKREMAII  
W88K T1A APQNITDLCA EYHNTQIYTL NDKIFSYTES LAGKREMAII 
W88K  TPQNITDLCA EYHNTQIYTL NDKIFSYTES LAGKREMAII 
W88K Q61E  TPQNITDLCA EYHNTQIYTL NDKIFSYTES LAGKREMAII 
W88E TPQNITDLCA EYHNTQIYTL NDKIFSYTES LAGKREMAII 
 
  41         51         61         71    
Wild-type TFKNGAIFQV EVPGSQHIDS QKKAIERMKD TLRIAYLTEA 
W88K T1A TFKNGAIFQV EVPGSQHIDS QKKAIERMKD TLRIAYLTEA 
W88K   TFKNGAIFQV EVPGSQHIDS QKKAIERMKD TLRIAYLTEA 
W88K Q61E  TFKNGAIFQV EVPGSQHIDS EKKAIERMKD TLRIAYLTEA 
W88E  TFKNGAIFQV EVPGSQHIDS QKKAIERMKD TLRIAYLTEA 
 
        81         91         101 
wild-type KVEKLCVWNN KTPHAIAAIS MAN 
W88K T1A KVEKLCVKNN KTPHAIAAIS MAN 
W88K  KVEKLCVKNN KTPHAIAAIS MAN 
W88K Q61E  KVEKLCVKNN KTPHAIAAIS MAN 
W88E  KVEKLCVENN KTPHAIAAIS MAN 
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Gel electrophoresis was performed to assess the product of the mutagenesis 
reactions and showed that the mutant plasmids had been amplified successfully 
(Fig 4.4). E. coli XL10 competent cells were transformed with the new plasmids. 
Plasmid preps were then performed to isolate each plasmid DNA for sequencing 
and for transformation into E. coli C41 cells for expression. 
 
 
Fig 4.4 Gel electrophoresis analysis of pTRB-W88K, pTRB -W88KQ61E and pTRB-W88E containing 
the genes for the new mutant proteins. 
 
Each new protein was expressed in E. coli by induction with IPTG and growth at 
30 °C for 24 h. After purification by ammonium sulfate precipitation, nickel affinity 
chromatography and then SEC, mutant proteins W88K, W88K-Q61E and W88E 
were isolated with yields of 2.6 mg L-1, 1.8 mg L-1 and 2.0 mg L-1 respectively. Mass 
spectrometry was used to confirm the mutations in the CTB protein. W88K was 
seen with a mass of 11583.9 Da (calculated 11584.3 Da), W88K-Q61E as 11584.4 
Da (calculated 11584.9 Da) and the W88E mutant as 11585.0 Da (calculated 
11584.9 Da) (Fig 4.5). A range of proteins were now available and could be tested 
to see which was most suitable for further reactions.  
 
The mutations were accommodated so that the proteins were all stable pentamers 
in solution, as evident from the Ni affinity chromatography purification. Purification 
by this method requires the protein to be in pentameric form to bind to the resin. 
There are five histidine residues on the bottom face of CTB, one from each 
monomer, that together provide the binding interaction with the resin.  
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Alternative purification methods were attempted to improve the yield of the proteins 
obtained from the E. coli. Osmotic shock was used to lyse the cells and liberate 
protein from the periplasm. Nickel affinity chromatography was used to isolate CTB 
from the resultant mixture but no protein was found. Cells were also lysed using the 
cell disruption system and again nickel affinity chromatography was used to purify 
the protein. This time the mutant protein was obtained but after the affinity column it 
was still very impure. SEC was employed to purify the sample but it proved too 
impure to be separated easily in one run. Due to the laborious nature of this 
purification method and the low yields attainable, the procedure was abandoned 
and for future preparations only the original ammonium sulfate precipitation method 
was used. 
 
 
     
 
 
Fig 4.5 Mass spectra of the three different mutant CTB proteins; (A) W88K, (B) W88K-Q61E and (C) 
W88E. (D) The mass spectrum of wild-type CTB for comparison 
 
4.1.2 Analysing the mutant proteins 
The mutant proteins all gave stable pentamers and expressed with similar yields. 
They were therefore analysed to see which would be most suitable to use for 
modification. SDS-PAGE was performed to confirm the pentamer stability under the 
conditions of electrophoresis and showed quite a difference between the mutants 
(A)            (B) 
 
 
 
 
 
 
 
 
 
 
 
 
(C)            (D) 
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(Fig 4.6). W88K was less stable than wild-type CTB and most of the protein 
denatured appearing as monomers on the gel. W88K-Q61E runs much higher than 
the expected pentamer; possibly due to the charge difference created by the 
mutations or the protein may be forming some dimers of pentamers that are quite 
stable. W88E was just as stable as the wild-type and appeared at the expected 
pentamer position on the gel. 
 
 
Fig 4.6 SDS-PAGE of all the CTB mutants, showing the variation in stability and position on the gel. 
 
ITC was performed to confirm whether the mutations introduced into CTB did 
actually prevent the protein from binding carbohydrates. GM1os (125 µM) was 
titrated into a solution of each mutant CTB (10 µM), as expected no binding 
interaction with the pentasaccharide was observed (Fig 4.7). Therefore, the 
mutations that had been introduced were sufficient to prevent GM1os binding. ITC 
did not, however, prove that there is no binding at all. The pentasaccharide may not 
be able to bind with the same high affinity as with wild-type CTB but if the 
interaction had been reduced to a millimolar affinity then this would not have been 
detected under the conditions used. This low affinity is perhaps unlikely as the 
mutation should disrupt the terminal galactose binding, which is the most important 
residue for the pentasaccharide interaction.[89] 
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Fig 4.7 ITC plots for GM1os binding to (A) wild-type CTB and showing no interaction between GM1os 
and the mutant proteins (B) W88K, (C) W88E and (D) W88K-Q61E. 
 
The mutant proteins showed a varying stability as pentamers when seen by 
SDS-PAGE. But under the conditions of the N-terminal oxime reaction any subtle 
difference in stability may be important for efficient modification. To compare the 
thermal stability of the proteins mutants, differential scanning fluorimetry (DSF) was 
performed (Fig 4.8). DSF can measure the melting temperature of proteins. As the 
temperature in the experiment is increased, proteins undergo unfolding and expose 
hydrophobic core regions. Sypro Orange is mixed with the protein samples, and its 
A            B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C            D 
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fluorescence is quenched in aqueous solution. Upon binding to the exposed 
hydrophobic regions of proteins the fluorescence is no longer quenched. This 
fluorescence is measured in real time over the temperature range and so the 
gradual unfolding of proteins can be observed indirectly.[154] The midpoint of the 
unfolding transition is defined as the melting temperature for the protein. Sometimes 
proteins may exhibit multiple local maxima due to various aspects of the tertiary 
structure unfolding separately. The data is plotted as the change in fluorescence 
per degree against the temperature, resulting in a curve with a peak that 
corresponds to the midpoint of the unfolding transition, the melting temperature 
(Tm). 
 
The Tm for each protein showed quite considerable variation given there are only 
one or two small differences in the amino acid sequences (Table 4.1). The wild-type 
CTB had a melting temperature of 81 °C which is slightly higher than the literature 
value of 74 °C as measured by DSC.[155] W88E had a very similar Tm at 79 °C. The 
W88K mutant had a lower thermal stability, melting at 72 °C. The second mutation, 
Q61E, did provide a small stabilising effect to the W88K protein, increasing the 
melting temperature to 74 °C. However, the W88K-containing mutants were 
noticeably less stable than wild-type CTB and the W88E mutant.  
 
 
Fig 4.8 DSF showing the change in fluorescence of Sypro Orange with the melting of the CTB 
mutants. The peaks of the curves indicate the Tm. 
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Table 4.1 Melting temperatures for CTB and the mutant proteins measured by DSF. 
 
Protein Melting temperature / °C 
CTB 81 
W88E 79 
W88K 72 
W88K Q61E 74 
 
4.1.3 Modification of the mutant proteins 
Modification of the N-terminus of all the three mutant proteins was tested with 
galactose ligand 42 (Fig 4.9). The mutants were first oxidised with NaIO4 and both 
the W88K and W88E mutants reacted within five minutes, as seen previously for 
wild-type CTB. The W88K-Q61E mutant, however, failed to oxidise fully even after 
1 h. An oxime bond was then formed between galactose ligand 42a and the 
oxidised mutant proteins using aniline as a catalyst at pH 7. ESMS confirmed a 
successful reaction with W88K and with W88E, and SDS-PAGE was used to 
assess the stability of the modified mutants (Fig 4.10).  
 
 
Fig 4.9 The structure of galactoside ligand 42 and the extended galactose ligand 39. 
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It was seen that W88E had reacted with the fluorescent ligand and was a stable 
pentamer on the gel (Fig 4.10). W88K was seen to dissociate into monomers on the 
gel and so the reaction conditions led to further destabilisation or the modified 
mutant itself was less stable. The more thermally stable W88K-Q61E mutant also 
appeared as a stable pentamer on the gel, but had not reacted with the fluorescent 
oxyamine. W88E had the best stability of the three mutants developed and also 
behaved as well as CTB in the oximation reaction. It was therefore decided that 
W88E would be used in all further studies. 
 
 
Fig 4.10 SDS-PAGE showing the reaction of the mutants with ligand 42, stained with Coomassie Blue 
and under visualised under UV. 
 
4.1.4 Modification of W88E with galactose ligands 
W88E was modified at the N-terminus with ligand 42a and also with the longer 
ligand 39a. The longer ligand was used to see if the length of the linker was 
important for the interactions. Ligand 39 has two additional glycine residues and the 
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dansyl lysine at a later position in the structure leading to a three amino acid 
extension compared to ligand 42. ESMS showed that the products had masses of 
12419.7 Da (calculated 12422.0 Da) and 12536.4 Da (calculated 12536.1 Da) for 
W88E(42) and W88E(39) respectively (Fig 4.11). The non-binding mutants now 
presented five galactose moieties and so could be thought of as pentavalent 
ligands. These ligands, W88E(42) and W88E(39), should be able to bind to CTB 
either with each carbohydrate binding to a different CTB pentamer or with all five 
forming a multivalent interaction with a single CTB pentamer (Scheme 4.1). These 
ligands resembled previous star-shaped multivalent ligands, 20 and 21, produced 
by Fan and Hol[118], with the essential difference that the central scaffold of the 
ligands presented here were proteins rather than a synthetic molecule.  
 
 
Fig 4.11 Mass spectra of W88E and the modified mutants W88E(42) and W88E(39). 
 
4.1.5 Analysis of interactions with wild-type CTB 
A pentavalent ligand had now been created bearing five galactose moieties. The 
individual affinity of each carbohydrate was quite low (12 mM for a simple 
galactoside), therefore a high concentration of the ligand would be needed to bind 
to five different CTB pentamers. However, it was thought that the multivalent effect 
created by having five carbohydrates should give an overall rise in affinity for 
binding to CTB. 
 
The modified mutant proteins, W88E(42) and W88E(39), were mixed with CTB and 
the protein solution was analysed by DLS (Fig 4.12). Both W88E(42) and W88E(39) 
were seen to have a hydrodynamic diameter of 6.5 nm which was slightly larger 
than CTB with a hydrodynamic diameter of 5.6 nm. The extra size of the attached 
ligands on the mutant protein may have contributed to the increased size seen by 
DLS. When W88E(42) was mixed with CTB in a 1:1 ratio at a pentamer 
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concentration of 27 µM, a peak at 5.8 nm was observed indicating no change in the 
size of the particles. The amount of CTB was increased to give a ratio of 1:5, with 
W88E(42) at 12 µM and CTB at 58 µM pentamer concentrations. A peak at 6.1 nm 
was observed for this ratio indicating that again there was no significant assembly 
into larger structures. The difference in size between CTB and W88E(42) was too 
little for the analysis to resolve two separate peaks and so the mixtures gave a 
single hydrodynamic diameter between those of CTB and W88E(42). Similar results 
were seen in the DLS experiments with W88E(39). At the 1:1 ratio a peak at 5.6 nm 
was observed and at with an increase of CTB at a ratio of 1:5 at peak at 6.5 nm was 
seen. This result showed that a small increase in the ligand length offered no 
change in the ability of the ligand to bind to CTB and form larger assemblies. 
 
 
 
Fig 4.12 DLS plot of (A) W88E(42) mixed with CTB and (B) W88E(39) mixed with CTB. At a ratio of 
1:1 with both components at 27 µM pentamer concentration no increase in size was observed for 
either modified mutant and at a ratio of 1:5 with the modified mutant at 12 µM and CTB at 58 µM 
pentamer concentrations no increase in size was also observed. 
 
SEC was also performed on the mixtures of CTB and W88E(42) and no change in 
particle size was observed (Fig 4.13). The protein mixtures were monitored at 330 
nm wavelength as this is where the dansyl group on the ligands absorbs. Using this 
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wavelength meant that only species containing W88E(42) would be seen and 
showed that CTB and the mixtures all eluted around the same retention volume of 
17.5 mL. 
 
 
Fig 4.13 Chromatogram for CTB (red) and mixtures of W88E(42) and CTB with ratios of 1:1 (green) 
and 1:5 (purple). CTB was monitored at 280 nm, while the mixtures were monitored at 330 nm to show 
only the absorbance from the fluorescent ligand. 
 
As the length of the ligand was unlikely to be the source of the problem for these 
ligands, ITC was performed to assess the binding affinity of the pentavalent 
galactose ligand. A titration was performed in which CTB (240 µM) was added into 
W88E(39) (5 µM) to reach 10 equivalents. The titration finished with CTB at a 
concentration of 40 µM and ligand W88E(39) at 4 µM, but no interaction was 
observed (Fig 4.14). It was concluded that the affinity of the galactose moieties on 
the ligand were too low for binding to be observed at the concentrations accessible 
with the proteins in ITC. The individual Kd of each galactose ligand on W88E(39) 
was likely to have been in the millimolar range, similar to the monovalent galactose 
affinity. No great increase in affinity was observed due to a multivalent effect and no 
binding of this ligand was observed with CTB. 
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Fig 4.14 ITC trace showing no interaction as CTB (240 µM) was injected into a solution of W88E(39) 
(5 µM). 
 
4.2 Increasing the ligand affinity 
There was no sign of the proteins assembling when millimolar affinity carbohydrate 
ligands were used. The binding enhancement expected from a multivalent system 
was not observed. Pentavalent galactose ligand 20, produced by Fan et al., did 
show binding interactions with CTB[118]. The divalent, tetravalent and octavalent 
galactose dendrimers, 18a-c, from the Pieters lab also showed low micromolar IC50 
values.[114] But a recent study from the Zuilhof lab gave contrasting results.[121] Using 
a pentavalent galactose compound on a calixarene core, the Zuilhof lab were not 
able to detect an IC50 value as it was above the limit of the assay and so was only 
calculated as >1 mM. The arms of these compounds were of a comparable length 
to the Fan ligands, which makes it surprising that such different results were seen. 
The differences seen with multivalent galactose ligands could be due to the length 
and flexibility of the ligands. The protein based system presented here may suffer 
from a reduced flexibility and accessibility of the ligand groups as they are 
constrained around a large rigid scaffold. 
 
Fan et al. did not report whether their compounds were forming 1:1 assemblies or 
binding to multiple proteins but investigations with the higher affinity pentavalent 
MNPG 21 ligand did yield 1:1 complexes as shown by DLS and crystallisation.[156] 
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Similarly the Zuilhof lab reported strong binding when pentavalent GM1os ligands 
were used.[121] These studies suggest that whilst low affinity ligands are not always 
ideal for building complexes, even with multivalent systems, increasing the size and 
flexibility of the ligands can aid assembly and moving to a higher affinity ligand will 
certainly aid the binding.  
4.2.1 Click chemistry on the protein 
The GM1 pentasaccharide, which has a nanomolar Kd for CTB, would give a 
significant increase in affinity over the simple galactoside. Therefore a pentavalent 
scaffold with the GM1os ligand would be expected to be able to bind to one or 
multiple CTB proteins. 
 
The Zuilhof lab in Wageningen provided a GM1os molecule with an 11 carbon chain 
and azide functional group 49. Taking advantage of the azide group, an alternative 
way of attaching ligands to CTB was envisaged using a copper-catalysed azide-
alkyne cycloaddition (CuAAC), known as “click chemistry”.[157, 158] An alkyne would 
need to be introduced on to the N-terminus of CTB, which could then be “clicked” 
with an azide on the ligands. Attaching an alkyne on to CTB via oxime chemistry 
could be done in bulk and this modified protein could be stored and used when 
necessary with a variety of ligands containing azides, including the GM1os 49. 
Another azide with a lactose group 51 was also provided by the Zuilhof lab to 
provide a comparison with a low affinity carbohydrate (Kd ca. 15 mM, similar to 
galactose) (Fig 4.15). Click chemistry is well studied and has become a well used, 
flexible tool with many conditions known for different reagents.  
 
In order to introduce an alkyne function onto CTB, alkyne 52 (synthesised by Dr. 
Tom McAllister) was used containing an aminooxy function that could be attached 
to the CTB N-terminus using oxidation and oxime chemistry (Fig 4.15).  
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Fig 4.15 Carbohydrate azide derivatives and alkyne counterpart for attachment to the CTB N-terminus. 
 
Ultimately the alkyne group would be needed on the W88E mutant but for ease of 
handling and issues with quantity of protein, trial reactions were carried out on 
wild-type CTB. The N-terminus of CTB was oxidised before successful modification 
with alkyne 52a via oxime ligation (Scheme 4.2) and then the modified protein was 
purified on a PD G-25 minitrap column (GE Healthcare). ESMS was used to confirm 
that the modified protein CTB(52) had a mass of 11709.8 Da (calculated 
11710.4 Da) (Fig 4.16). SDS-PAGE was performed to check the stability of the 
protein and showed the alkyne-labelled protein to be a stable pentamer (Fig 4.17). 
 
 
Scheme 4.2 Modification of CTB with alkyne 52a. 
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Fig 4.16 Mass spectrum of the alkyne modified CTB. 
 
 
Fig 4.17 SDS-PAGE of CTB plus alkyne ligand 52a. The gel shows that CTB modified with a small 
molecule containing a terminal alkyne is still stable as a pentamer. 
 
The CuAAC was tested using alkyne-modified CTB(52) in a reaction with the 
lactose azide 51. Protein CTB(52) was mixed with lactose azide 51, the catalyst 
CuSO4 and reducing agent tris(2-carboxyethyl)phosphine (TCEP) in phosphate 
buffer. Copper ligand tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) in 
DMSO was added to stabilise the copper(I) oxidation state and the mixture was left 
to react at room temperature. The reaction conditions used were a modification of 
the procedure reported by Wang et al.[159] DMSO was used to initially solubilise the 
TBTA rather than t-butanol, as reported by Wang et al., as it was found to be 
completely insoluble in both t-butanol and H2O. However after addition of the TBTA, 
the mixture still turned a cloudy white. After 48 h the reaction was centrifuged at 
13 krpm for 1 min to remove the white precipitate, before purification. The reaction 
was not entirely successful as the modification only proceeded to around 60% 
conversion as estimated from the mass spectrum (Fig 8.2 see experimental). The 
product had a mass of 12247.5 Da (calculated 12247.7 Da). The incomplete 
reaction was thought to be due to the insolubility of the TBTA in water, which may 
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also have also caused some of the protein to precipitate. It was important for this 
reaction to reach completion as there is no way to purify the product from unreacted 
protein and so only a semi-modified protein could be purified which is neither 
reproducible nor useful for this project.   
 
 
Fig 4.18 The structures of the copper ligands for CuAAC reactions. 
 
The number of equivalents of azide was also found to be important. In the above 
reaction a conversion of ~60% was seen when there were 50 equivalents of azide 
present but when this number was reduced to 5 equivalents the conversion was 
reduced to ~10%. Other attempts were made to increase the conversion by keeping 
the TBTA in solution. TBTA was found to be more soluble at lower concentrations 
and so the CuAAC reaction was investigated following conditions closer to those 
reported by Heal et al. with all reagents at a lower concentration (TBTA now 20 × 
more dilute at 100 µM).[160] However, this proved to be unsuccessful and no product 
was obtained after 48 h with all the protein remaining as the alkyne. The low 
concentrations, whilst aiding the TBTA solubility, probably contributed to the failed 
reaction. 
 
With the insolubility of TBTA proving to be a problem, a new copper ligand, 
bathophenanthrolinedisulfonic acid (BPSA), was used (Fig 4.18). This ligand is 
water soluble and had been reported as better than the TBTA for protein CuAAC 
reactions.[161] The CuAAC reaction was again performed on the alkyne modified 
protein under similar conditions to those that had previously led to a 60% 
conversion, but now with everything in aqueous solution.[162] However, reactions 
employing this new ligand proved unsuccessful and no product was seen. 
 
The same reaction was performed on a simpler azide in order to assess whether 
the reaction was failing due to the nature of lactose azide 51 or the reaction 
conditions. It was thought that the carbon chain of lactose azide 51 may have 
formed micelles and so a simple galactosyl azide 50 (synthesised by Mr Daniel 
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Williamson) was used in parallel reactions with TBTA or BPSA and alkyne CTB(52). 
The reactions with TBTA progressed only as well as before, again not reaching 
completion after 48 h. Similarly, no product was seen when BPSA was used and so 
this copper-chelating ligand was not investigated further. 
4.2.2 Microwave-assisted click chemistry 
After CuAAC reactions directly on the protein proved difficult, it was thought that the 
reaction could be done first in organic solution and then the triazole-containing 
product could be attached to the protein by oximation. Conditions used were from a 
study by the Pieters lab for the microwave-assisted reaction of carbohydrates.[163] 
Alkyne 52 plus 1.5 equivalents of galactosyl azide 50, 30 mol% CuSO4 and 60 
mol% sodium ascorbate were mixed together in DMF:H2O 4:1 and reacted in a 
microwave for 20 min at 80 °C, 150 W power (Scheme 4.3). After the reaction had 
cooled, TLC showed no alkyne remaining and mass spectrometry confirmed the 
triazole containing product 53 with a mass of 433.2 Da (calculated 433.2 Da). The 
mixture was aliquoted out and lyophilised. No alkyne remained in the reaction 
mixture and so the product was not purified further. The only molecule, with an 
aminooxy group, that could react with the protein in further experiments would be 
the triazole product. 
 
 
Scheme 4.3 Microwave-assisted click chemistry. 
 
An aliquot of 53 was deprotected with TFA to give 53a before reaction with CTBox, 
at 200 µM to avoid any potential aggregation, in the presence of aniline as a 
catalyst (Scheme 4.4). The reaction went to completion overnight with ESMS 
confirming the mass of the product CTB(53) to be 11915.4 Da (calc 11915.6 Da) 
(Fig 4.19). SDS-PAGE was performed and showed that the modified protein was 
stable as a pentamer during the reaction and after purification (Fig 4.20). A sample 
was taken before purification and centrifuged to ascertain if any protein had 
precipitated. This analysis is shown on the gel as the “pellet” fraction and it can be 
seen that the majority of the protein was stable in the “supernatant”. This method of 
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first forming the triazole before the oxime formation with the protein proved 
successful and a much better alternative to performing the CuAAC directly on the 
protein. 
 
 
Scheme 4.4 Protein modification with ligand 53a. 
 
 
Fig 4.19 Mass spectrum of the modification of CTB with ligand 53a. 
 
 
Fig 4.20 SDS-PAGE of CTB plus galactose ligand 53a. The gel shows the modified protein stable as a 
pentamer after purification. During the reaction the pentamer was stable with very little precipitating 
(pellet) and most of the protein still present in the supernatant. The protein was isolated as a stable 
pentamer with no evidence for larger aggregates forming. 
 
After a successful reaction with the simple galactosyl azide 50, the microwave 
reaction was attempted on the larger lactose compound 51. Similar conditions were 
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used as before but with all concentrations being reduced due to limitations with the 
minimum volumes possible in the microwave reaction vessel. Reactions proved 
unsuccessful probably due to the limitations on the concentrations of the reaction 
mixture. 
 
In a parallel study, Dr. Tom McAllister performed the CuAAC reaction using a 
different procedure to connect GM1 azide 49 and alkyne 52. This CUAAC reaction 
was successful at room temperature with stirring for two days (see appendix). After 
purification on a reverse phase column, the correct product GM1 54 was isolated 
and could now be used in oxime reactions with the protein (Fig 4.21). 
 
 
Fig 4.21 Structure of GM1 ligand 54 for protein modification. 
 
This ligand was now used with the mutant protein in order to create the pentavalent 
ligand. The mutant protein was first oxidised and then W88Eox was purified using a 
PD G-25 minitrap column to remove the NaIO4 that might oxidise the diol on the 
sialic acid residue of the GM1os in the subsequent reaction. GM1 54a was 
successfully attached to W88Eox to give pentavalent ligand W88E(54), with ESMS 
confirming the mass for the product of 12844.51 Da (calculated 12844.41 Da) (Fig 
4.22). The modified protein was purified using a PD G-25 minitrap column and 
SDS-PAGE confirmed it to be present as the pentamer with no aggregation taking 
place (Fig 4.23). 
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Fig 4.22 (A) Mass spectrum of W88E modified with the GM1 ligand 54a and (B) the deconvoluted 
spectrum for W88E(54). 
 
 
Fig 4.23 SDS-PAGE of the protein modified with GM1 ligand 54a. The gel shows CTB, W88E and 
W88E modified with GM1 all as pentamers. 
 
4.2.3 Pentavalent GM1os interactions with wild-type CTB 
Now that GM1 was attached to a non-binding CTB protein, a pentavalent ligand had 
been created with potential for high affinity binding. The affinity of pentavalent 
ligand W88E(54) for wild-type CTB was therefore tested by ITC (Fig 4.24, Table 
4.2). With CTB in the cell (4 µM) and ligand W88E(54) injected (43 µM) from the 
syringe a Kd was detected of 30 nM that indicated a slightly stronger interaction 
than for the monovalent interaction of GM1 azide 49 which had a Kd of 56 nM. This 
affinity was surprisingly similar to the monovalent interaction as the multivalent 
effect of binding five ligands on one scaffold was expected to give rise to a 
significant increase in affinity. The stoichiometry of 1.1 for the titration indicated a 
binding model in which the protein-based ligand forms a 1:1 complex with CTB. The 
ΔH° for the binding interaction was a little smaller than that of the monovalent 
(A)            (B) 
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ligand. The prearrangement for the second interaction after a first GM1 unit has 
bound may mean that the enthalpy change upon binding is less for subsequent 
binding interactions. 
 
Performing the ITC experiment but with the components in the cell and syringe 
reversed, so that CTB (50 µM) was injected into ligand W88E(54) (5 µM), gave a 
different result. The Kd was much the same at 32 nM and again within the same 
range as the monovalent interaction. The enthalpy value was higher than the 
reverse titration and similar to the monovalent interaction. However, this time a 
stoichiometry of 0.54 was observed. This stoichiometry of less than 1 implies that 
now there is not 1:1 binding but instead suggests that one CTB injected is using up 
the ligands of two full W88E(54) pentamers. The increasing ratio of components 
may play a role in the stoichiometry as initially there is a large excess of the ligand 
which may bind to more than one pentamer (Scheme 4.5). The build up of large 
aggregates may then occur that results in not all the binding sites being accessible 
to the ligands. For the stoichiometry to be 0.5, this 2:1 arrangement must be stable 
and prevent the binding of the other ligands to different CTB units. This finding is 
unexpected as the reverse titration showed 1:1 binding and can simply be explained 
with the formation of face-to-face dimers of pentamers. 
 
 
Scheme 4.5 Proposed 2:1 and 1:1 binding models observed by ITC. 
 
Table 4.2 ITC results for ligand W88E(7) binding to CTB compared to GM1os. 
Cell 
component 
Syringe 
component 
Kd / nM ΔH° / kcal mol
-1 n 
CTB W88E(54) 29.6 ± 7.5 -10.48 ± 0.98 1.11 
W88E(54) CTB 32.4 ± 10.7 -15.39 ± 1.71 0.54 
CTB GM1 49 55.6 ± 6.4 -14.92 ± 0.15 0.91 
 
The Whitesides group found that trivalent ligands and antibodies initially formed 
aggregates before rearrangement over time into discrete particles.[69] In the ITC 
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experiment presented here, the same type of rearrangement may happen to form 
discrete dimers of pentamers. The timescale of the ITC experiment may be too 
short to see this rearrangement, whereas AUC experiments that are performed over 
a larger timescale may show stable structures. 
 
 
Fig 4.24 ITC traces of the binding between CTB and ligand W88E(54). The ITC results show the 
strong interaction between CTB and ligand W88E(54), and the differences observed when the 
components in the syringe and the cell are reversed. A) W88E(54) injected into CTB, B) CTB injected 
into W88E(54) and C) GM1 azide 49 injected into CTB. 
 
(A)             (B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(C) 
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AUC was performed at varying ratios of CTB and pentavalent ligand W88E(54) (Fig 
4.25). At a ratio of 1:1 with both components at 20 µM pentamer concentration, the 
AUC showed a large peak at 6.3 S and a smaller peak at 3.6 S resulting in masses 
of 113 kDa and 49 kDa respectively. These peaks corresponded to a dimer of 
pentamers and for the single protein pentamer. The smaller peak was likely to be 
caused by a slight inaccuracy with the concentrations of the two components not 
being exactly equal. When the concentration of ligand W88E(54) was decreased to 
4 µM, so the ratio with CTB was now 1:5, the pentamer peak was greatly increased. 
This was not surprising as there was now an excess of CTB. The peak for a dimer 
of pentamers also decreased, which was because now there was less W88E(54) 
present and so less to form dimers. Sisu et al. used AUC to analyse the structures 
formed by GM1os dendrimers and showed similar results for dimers of pentamers. 
The dendrimers gave a mismatched valency with CTB which caused aggregation of 
the protein.[116] Crucially in the work presented here, there were no other larger 
peaks observed. There was also little change to the concentration of proteins in the 
cells following AUC, indicating that no protein was lost from the formation and 
pelleting of large aggregates. Matching of the valencies led to the formation of only 
dimers of pentamers. The formation of a six component complex or any larger 
structures was not observed.  
 
 
Fig 4.25 c (s) plot of CTB with pentavalent ligand W88E(54). When ligand W88E(54) and CTB were 
mixed in equal quantities, a dimer of proteins was observed in the AUC (green). When the ratio of the 
components was altered to 1 to 5 so more wild-type CTB was present (purple), some dimer was still 
observed but more protein pentamer was seen due to the excess of CTB not binding to any ligand.  
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SDS-PAGE performed on the AUC samples confirmed the AUC results; a band for 
a dimer was seen in the 1:1 sample whilst a stronger band for pentamer as well as 
the dimer was seen in the 1:5 sample (Fig 4.26). 
 
 
Fig 4.26 SDS-PAGE of AUC samples. The gel shows dimer formation in the 1:1 sample and some 
dimer in the 1:5 sample although due to the excess CTB there is a stronger pentamer band. 
 
DLS was also used to assess the size of the assemblies (Fig 4.27). The samples 
from the AUC experiment were filtered before measurement by DLS, which 
confirmed the formation of species larger than CTB. At a 1:1 ratio, the DLS showed 
a peak at 8.4 nm, and at 1:5 ratio the peak was slightly shifted down to 7.8 nm 
indicating the formation of protein dimers in both cases. At the 1:5 ratio the peak 
was slightly lower, possibly due to the presence of the excess CTB with a size of 
5.7 nm causing the peak to shift as the analysis could not differentiate well between 
the two species of similar size. The crystal structure of CTB indicates a diameter of 
6.5 nm, however, the protein is not spherical. It has a depth of 3.5 nm and so it 
could be envisaged that a face-to-face dimer would have dimensions of 6.5 nm by 
at least 7 nm. The diameter measured by DLS was therefore in agreement with the 
expected result for a dimer of pentamers. 
 
The combination of AUC, SDS-PAGE and DLS confirms that protein based 
pentavalent ligand W88E(54) is mostly binding to CTB in a 1:1 ratio causing the 
formation of protein heterodimers of around 8.4 nm diameter. Little evidence for 
larger aggregates was seen indicating that this ligand does not bind to multiple CTB 
proteins. The formation of a six pentamer complex that would be half a 
dodecahedron was not observed; only face-to-face protein heterodimers (Scheme 
4.6). The GM1 ligands are the highest affinity ligands to which we have access and 
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so there are no other ligands that could be used to inhibit these interactions. 
Therefore this system with the high affinity ligands will not be useful for building 
structures larger than dimers of pentamers or more complex protein assemblies. 
 
 
Fig 4.27 DLS results for CTB plus ligand W88E(54). The DLS results show that mixing the ligand with 
wild-type CTB causes an increase in the size of the particles in solution compared to wild-type CTB 
(red). At a ratio of 1:1 (green), 8.4 nm particles are observed indicating dimer formation. When the 
ratio is increased (blue), no larger species are seen and the peak slightly shifts to a lower value 
possibly due to the presence of more pentamers of a smaller size to the dimers. 
 
 
Scheme 4.6 Formation of protein heterodimers with ligand W88E(54) and CTB. 
 
Whilst this assembly was perhaps a dead end for producing a dodecahedron, it did 
however present an alternative opportunity. As pentavalent ligand W88E(54) binds 
1:1 to CTB with high affinity, there was potential for it to be used as a novel 
protein-based cholera toxin inhibitor. 
4.2.4 Inhibition of CTB binding 
The modified mutant protein is the perfect size for binding to CTB. The individual 
GM1 ligand groups are perfectly placed with the correct spacing for binding to CTB, 
which could make ligand W88E(54) a very powerful inhibitor of cholera toxin. Other 
inhibitors of the AB5 bacterial toxins have varied in design from polymers and 
dendrimers to more tailor-made star structures (see chapter 1 part II).[70] The 
star-shaped structures with 5-fold symmetry represent some of the best inhibitors 
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due to a precise match of the ligand groups and binding sites. ITC had already 
showed that ligand W88E(54) has a strong binding affinity for CTB, but no increase 
in affinity from the monovalent interaction was seen. It was seen by Sisu et al. that 
multivalent GM1os dendrimers gave no increase in the Kd for the binding affinity as 
measured by ITC, but enzyme-linked immunosorbent assays (ELISA) showed a 
much increased inhibition of CTB.[116] Therefore further experiments were needed to 
show the inhibitory potential of pentavalent ligand W88E(54). 
 
An Enzyme-linked lectin assay (ELLA) was performed to determine the inhibitory 
potential of ligand W88E(54). The inhibitor was premixed with horse-radish 
peroxidase-conjugated CTB (HRP-CTB) and then added to the plate. Unbound 
HRP-CTB was washed off the plate before a colorimetric assay with ortho-
phenylenediamine (OPD) to determine the amount of HRP-CTB bound to the plate. 
The assay therefore tests the ability of ligands to inhibit the binding of CTB to 
ganglioside GM1 adsorbed on to the surface of the microtitre plate. Pentavalent 
ligand W88E(54) showed a very low IC50 value of 104 pM. The monovalent GM1 
ligand 49 was also tested and a much higher IC50 value of 1.49 µM was found (Fig 
4.28). Comparing the difference in potency from a mono- to pentavalent ligand 
showed a 14 thousand times increase, which gave an impressive relative inhibitory 
potency of 3 thousand times per GM1os ligand group (Table 4.3). The unmodified 
W88E protein was used as a control and as expected showed no inhibition of CTB. 
This result compared well with other pentavalent ligands such as GM1os-
calix[5]arene that was recently shown to have an IC50 of 450 pM.
[121]  
 
However, the assay used a CTB-HRP concentration of 340 pM and so, with a 1:1 
binding model, when the concentration of inhibitor went below the concentration of 
CTB-HRP then there would be excess CTB-HRP that could bind to the plate and 
give an absorbance signal. Therefore the limit of detection for this assay was 
reached with the W88E(54) as an inhibitor. If the concentration of CTB-HRP could 
be lowered then the assay could be performed again to better determine the true 
inhibitory potential of the pentavalent ligand.  
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Fig 4.28 Fitted curves of the ELLA inhibition data for (A) pentavalent W88E(54), (B) monovalent GM1 
azide 49 and (C) the W88E protein. 
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The octavalent GM1os ligand 19c from the Pieters group was tested using a similar 
assay and was found to have an IC50 of 50 pM which is the most successful 
inhibitor of CTB produced so far.[115] With a more sensitive assay, W88E(54) could 
be seen to rival this octavalent inhibitor. The protein based inhibitor also has the 
advantage that it is comparably easier to synthesise. The protein can be produced 
easily in large quantities and the reaction to modify and purify the protein is simple. 
Whilst the synthesis of the carbohydrate ligand itself is not trivial[164], overall a much 
more accessible structure can be produced compared to the calixarene or 
dendrimer inhibitors. 
 
Table 4.3 Potency of the inhibitors measured by an ELLA. 
a 
No inhibition was detected. 
b 
Potency was 
measured relative to the monovalent ligand 49. 
Inhibitor Valency log(IC50) IC50 / nM 
Relative potency 
(per GM1os)b 
GM1 azide 49 1 -5.83 ± 0.11 1490 1 (1) 
W88E(54) 5 -9.98 ± 0.08 0.104 14,300 (2,860) 
W88E 0 - a - a - 
 
4.3 Conclusions 
A mutation was introduced into the GM1os binding site of CTB which prevented any 
binding with the oligosaccharide. This mutant was modified with carbohydrate 
ligands and it was found that a simple galactoside ligand did not have a high 
enough affinity to bind to other proteins. A GM1 ligand was used which did induce 
interactions and binding between the modified protein and wild-type CTB. Dimers of 
pentamers were formed and no larger structures were seen. Whilst this observation 
meant that a dodecahedron or other larger structures were not accessible with 
these components, it nevertheless provided a potential CTB inhibitor. An IC50 value 
for GM1 modified mutant protein, W88E(54), was found as 104 pM. This value is in 
the best of any pentavalent CTB inhibitors produced so far and in the same range 
as the best dendrimer structures. 
 
Due to the strength of the five GM1os interactions, the reversibility of pentavalent 
ligand W88E(54) is limited. To allow the formation of the complex to be more 
reversible, lower affinity ligands could be used. It was already seen that galactoside 
ligands were not strong enough but studies have shown MNPG ligands to be 
suitable for protein binding.[156] MNPG ligands have a micromolar Kd and may be 
strong enough to bind to CTB but still lower in affinity than GM1, with a nanomolar 
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Kd. Use of the MNPG ligands could provide some reversibility to the system. The 
linker length of the GM1 ligands could also be shortened which may affect which 
interactions can take place. With shorter ligands it may not be possible for all five 
ligands to reach around and form a dimer of pentamers with CTB. Instead they 
could bind one CTB pentamer on each GM1 arm of the ligand. These studies could 
be performed to access a larger range of structures with this two component 
system. 
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5 Templating the construction 
 
 
 
 
 
Investigations into the use of a template to 
preorganise the proteins 
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Uncontrolled aggregation occurred when ligands were attached directly to CTB at 
the N-terminus. The lack of control over the assembly process meant the structures 
were free to form any arrangement and so the creation of discrete particles was not 
observed. This represented the major challenge for the project; guiding the 
self-assembly process towards discrete complexes and away from disordered 
aggregates.  
 
A new strategy for the formation of a dodecahedron from CTB was to use a scaffold 
to prearrange the proteins. Viral particles are often seen to be templated by their 
RNA genome[165] and supramolecular chemistry also often makes use of templates 
to give rise to complex architectures[73]. To arrange CTB proteins into a 
dodecahedral configuration, a spherical template was required. 
 
This chapter will discuss the suitability and use of a micelle template for the 
prearrangement of CTB proteins. 
  
5.1 Micelles 
Triton X-100 (TX-100) 55 is a detergent that forms micelles of 7-10 nm in diameter. 
The size and the aggregation number (Nagg) can be varied with temperature.
[166] A 
micelle of this size would fit inside the target protein dodecahedron and therefore 
could be used to template the formation of these structures. Tyloxapol 56 has a 
similar structure to TX-100 but is known to form more stable micelles with a lower 
critical micelle concentration (CMC) (Fig 5.1).[167] TX-100 and tyloxapol were 
investigated to assess their suitability for providing a template with tuneable size. If 
the micelles were modified with carbohydrate ligands then they would act as 
scaffolds for the proteins to assemble around and the degree of modification could 
be varied to adjust the valency of the micelles. Multivalent ligands could then be 
introduced to cross-link the pentamers on the micelles (Fig 5.2). Alternatively, the 
pentamers themselves could be modified directly with ligands at the N-terminus 
after assembly around the micelles and due to the prearrangement from the 
template, the pentamers should bind in the desired arrangement. 
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Fig 5.1 Structures of TX100 55 and tyloxapol 56. 
 
 
Fig 5.2 Templating strategy with micelles. 
 
5.1.1 Analysis and modification of the micelles 
The size of the micelles formed by TX-100 55 and tyloxapol 56 was measured by 
DLS at a detergent concentration of 1 mg ml-1 (Fig 5.3). The data clearly show a 
slight difference between the two detergents. The size of the micelles measured for 
TX-100 55 were 6.5 nm and for tyloxapol 56 were 7.6 nm at 20 °C which compare 
well with literature values.[166] 
 
 
Fig 5.3 DLS showing TX-100 55 (purple) and tyloxapol 56 (dark blue) with diameters of 6.5 nm and 
7.6 nm respectively measured at 20 °C. 
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Both TX-100 55 and tyloxapol 56 were modified with carbohydrate ligands. TX-100 
galactoside 57, tyloxapol galactoside 59 and TX-100 lactoside 58 were prepared 
(synthesised by Dr. Martin Fascione) (Fig 5.4). These modified detergents should 
present their carbohydrate ligands around the surface and so allow the binding of 
CTB. The attachment of a carbohydrate group on the detergents was not entirely 
successful with only 60% of the detergent molecules becoming modified. However, 
despite the incomplete conversion of the detergents, at 60% there would be 
approximately 60 carbohydrates per micelle because the Nagg of TX-100 is around 
100 at 20 °C.[166] A micelle with 60 carbohydrate ligands would provide one ligand 
for each of the binding sites of the 12 pentamers that would be needed to form a 
dodecahedron. If it was found that binding to all the potential binding sites was not 
required or if it proved difficult to displace the template ligands then the percentage 
of modification could easily be lowered by dilution with unmodified TX-100 55 or 
tyloxapol 56. 
 
 
Fig 5.4 Structures of the detergents modified with carbohydrates. 
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To determine the CMC of the original and modified detergents, ITC titrations were 
performed. During the experiment the detergent at a concentration above its 
predicted CMC was titrated into water and heat was released as micelles 
dissociated.[168] Once the concentration of the detergent in the cell became greater 
than the CMC, then increasing the concentration resulted in no further heat change 
and, thus allowing the CMC to be calculated (Fig 5.5). The CMC for TX-100 55 was 
found to be 0.27 mM which was in good agreement with a literature value of 
0.31 mM found previously by ITC.[168] The ΔH° of -2.26 kcal mol-1 was also in good 
agreement with the literature value of -2.06 kcal mol-1.[168] The CMC values for the 
TX-100 detergents 50% modified with carbohydrates 57 and 58 were found to be 
higher than the original detergent (Table 5.1). Galactoside 57 had a CMC of 0.40 
mM and lactoside 58 was 0.59 mM which suggested that the modifications provided 
a slight hindrance to the micelle formation. The ΔH° for the glycosylated detergents 
was also reduced compared to TX-100. When the micelles formed the 
carbohydrates may not have packed as well into the structures and so ΔH° for the 
interactions was reduced. Tyloxapol 56 was known to have a CMC at least 10-fold 
lower than TX-100 55, with a literature value of 8.4 µM.[167] The ITC titration was 
performed at a lower concentration for this detergent, but there is no obvious heat 
change upon crossing the CMC value and so an accurate value for the CMC could 
not be resolved. Tyloxapol galactoside 59 was not analysed as it was thought that 
ITC would again not be able to give an accurate value.  
 
Table 5.1 CMC values from ITC titrations 
Detergent CMC / mM ΔH° / kcal mol-1 
TX-100 55 0.27 -2.26 ± 0.04 
TX-100 gal 57 0.40 -1.64 ± 0.02 
TX-100 lac 58 0.59 -1.00 ± 0.01 
 
The Nagg value of 100 at 20 °C for TX-100 55 meant that at a concentration of 1 
mM, crucially above the CMC, the concentration of actual micelles would be 10 µM. 
To arrange 12 CTB pentamers around each micelle, the CTB (monomer) 
concentration would need to be 600 µM, which was within an easily accessible 
range for the protein. 
 
132 
 
 
Fig 5.5 ITC traces to find the CMC of the detergents A) TX-100 55, B) TX-100 galactoside 57, C) 
TX-100 lactoside 58 and D) tyloxapol 56. 
 
The sizes of the modified detergents were analysed by DLS (Fig 5.6). The samples 
were analysed at 1 mM concentration so that they were above the CMC for each 
detergent, and the percentage of carbohydrate components was varied to see if 
their addition would alter the size of the micelles formed.  
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Fig 5.6 DLS of modified detergents at different percentages. (A) TX-100 galactoside 57, (B) TX-100 
lactoside 58 and (C) tyloxapol galactoside 59. 
 
It was found that for TX-100 galactoside 57 with 50% modified detergent, particles 
with a diameter of 380 nm were formed as well as the small micelles at 6.6 nm. 
When the amount of carbohydrates used was reduced to 25% or lower, this higher 
species disappeared and only the smaller micelles at 6.5 nm were observed. This 
effect was more pronounced for TX-100 lactoside 58. A variable amount of large 
particles ranging 310-850 nm were observed with the higher percentage of 
modification. When the amount of carbohydrate was reduced to 10%, only 6.8 nm 
micelles were seen. Conversely, tyloxapol galactoside 59 was much more 
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representative of its parent detergent as, at 50% carbohydrate, only micelles of 7.0 
nm were observed. The stability of tyloxapol 56 is known to be greater than TX-100 
55 and so it was not surprising that this detergent still formed stable micelles once 
modified. The glycosylated TX-100 detergents, however, were not as stable and led 
to the formation of large particles of unknown shape. The bulky carbohydrate 
groups presumably disrupted the hydrophilic interactions at the surface of the 
micelles or caused steric clashes when too many were present. This interference 
may have led to a rearrangement of the structures into much larger particles.  
 
Reducing the amount of carbohydrate present to only 10% of the detergent 
concentration meant that there would be only around 10 of these groups present 
per micelle. This low amount may not be enough to bind multiple copies of CTB 
around its surface. The system however may reorganise to bind one CTB pentamer 
with the carbohydrates forming clusters in the micelles. This arrangement could be 
enough to start the templating of other CTB pentamers around the micelles with the 
introduction of additional divalent ligands. Ideally the amount of carbohydrates 
would need to be at least 12% so that each micelle could still potentially bind 12 
pentamers. 
5.1.2 CTB binding to the micelles 
TX-100 galactoside 57 was mixed with increasing concentrations of CTB and DLS 
was used to observe any changes in the size of particles. If even a single CTB 
pentamer were to bind to the surface of a micelle, the particle size observed should 
be larger than that of the micelle or CTB. With more CTB units binding the change 
in size should be easily distinguishable. 10% TX-100 galactoside 57 (1 mM) was 
used which gave a micelle concentration of 10 µM, assuming an Nagg of 100. This 
amount of modified detergent was used to be sure that larger structures did not 
form and only particles of 7.2 nm were observed. CTB was then titrated into the 
solution at an initial ratio of 8 pentamers per micelle; this ratio was increased to 12 
and then 16 (Fig 5.7). For tyloxapol galactoside 59, 50% carbohydrate was used as 
the problems with micelle sizes did not seem to affect the tyloxapol based system. 
Again at 1 mM detergent, CTB was mixed at ratios of 8, 12 and 16 to the micelles. 
With the addition of CTB, no larger structures were observed by DLS with either the 
TX-100 or tyloxapol-based micelles. The analysis showed only one species present 
at a size equal to the CTB pentamer as there was now excess CTB present the 
signal shifted to show only this size particle. With both tyloxapol and TX-100 mixed 
with CTB, the two components did not appear to interact to form larger structures. 
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Fig 5.7 DLS of 1 mM detergents at 10% modification mixed with CTB at varying ratios. (A) TX-100 
galactoside 57 and (B) tyloxapol galactoside 59. 
 
As no interactions had been observed by DLS, further analysis was needed to show 
whether the glycosylated micelles were capable of binding to CTB. Competition ITC 
titrations were therefore performed to further understand the binding interactions 
between the modified detergents and CTB. CTB was premixed with the modified 
detergents before GM1os was titrated in. Interactions between the detergents and 
CTB would lead to an apparent reduction in the GM1os interaction. Using a 
competing detergent concentration of 3.2 mM and the carbohydrate modification at 
50% of detergent molecules gave a competing ligand concentration of 1.6 mM. The 
detergents were mixed with CTB (12 µM monomer concentration) and GM1os (140 
µM) was titrated into the solution (Fig 5.8). 
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Fig 5.8 ITC traces of competition titrations with A) Tyloxapol galactose 59, B) TX-100 galactose 57, C) 
Tx100 lactose 58 and D) only the GM1os titration. 
 
Titrations with all three modified detergents, 57, 58 and 59, showed no change to 
the usual GM1os binding (Table 5.2). The observed Kd for each titration was within 
the same range as the direct GM1os titration and there was no change in the 
enthalpy for the interaction which is often seen in competition titrations.[89] The ITC 
titrations were performed with the concentration of competing ligand at 1.6 mM 
which was around the expected Kd for galactose (12 mM). Whilst this concentration 
was not greater than the Kd it was hoped that a multivalent effect of having multiple 
A B 
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ligands fairly closely packed on the micelles may have contributed towards an 
enhanced binding affinity.  
 
Table 5.2 ITC data for the titrations with premixed detergents and for the direct titration with GM1os. 
 
 
Ligand Kd / nM ΔH° / kcal mol
-1 n 
GM1os 81 ± 15.0 -12.6 ± 0.2 1.05 
 
The micelle concentration was only 32 µM, 100 times less than the overall 
detergent concentration due to the Nagg. Therefore the ligands were clustered in 
groups of around 10 galactose units at the concentration of 32 µM. This 
concentration is well below the Kd for galactose and so it is perhaps not surprising 
that no binding was observed by ITC. The micelles would present a higher effective 
concentration but in solution the ligands would be more disperse. The nature of the 
weak galactose interactions restricts the concentration range that is workable for 
the system and may have contributed to the failure of the modified micelles to bind 
to CTB. 
 
The same problem was likely the cause for failure in the DLS experiments; the 
concentrations used were simply too low. But it would not have been practical to 
increase the concentrations enough to approach the Kd of galactose. The enhanced 
binding of a multivalent system previously seen with polymers and dendrimers was 
not observed with these micelles.[102, 114]  
 
5.1.3 Conclusions 
The TX-100 and tyloxapol micelles are potentially the perfect size to be templates 
for CTB. However, the unpredictable micelle structure when high percentages of 
carbohydrates were incorporated onto the detergents made their use with TX-100 
unfeasible. Tyloxapol, however, provided a more stable structure with a lower CMC 
value. The low affinity of the carbohydrate interactions was proved to be an issue 
Competing ligand Kd / nM ΔH° / kcal mol
-1 n 
TX-100 galactoside 57 37 ± 19.2 -11.9 ± 0.4 0.99 
TX-100 lactoside 58 72 ± 33.3 -12.5 ± 0.4 1.06 
Tyloxapol galactoside 59 90 ± 29.5 -12.8 ± 0.1 0.99 
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and was likely the deciding factor in why no interactions were seen between the 
micelles and CTB. 
 
A solution to the low affinity problem could be to use detergents modified with 
GM1os ligands. Whilst this is a larger carbohydrate and so may prove more of a 
problem for forming stable micelle structures, the use of tyloxapol could overcome 
these problems. The GM1os ligand has a much higher affinity for CTB and could be 
used at lower concentrations which did not work for the galactose-based system. 
Less ligands may be needed as well as a single GM1os should be strong enough to 
hold a CTB unit to the surface of the micelle. However, using GM1os ligands brings 
the problem of reduced reversibility of the interactions. There are no ligands 
available that could out-compete the GM1os ligands and so CTB could become 
stuck to the micelle surfaces without the subsequent options to cross-link them, to 
remove them or to rearrange the structures.  
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6 Tying the assembly together 
 
 
 
 
 
Using the AB5 complex to preorganise assembly 
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Cholera toxin exists as an AB5 protein. After removal of the toxic subunit (CTA1), 
the CTA2 α helix extends from CTB out of the opposite face to the GM1os binding 
sites (Fig 6.1 A). The N-terminus of CTA2 is positioned at the end of this α helix and 
is an attractive target for site-specific modification. The N-terminus of CTB has been 
modified with ligands (chapter 2) and so the CTA2 N-terminus could also be 
targeted in a similar way (Fig 6.1 B). 
 
The CTA2 peptide, whilst existing as an α helix when the full CTA unit is present, 
may actually become an unstructured peptide chain once cleaved. This 
unstructured nature may be beneficial for modification as it should add more 
flexibility to the peptide. If multiple copies of the AB5 protein could be grouped 
together by clustering their CTA2 peptides, then the CTB units would all be 
presented facing outward (Scheme 6.1). With the CTB proteins now in close 
proximity, they could be linked together with multivalent ligands and there would be 
no need for a separate template.  
 
  
Fig 6.1 (A) Surface representation of the cholera toxin AB5 after the removal of toxic CTA1, with the 
N-termini of both CTB and CTA2 highlighted (yellow) and the GM1os binding shown (blue). (B) 
Cartoon model for the potential modifications of the N-temini of CTB or CTA2 with ligands. 
 
This chapter outlines the steps taken to modify the CTA2 peptide with ligands with 
the aim of bringing together multiple copies of the AB5 protein. The use of a number 
of ligands is discussed and the different methods of their attachment onto CTA2. 
 
6.1 Making use of metal complex formation 
A strategy was needed to modify the CTA2 N-terminus with a ligand or functional 
group that could be used to join the proteins together. One method for achieving 
A             B 
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this arrangement would be to attach a metal binding group to the CTA2 proteins 
and then coordinate multiple copies around a metal centre (Scheme 6.1). The use 
of metal coordination has been shown recently in a number of studies to be a useful 
method for the design of protein assemblies.[169, 170] A metal favouring an octahedral 
geometry binds three bidentate ligands. Once three AB5 proteins were clustered 
around a metal centre then a trimeric ligand could be used to bind to the CTB 
subunits and crosslink the proteins. The arrangement would be constrained into a 
trimer of pentamers that would be effectively a quarter of a dodecahedron made up 
of AB5 proteins. To achieve a full dodecahedron, further ligands could be introduced 
to cluster four of the trimers together to form a dodecamer. The flexibility of the 
CTA2 peptides would be of great importance as they would have to be able to bind 
to the metal and still bend around so the CTB moeities were in close proximity. The 
length and flexibility of the trimeric ligand would also have to be quite specific; being 
long enough to reach three CTB pentamers but not so long or flexible as to bind two 
or more binding sites on the same pentamer.  
 
 
Scheme 6.1 The use of metal (M) binding to arrange three AB5 proteins with bidentate ligands in an 
octahedral geometry. A trimeric carbohydrate ligand could then be used to constrain the proteins.  
 
6.1.1 Investigating the metal binding 
Fe2+ exhibits an octahedral coordination geometry with bound ligands. The ligand 
2,2’-bipyridine (bpy) was chosen as a bidentate ligand which binds to Fe2+ in a 3:1 
ratio. The binding of bpy derivatives produces a deep red colour with an 
absorbance maximum at 544 nm and an extinction coefficient of 8650 M−1 cm−1 (Fig 
6.2). The absorbance was sufficient that, if in a complex with proteins at high 
micromolar concentrations, the red colour change and 544 nm peak would still be 
observable at the concentrations used in our studies. The bpy coordination to Fe2+ 
has also been shown to be dynamic and can adjust the spatial arrangement of the 
ligands to fit the needs of the system.[171] 
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Fig 6.2 UV spectrum of depsipeptide 60 (150 µM) binding to Fe
2+
 (50 µM). 
 
 
Fig 6.3 Structure of bpy containing depsipeptide 60. 
 
Fe2+ is incompatible with many buffers as it precipitates, but even in the presence of 
many buffer salts (HEPES, TRIS, NaCl, PO4 etc) the complex with bpy is still 
formed and remains stable in solution. If AB5 proteins were modified with 
bpy-depsipeptide 60 (Fig 6.3), they should be able to complex the metal in the 
same way, bringing three proteins together stable in a buffered solution. 
 
The sortase enzyme was used to attach the metal binding bpy group to CTA2. The 
enzyme is a trans-peptidase from S. aureus that can be used for ligating peptides 
that contain a C-terminal LPETG sequence and an N-terminal glycine residue. A 
cysteine residue in the sortase enzyme becomes covalently attached to the LPET 
motif forming a thioester. The N-terminal glycine motif can then react with this 
intermediate to form an amide bond.  
 
It had been seen previously by work in the Turnbull lab that depsipeptides 
containing ester linkages rather than amide bonds can enhance the reaction of an 
LPETG motif to GGG with the sortase enzyme.[172] The use of the ester linkage in a 
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depsipeptide, rather than an amide bond, means that once the ester bond was 
cleaved from the LPETG sequence then the hydroxyacetyl byproduct is not a 
substrate for the reverse reaction with the enzyme.[172] The enzymatic reaction is 
therefore no longer in equilibrium and can reach completion without a large excess 
of substrate. Hydrolysis of the ester can be a problem over time, but this can be 
overcome by using more equivalents in the reactions. The short depsipeptide 60 
was synthesised by SPPS containing the bpy function and the C-terminus ending 
with an LPETG sequence (synthesised by Miss Fiona Ng) (Fig 6.3).  
 
After the purification of depsipeptide 60 the UV spectrum showed a very small 
residual absorbance at 544 nm indicating a small amount of metal was bound that 
could not be removed by purification (Fig 6.2). FeCl2 was titrated against bpy 60 to 
analyse the absorbance and find the amount of metal already bound to the ligand 
(Fig 6.4). The absorbance increased as Fe2+ was titrated in to the bpy 60 solution. 
The absorbance then reached a maximum when all the Fe2+ was bound to the 
ligand at a ratio of 0.22. This was below the expected ratio of 0.33 and showed that 
34% of the ligand was already bound to a metal. As depsipeptide 60 did bind Fe2+ it 
was thought that the impurity would not significantly interfere with further studies. 
 
The strength of the binding interaction in the metal complex was investigated by 
ITC. FeCl2 (500 µM) was titrated into bpy depsipeptide 60 (50 µM) and an apparent 
affinity with a Kd of 2.9 µM was found for the interaction (Fig 6.5). A stoichiometry of 
0.72 was observed which was difficult to interpret as a stoichiometry of 0.33, or 
lower if some of the ligand was already bound to metal, was expected due to the 
3:1 ratio of ligand to metal binding. As excess iron enters the system, the 
complexes may adjust to form not only Fe(bpy)3 but also Fe(bpy)2 or even Fe(bpy) 
which would mean that the curve no longer represents the binding stoichiometry. 
However, the low micromolar Kd showed that the interaction would be strong 
enough and accessible at the micromolar concentrations normally used for protein 
reactions and other biophysical analysis. 
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Fig 6.4 Titration of FeCl2 against depsipeptide 60 showing the absorbance at 544 nm. 
 
 
Fig 6.5 ITC trace for Fe
2+
 binding to bpy depsipeptide 60. 
 
6.1.2 AB5 purification and modification 
A suitable AB5 protein needed to be made for attachment of bpy depsipeptide 60 to 
CTA2. The AB5 protein was expressed as the CTB protein and a maltose binding 
protein fusion with CTA2 (MBP-CTA2). The two proteins were encoded in the same 
plasmid and expressed together forming the AB5 in the bacteria before being 
exported into the growth medium. The MBP-CTA2 fusion was constructed to aid the 
solubility of CTA2 and help the purification process. The MBP protein would first 
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have to be cleaved before later reactions could be performed on the CTA2 
N-terminus.  
 
The tobacco etch virus (TEV) protease is specific to the recognition sequence of 
ENLYFQG with cleavage occurring between the Q and G residues of the protein. A 
TEV cleavage site had been incorporated into the sequence between MBP and 
CTA2 in the fusion protein and so after cleavage would reveal a GGG motif on the 
N-terminus of CTA2 (Scheme 6.2). This motif would then be accessible for the 
sortase enzyme to append a peptide containing a LPETG C-terminal sequence, 
such as depsipeptide 60. TEV cleavage can occur at unspecific sequences in the 
protein after a long incubation period or if a large mol% of TEV is used. Care was 
needed to optimise the cleavage conditions for the use with the MBP-CTA2 protein. 
 
 
Scheme 6.2 TEV cleavage of MBP-CTA2 followed by the attachment of a short depsipeptide to the 
revealed N-terminus of CTA2 via sortase ligation. The proteins are CTB (red), CTA2 (green) and MBP 
(cyan). 
 
The MBP-AB5 protein was encoded in plasmid pSAB2.1T. The N-terminus of the 
CTB protein encoded by this plasmid was a threonine residue (DNA constructed by 
Mr James Ross) so that oxime chemistry may also be possible with the CTB 
subunit. The protein complex was expressed in E.coli by induction with IPTG and 
growth at 30 °C for 24 h. After purification by ammonium sulfate precipitation, nickel 
affinity chromatography and then SEC, a yield of 2.5 mg L-1 was obtained (Fig 6.7). 
The concentration of the MBP-AB5 protein was measured by UV spectroscopy at 
280 nm, using a theoretical molar extinction coefficient of 128,745 M-1 cm-1, 
calculated from the sequence by ExPASy Proteomics. ESMS showed two proteins 
with masses 48831.2 Da and 11643.2 Da for MBP-CTA2 and CTB respectively 
(calculated 48823.9 Da and 11642.9 Da) (Fig 6.8). The accuracy of the mass 
measured by ESMS reduced as the size of the proteins increased. The increased 
broadness of the high charge states led to a less precise measurement, but this 
was still within the right range for the expected mass of MBP-CTA2. 
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Fig 6.6 SDS-PAGE of AB5 expression and purification in a Ni affinity column. 
 
 
Fig 6.7 Chromatogram showing purification of MBP-AB5 after expression and initial purification by Ni 
affinity chromatography. 
 
 
Fig 6.8 Mass spectrum of the purified AB5 showing the separate MBP-CTA2 and CTB. 
 
The MBP-AB5 protein was found to be fairly unstable at room temperature or after 
incubation at 4 °C for more than a few days. The MBP-CTA2 fusion was seen to 
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denature and no longer stayed as the MBP-AB5 complex. AUC was performed on a 
freshly purified sample and a sample that had been stored at 4 °C for 7 days, to 
analyse the size of the protein and its stability (Fig 6.9). The fresh sample showed a 
peak at 7.6 S which corresponded to a mass of 92.7 kDa matching fairly well with 
the expected mass of the MBP-AB5 of 107 kDa. But the “old” sample showed a 
single peak at 5.8 S corresponding to a mass 45.6 kDa showing that the MBP-AB5 
was no longer stable in solution and had dissociated to yield the CTB and 
MBP-CTA2 separately.  
 
 
Fig 6.9 AUC c (s) plot of MBP-AB5 performed at 30 krpm. A “fresh” sample showed clearly as the 
MBP-AB5 protein and an “old” sample incubated at 4 °C for 7 days showed only a smaller species 
around the size of both CTB and MBP-CTA2. 
 
The AUC samples were further analysed by SEC which confirmed the difference 
between the samples (Fig 6.10). For the fresh sample SEC showed a large peak 
with a retention volume of 15.8 mL for the AB5 protein and a smaller peak that 
showed some of the tertiary structure had began to dissociate. The old sample 
showed a single peak with retention volume 18.5 mL for the CTB and MBP-CTA2 
moeities. 
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Fig 6.10 Chromatogram of the samples from the AUC experiment, showing the degradation of the 
MBP-AB5 protein over time. 
 
TEV (5 mol%) was incubated with MBP-AB5, to cleave the protein, at room 
temperature in HEPES buffer and after 1.5 h the cleaved AB5 was purified on a Ni 
affinity column. This affinity column captured CTB, and therefore the associated 
CTA2, bound to the resin and the cleaved MBP and TEV protease were removed. 
The AB5 protein was eluted with 500 mM imidazole and ESMS analysis showed a 
mass of 5056.4 Da (calculated 5055.5 Da) for the cleaved CTA2 and the still intact 
CTB with a mass of 11642.9 (calculated 11642.9) (Fig 6.11).  
 
6.1.3 The complexation of bpy-AB5 
After MBP-AB5 was cleaved and purified to reveal the CTA2 N-terminus, the AB5 
protein was then incubated with sortase (10 mol%) at 37 °C and bpy depsipeptide 
60 (5 equivalents). After 4 h the reaction product was purified by SEC and ESMS 
gave a result of 5984.3 Da (calculated 5983.5 Da) for the modified CTA2 (Fig 6.11) 
as part of the A(60)B5 complex . 
 
A(60)B5 (25 µM) was mixed in a 3:1 ratio with FeCl2 with the aim to form a complex 
around the metal with three AB5 proteins. DLS was used to analyse the mixture but 
no complexation was observed (Fig 6.12). A(60)B5 showed a peak corresponding 
to a diameter of 8.1 nm which was larger than the 5.8 nm observed for CTB. But 
when FeCl2 was added no change in the size distribution was observed. 
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Fig 6.11 Mass spectrum of A(60)B5 showing complete modification of CTA2 and unmodified CTB. 
 
 
Fig 6.12 DLS results for A(60)B5 (blue) giving a diameter of 8.1 nm compared to CTB (red) at 5.8 nm 
but no increase in size shown on addition of FeCl2 to A(60)B5 (dark blue). 
  
The metal complex formation was investigated using UV spectroscopy. The 544 nm 
peak could be clearly seen when complexation occurred between the free bpy 
ligand 60 and FeCl2. However when A(60)B5 was mixed with FeCl2 at the same 
concentration (25 µM) no peak at 544 nm was observed and so the metal and 
protein were presumably not interacting (Fig 6.13). There was also no change in 
absorbance seen when the amount of Fe2+ was in excess at 10 equivalents. 
 
As the metal binding was not seen to take place once the bpy ligand was attached 
to the protein, it was thought that the Fe(bpy)3 complex could be formed first and 
then ligated to three CTA2 peptides simultaneously. The bpy depsipeptide 60 was 
premixed with FeCl2 at a ratio of 3:1, resulting in the solution turning an intense red 
colour indicating that metal complexation was successful. Sortase was used to 
react the AB5 protein with this metal complex and after 1 h the red colour had been 
lost to leave a colourless solution. After incubation for 4 h at 37 °C ESMS indicated 
that no reaction had taken place and only unreacted AB5 was present. The 
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disappearance of the red colour suggested that the metal complex was being 
disrupted and an interaction between AB5 and either the bpy group or the metal was 
taking place. This interaction must be of higher affinity than the Fe(bpy)3 complex in 
order to disrupt it. 
 
 
Fig 6.13 UV spectrum showing the 544 nm peak for bpy depsipeptide 60 binding FeCl2 (purple) 
(25 µM). No peak was observed when A(60)B5 was mixed at a 3:1 ratio with Fe
2+
 (dark blue) or with 
excess Fe
2+
 (light blue). 
 
UV spectroscopy was used to analyse conditions under which the metal complex 
formed. The Fe(bpy)3 complex formation was tested in the presence and absence 
of the CTB and AB5 proteins (Fig 6.14). It was found that the complex was formed 
as normal in the presence of CTB but not in the presence of AB5 or when bpy 60 
was attached to the AB5 as A(60)B5. Even increasing the Fe
2+ concentration to 10 
equivalents of Fe2+ per bpy 60 failed to form a complex in the presence of the AB5 
protein. These results indicated that Fe2+ was not complexing to the CTB protein 
and this protein did not inhibit the metal complexation. Therefore it was concluded 
that it was the CTA2 peptide that was interacting with the bpy group and preventing 
the formation of the metal complex. This interaction may be due to the sequence 
and unstructured nature of the CTA2 peptide that could be binding to the bpy group 
preventing any interactions with the metals. 
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Fig 6.14 UV spectra of the proteins mixed with bpy 60 in the absence of Fe
2+
 (blue), at a ratio of 3:1 
with Fe
2+
 (purple) and with an excess of the metal at 1:10 Fe
2+
 (red). The 544 nm peak was present in 
(A) CTB and bpy 60, and (B) no protein and bpy 60. But no absorbance was seen with (C) AB5 and 
bpy 60, or (D) A(60)B5. 
 
6.1.4 The creation of a new CTA2 sequence 
The bpy metal binding motif failed to bind to Fe2+ in the presence of the AB5. It was 
therefore postulated that changing the amino acid sequence of the CTA2 peptide 
might encourage binding. A polyasparagine chain was chosen as an appropriate 
sequence as it should form an extended chain giving plenty of space for the metal 
complex to form and UV spectroscopy showed that a polyasparagine sequence did 
not prevent the bpy 60 complex formation with Fe2+.  
 
A new gene was designed to encode the CTA2 peptide with the ENLYFQGGG 
sequence still intact for TEV cleavage, followed by five asparagine amino acids. All 
subsequent amino acids were removed up until the point at which the CTA2 peptide 
started to interact with the CTB pentamer and penetrate the centre of the pentamer 
(Fig 6.15). It was hoped that these alterations to the original sequence should 
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remove as much of the peptide sequence as possible and so prevent the binding to 
bpy 60 whilst still keeping the oligoglycine sortase tag and not affecting the 
interactions between CTA2 with CTB. 
 
 
Fig 6.15 Representation of the interface where CTA2 penetrates through the centre of CTB. A surface 
is shown on CTB (red) and CTA2 is shown as a stick representation of the amino acids (green) with 
the polyasparagine mutations (orange). 
 
The new gene was constructed from four short DNA parts by polymerase cycling 
assembly (PCA). After a successful PCA reaction, the original CTA2 gene was cut 
from plasmid pSAB2.1T before the new gene was ligated in to form the new 
plasmid pTRBAB5-D4N. E. coli XL10 cells were transformed with the new plasmid 
before a plasmid prep was performed to purify the DNA for sequencing and for 
transformation into E. coli BL21gold cells for expression. The new plasmid encoded 
the MBP-CTA2 fusion protein with the new polyasparagine CTA2 sequence and the 
CTB protein. 
 
The new MBP-AB5 (D4N) protein was expressed in E. coli BL21gold containing the 
new pTRBAB5-D4N plasmid by induction with IPTG and growth at 30 °C for 24 h. 
Purification by ammonium sulfate precipitation and nickel affinity chromatography 
was shown by SDS-PAGE (Fig 6.16). SEC was used to isolate the MBP-AB5 (D4N) 
protein and ESMS was performed that gave a mass of 47529.9 Da (calculated 
47488.3 Da) for the MBP-CTA2 (D4N) fusion and a mass of 11647.1 Da (calculated 
11643.3 Da) for CTB (Fig 6.17). 
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Fig 6.16 SDS-PAGE of the expression of AB5 (polyasparagine CTA2) and purification by Ni affinity 
chromatography. 
 
 
Fig 6.17 Mass spectrum of MBP-AB5 (D4N) showing the two separate subunits MBP-CTA2 (D4N) and 
CTB. 
 
After the new AB5 protein was purified, the MBP-CTA2 (D4N) fusion was cleaved 
with TEV protease. ESMS showed the new CTA2 (D4N) peptide with a mass of 
3723.2 Da (calculated 3719.9 Da) (Fig 6.18). The metal binding bpy depsipeptide 
60 was conjugated on the CTA2 (D4N) N-terminus using the sortase enzyme to 
form A(60)B5 (D4N).The resultant modification was confirmed by ESMS showing 
the mass of 4651.2 Da (calculated 4647.9 Da) for the modified CTA2 (D4N) and an 
unaltered mass of 11643.2 Da (calculated 11642.9 Da) for CTB (Fig 6.18). 
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Fig 6.18 Mass spectrum of the new AB5 (D4N) protein with the polyasparagine containing CTA2 
peptide cleaved and after modification with bpy 60. 
 
Formation of the metal complex was again investigated using UV spectroscopy. 
The new A(60)B5 (D4N) protein was mixed at 3:1 with FeCl2 but just as before no 
absorbance was seen at 544 nm (Fig 6.19). The bpy ligand and the Fe2+ were again 
not able to form the complex in the presence of the protein. The new CTA2 (D4N) 
peptide had the same effect as before, preventing the metal binding. When bpy 60 
and AB5 (D4N) were mixed together with FeCl2 at a ratio of 3:3:1 there was no 
absorbance seen at 544 nm as before. When the amount of free bpy was doubled 
again no change was seen but when the amount was tripled there was a sudden 
change in the absorbance profile. At three equivalents of bpy 60 to AB5 (D4N), the 
ligand was able to bind to Fe2+ resulting in an absorbance peak at 544 nm. This 
observation suggested that the AB5 protein was able to block two bpy ligands 
preventing their binding to the metal but addition of a third allows the metal complex 
formation.  
 
This lack of metal complexation may have been the result of the bpy ligand binding 
to an unstructured peptide sequence as thought with the original CTA2 sequence. 
Polyasparagine sequences are used in the multiple cloning site of MBP fusion 
proteins to provide a spacer section between the MBP and protein of interest, and 
so it was thought that this new polyasparagine-containing sequence would provide 
the same elongated structure. The metal binding was seen to occur in the presence 
of a larger polyasparagine sequence and so the new sequence was not expected to 
cause these problems. Most of the peptide sequence had been changed and so 
this negative result may have been due to the small amount of CTA2 that remained 
as before. The section of the CTA2 sequence that begins to interact with and 
penetrate CTB may be the site of bpy binding. If this section of the CTA2 peptide is 
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to blame for the inactivity of the bpy groups towards Fe2+ binding then there is little 
more that can be changed. Altering this section of the peptide might seriously affect 
how the tertiary structure of AB5 forms or if it forms at all.  
 
 
Fig 6.19 UV spectroscopy plots. (A) The polyasparagine CTA2 in A(60)B5 in the absence of Fe
2+
 
(blue), with a ratio of 3:1 Fe
2+
 (purple) and with excess metal at 1:10 Fe
2+
 (red). (B) The 
polyasparagine CTA2 in the AB5 protein mixed with bpy 60 with Fe
2+
 at ratios of 3:3:1 (dark blue), 
3:6:1 (green) and 3:9:1 (orange). 
 
The CTA2 (D4N) sequence did, however, provide a more robust protein for TEV 
cleavage. Unspecific cleavage was seen with the original MBP-CTA2 sequence 
when extended incubation times and a large mol% of TEV were used. This 
unspecific cleavage was not observed with the MBP-CTA2 (D4N) protein, due to 
the alternative CTA2 sequence. This new protein could therefore be used in place 
of the original for further studies when TEV cleavage was required. 
 
6.2 Protein-ligand interactions for assembly of the AB5 complex 
Another strategy considered for using the AB5 protein to initiate assembly of the 
proteins was to attach a ligand for binding to a different protein. If the second 
protein had multiple binding sites then it could bring the multiple copies of AB5 into 
close proximity for crosslinking with multivalent ligands. As the AB5 protein would 
present only one ligand, a strong interaction would be needed to cluster the 
proteins.  
 
An obvious protein-ligand system to use was the streptavidin-biotin interaction 
which has a Kd of 10
-14 M.[173] This affinity is exceptionally high for a protein-ligand 
interaction and easily high enough for the needs of this project. Streptavidin is a 
tetramer resembling a cuboid with dimensions of 6 × 5 × 4 nm with biotin binding 
sites in pairs on opposite faces of the protein (Fig 6.20).[174] If the AB5 protein was 
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modified with biotin then potentially four AB5 proteins could be bound to streptavidin 
(Scheme 6.3). The AB5 proteins brought together in this large complex could then 
be used to seed the assembly of larger structures. A similar strategy to this was 
demonstrated recently by Mori et al. with the incorporation of biotin and bis-biotin 
ligands onto an alkaline phosphatase.[175] This work showed that the positioning and 
flexibility of the ligands could control the nature of the protein complexes formed 
with streptavidin.  
 
   
Fig 6.20 The structure of biotin oxyamine 61 and the crystal structure of streptavidin (pink). 
 
 
 
Scheme 6.3 The proposed assembly of streptavidin (pink) and a modified AB5. 
 
6.2.1 More AB5 mutations  
A biotin oxyamine 61 was commercially available (Thermo Scientific) and was 
suitable to be ligated onto the CTA2 peptide of the AB5 protein. Oxime chemistry 
could be used, in the same way as previous reactions on CTB, which would expand 
the options for modification on AB5 complexes. Before the ligation could be 
achieved, two changes to the AB5 sequence needed to be made. The N-terminus of 
CTA2 had to be changed to a threonine or serine residue so that it was suitable for 
oxidation and the N-terminal threonine residue of CTB needed to be changed so 
that the reaction would be site-specific for only CTA2. 
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Plasmid pSAB2.1A contains the genes for MBP-CTA2 and CTB for expression in 
E. coli. The original plasmid encoded for CTB with an alanine residue at the 
N-terminus and so only the CTA2 peptide needed to be altered. Site-directed 
mutagenesis was performed to introduce a serine residue into the CTA2 gene so 
that the protein was suitable for N-terminal modification. Serine was chosen rather 
than threonine as the change from a glycine residue only required one mutated 
base pair (GGT to AGT) and still provided the amino alcohol group needed for 
oxidation. Gel electrophoresis was performed to assess the PCR and showed that 
the reaction had been successful to create plasmid pTRBAB5-G1S. E. coli XL10 
competent cells were transformed with the new plasmid. A plasmid prep was then 
performed to isolate the DNA for sequencing and for transformation into E. coli C41 
cells for expression. 
 
The protein was then expressed from the E.coli by inducing with IPTG and growth 
at 30 °C for 24 h. After purification by ammonium sulfate precipitation of the media, 
a nickel affinity column and then SEC, a yield of 5.5 mg L-1 was obtained. 
SDS-PAGE confirmed the successful expression and the purification of MBP-AB5 
(G1S) (Fig 6.21) although SEC was needed to fully purify the MBP-AB5 complex 
from excess uncomplexed CTB (Fig 6.22). MBP-AB5 appears mostly as the 
complete complex on the gel but when boiled it fully dissociates into the 
MBP-CTA2 (G1S) fusion and CTB. 
 
 
Fig 6.21 SDS-PAGE for MBP-AB5 (G1S) nickel affinity column and SEC purification. 
 
The concentration of the MBP-AB5 (G1S) protein was measured by 
UV spectroscopy at 280 nm, using a theoretical molar extinction coefficient of 
128,745 M-1 cm-1, calculated from the sequence by ExPASy Proteomics. ESMS 
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showed two proteins with masses 48881.2 Da and 11613.2 Da for MBP-CTA2 and 
CTB respectively (calculated 48853.9 Da and 11611.9 Da). 
 
    
Fig 6.22 Chromatogram of MBP-AB5 (G1S) purification. 
 
6.2.2 AB5 modifications 
The MBP-CTA2 (G1S) fusion had to be cleaved to reveal the serine on the 
N-terminus of CTA2 before an oxime ligation was performed. This was achieved 
with TEV protease in the same way as previously done to reveal the sortase tag. 
The TEV protease is specific to the recognition sequence of ENLYFQG or 
ENLYFQS, working with the same efficiency for either sequence. Therefore it could 
still be used to cleave the MBP-CTA2 (G1S) fusion even after the mutation to 
introduce the serine residue. 
 
The MBP-AB5 (G1S) protein was mixed with TEV and the cleaved protein was 
purified by nickel affinity chromatography which removed the protease. SDS-PAGE 
was performed which shows MBP-AB5 (G1S) before cleavage and after when the 
MBP has been removed (Fig 6.23). Analysis by ESMS showed the cleaved CTA2 
(G1S) with a mass of 5085.6 Da (calculated 5085.5 Da) and CTB with a mass of 
11612.0 Da (calculated 11611.9 Da). 
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Fig 6.23 SDS-PAGE for the TEV cleavage of MBP-AB5.(G1S). After cleavage and purification by Ni 
affinity chromatography no MBP remains. 
 
The N-terminal serine residue revealed after TEV cleavage could now be oxidised 
using the same method as for CTB N-terminal oxidation using NaIO4. After five 
minutes ESMS confirmed the site-specific oxidation of CTA2 (G1S) with a mass of 
5076.4 Da for the hydrated form (calculated 5072.5 Da).  
 
 
Scheme 6.4 Modification of the CTA2 N-terminus in the AB5 complex by oxidation and then oxime 
formation with an aminooxy ligand at neutral pH using an aniline catalyst. 
 
CTA2ox in the AB5 complex was then modified with biotin ligand 61 in a reaction 
catalysed with aniline that went to completion overnight to produce ligand A(61)B5 
(Scheme 6.4). ESMS confirmed that a successful reaction had taken place with 
modified CTA2 having a mass of 5470.7 Da (calc 5470.7 Da) (Fig 6.24). 
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Fig 6.24 Mass spectrum of the AB5 protein showing the two separate proteins CTB (red) and CTA2 
(G1S) (green). Selective modification with the biotin ligand yields an unmodified CTB and CTA2(61) 
(blue). 
 
6.2.3 Analysis of the interactions with streptavidin  
The affinity of the biotin ligand for streptavidin was measured to assess the 
interaction and determine whether the PEG linker affected the affinity. ITC was 
performed with biotin 61 (30 µM) titrated into streptavidin (3 µM) and showed a very 
high affinity, with an apparent Kd of 1.72 nM (Table 6.1). This affinity however had a 
large error and the steepness of the curve in the ITC analysis suggested that the 
actual affinity was much higher (Fig 6.25 A). The c value for this isotherm is too 
high, because the transition is too steep and so an accurate Kd could not be 
determined. However, accurate values for the enthalpy and the stoichiometry are 
still available. A stoichiometry of 1.01 showed that biotin 61 was filling all the 
binding sites. 
 
ITC was performed on the modified protein A(61)B5 to see the effects of having the 
biotin ligand attached to a protein and determine whether the high affinity interaction 
was still taking place. The A(61)B5 protein (30 µM) was titrated into streptavidin (5 
µM). The apparent Kd for this interaction was found to be very similar to the 
interaction with biotin ligand 61, at 0.70 nM (Table 6.1) which may have been 
because the limit of detection for the technique had been reached. Again the curve 
was steep and the error in the affinity was large, indicating a potentially stronger 
interaction (Fig 6.25 B). The enthalpy for the protein binding was much higher than 
for just the biotin ligand which may have been due to extra interactions between the 
proteins. An interesting point from this ITC result was the stoichiometry of 0.5, 
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which meant that only half the binding sites on streptavidin were being filled. Two 
A(61)B5 ligands were binding to the streptavidin tetramer and presumably the bulk 
of the attached protein blocked the interaction of a second A(61)B5 ligand binding to 
that side of streptavidin (Scheme 6.5). 
 
 
Fig 6.25 ITC trace for biotin binding to streptavidin. (A) Biotin ligand 61 (30 µM) injected into 
streptavidin (3 µM). (B) A(61)B5 (30 µM) injected into streptavidin (5 µM). Both titrations had a high 
affinity but titrating in the A(61)B5 protein resulted in an increased enthalpy and a stoichiometry of 0.5. 
 
Table 6.1 ITC results for the interaction with streptavidin and biotin ligand 61 and A(61)B5. 
ligand Kd / nM ΔH° / kcal mol
-1 n 
biotin 61 1.72 ± 1.00 -25.74 ± 0.52 1.01 
A(61)B5 0.70 ± 0.20 -64.48 ± 0.15 0.51 
 
 
 
Scheme 6.5 The proposed formation of a 2:1 complex between A(61)B5 and streptavidin 
 
To determine the size of the protein assemblies being formed, SEC was performed. 
Streptavidin had a retention volume of 17.1 mL and the slightly larger A(61)B5 had 
A             B 
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a retention volume of 16.1 mL. A mixture of the two proteins was prepared at a ratio 
of 2:1 with A(61)B5 at 20 µM and streptavidin tetramer at 10 µM. The SEC trace of 
the mixture showed a main peak with retention volume of 13.0 mL which could be 
attributed to the 2:1 protein complex (Fig 6.26). There was also a small peak at 
15.7 mL indicating a small amount of excess A(61)B5 due to inaccuracies in the 
concentration measurement. Analysis of the chromatogram peak with the 
calibration plot for the column revealed that a model of a 3:1 complex was the best 
fit for the protein assembly (Fig 6.27). However, due to the nonspherical nature of 
the protein assembly, the model is likely to overestimate the actual size of the 
complex being formed and in reality it may behave as a much larger structure when 
analysed by SEC.  
 
 
 Fig 6.26 Chromatogram of the assembly of streptavidin and A(61)B5. 
 
 
Fig 6.27 Analysis of the SEC calibration with the potential assembly products. The assembly comes at 
1.5 Ve/Vo and the diferent possible assemblies of A(61)B5 and streptavidin are compared.  
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Another method was needed to confirm the size of the particles being formed and 
so AUC was performed. A(61)B5 was mixed with a fluorescently labelled 
streptavidin protein (Alexa Fluor 555 Streptavidin, Life Technologies) that absorbed 
at 555 nm. It was possible by using this extra wavelength to analyse only the 
assemblies involving streptavidin. A solution of pure streptavidin was seen to 
contain a single species with a sedimentation coefficient of 3.7 S corresponding to 
the expected mass of 65 kDa for the tetramer. The AUC was performed at different 
ratios of A(61)B5 ligand to streptavidin and showed that, as the two proteins were 
mixed, a larger species emerged (Fig 6.28). Increasing additions of A(61)B5 led to 
the increased formation of the new species with a sedimentation coefficient of 6.7 S 
corresponding to a mass of 150 kDa. This mass was between the expected mass of 
130 kDa for a 1:1 complex and 193 kDa for a 2:1 complex. Again, the nonspherical 
shape of the complex may not have been described well by the fitting model leading 
to a less accurate estimate of the mass. 
 
 
Fig 6.28 AUC c (s) plot of fluorescent streptavidin mixed with the biotinylated A(61)B5 protein 
measured at 555 nm and performed at 30 krpm. Only the assemblies with the fluorescent streptavidin 
are shown at this wavelength. The emergence of a second peak at 6.7 S was seen with increasing 
amounts of A(61)B5. 
 
Not all of the streptavidin was converted to the larger size particle even after the 
addition of 4 equivalents of A(61)B5. This observation could suggest that there was 
a substantial error in the concentrations, with the A(61)B5 concentration being 
overestimated and so not enough A(61)B5 had been added. Another explanation 
would be the complex was not as stable as first thought. A(61)B5 may bind to 
streptavidin but then the CTA2 peptide could come loose from the CTB pentamers 
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leaving two different species, CTB and streptavidin with two CTA2-biotin peptides 
bound. 
 
It can be concluded from a combination of the ITC, SEC and AUC data that a 2:1 
complex with two AB5 proteins facing out opposite sides of streptavidin is the most 
likely outcome for the species being formed. AFM could be used to visualise the 
assembly and so provide further evidence to support this hypothesis. 
 
6.2.4 Conclusions and further work 
Enzymatic modification of the CTA2 N-terminus was achieved by the sortase 
ligation of depsipeptides. A bpy group for metal binding was attached to CTA2 but 
no complexation with Fe2+ was observed. The CTA2 sequence was almost 
completely altered but still no binding was observed. It was thought that the CTA2 
peptide was interacting with the bpy ligand at the point that CTA2 penetrates into 
CTB. If a different metal ligand could be used with a more stable binding interaction 
then this may overcome the ligand binding to the CTA2 peptide. A phenathroline 
ligand could be used which is known to bind Fe2+ in a 3:1 ratio and provides a 
stronger binding due to the restricted conformation of the molecule with the two 
nitrogen lone pairs fixed in position ready for metal binding (Fig 6.29).[176] 
 
 
Fig 6.29 Structure of phenanthroline. 
 
Strong protein-ligand interactions were demonstrated to be able to bring different 
proteins together. A biotin-modified AB5 protein bound to streptavidin resulted in the 
formation of a 2:1 assembly which was a significant initial step towards the 
construction of larger complex structures.  
 
The streptavidin-A(61)B5 system presented here would assemble two CTB units 
pointing in opposite directions. These CTB proteins have five GM1os binding sites 
each and so divalent GM1 ligands could potentially crosslink two separate CTB 
proteins producing a -A-B-A-C- polymeric system with three components (Fig 6.30). 
The A(61)B5 proteins could also bind to a GM1 coated surface and vertical 
constructions could then be made. There are many possibilities for using this basic 
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two protein system to build larger structures. The step wise introduction of other 
multivalent ligands and proteins could be used to make the system more complex. 
 
 
Fig 6.30 Potential polymeric assembly of “A” A(61)B5, “B” divalent GM1 and “C” streptavidin. 
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7 Where do we go from here? 
 
 
 
 
 
Conclusions and future work 
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7.1 Conclusions from the project 
A range of protein assemblies have been created via protein-ligand interactions and 
these assemblies can be analysed by a variety of biophysical techniques. ESMS 
allowed the precise modification of proteins to be seen. ITC has been used to 
investigate the binding interactions of the ligands and gave information on the 
assembly stoichiometry. DLS, SEC and AUC were used to assess the size and the 
mass of the complexes formed. 
7.1.1 Initial investigations 
The site-specific modification of proteins was achieved at the N-terminus of both 
CTB and CTA2 (Scheme 7.1). Improvements on the original reaction conditions[146] 
to form an oxime bond were achieved by performing the reaction at pH 7 with an 
aniline catalyst[52]. 
 
 
Scheme 7.1 Modification of the N-temini of CTB or CTA2 with ligands. 
 
Protein assembly was achieved via the attachment of a galactose ligand to the 
N-terminus of wild-type CTB. The assembly created with these modified proteins 
was uncontrolled and led to aggregation and precipitation of the proteins. The 
aggregation could be mostly prevented with the introduction of a simple galactoside 
as a competing ligand at 200 mM and by maintaining the protein at a low 
concentration of 200 µM . The length of the ligand was also found to be important; 
too short and there was not enough space for binding interactions to take place. 
The exact analysis of the large aggregates proved difficult as only the stable 
pentamer could be isolated from solution.  
 
This initial strategy of creating a building block that has both multiple ligands and 
multiple binding sites was difficult to control. The correct concentration, the precise 
length of ligand and a suitable amount of competing ligand may all need to be 
varied systematically for the modified proteins to be controlled. 
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7.1.2 Two component systems 
 
A number of mutations were introduced into the GM1os binding site of CTB which 
prevented binding with the GM1 oligosaccharide. W88E was chosen as the best 
mutant and so was modified with carbohydrate ligands. A simple galactoside ligand 
did not have a high enough affinity to bind to other proteins, but when a GM1 ligand 
was used, interactions with the wild-type CTB did occur. A combination of ITC, AUC 
and DLS led to the conclusion that heterodimers of pentamers were being formed 
and no larger structures (Fig 7.1). 
 
 
Fig 7.1 A 1:1 heterodimer of pentamers formed by W88E(54) binding to CTB. 
 
Whilst this observation meant that a dodecahedron or other larger assemblies were 
not accessible with these components, it did provide a potential cholera toxin 
inhibitor. Inhibition studies showed an IC50 value for the GM1 modified mutant 
protein, W88E(54), of 104 pM which was the best pentavalent CTB inhibitor 
reported thus far in the literature. 
 
An investigation into the amino acid composition on the bottom face of the W88E 
protein may reveal positions that could be mutated to provide favourable 
interactions with the wild-type cholera toxin. These mutations may contribute to a 
more favourable protein-protein interaction when the two components come into 
close proximity. This effect could provide better overall binding and an enhanced 
affinity of the inhibitor. 
 
If the length of the GM1 ligands was shortened this may affect the conformation that 
the ligand can take and therefore what interactions can take place. Shorter ligands 
may restrict each GM1os group to bind to a separate CTB protein, assembling five 
around the central modified mutant. A larger range of assembly structures could 
then be accessed with this system. 
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7.1.3 Templated assemblies 
TX-100 and tyloxapol micelles modified with simple galactose and lactose groups 
were analysed. The introduction of the carbohydrates led to unpredictability in the 
micelle sizes. The amount of carbohydrate groups incorporated was therefore 
limited to around 10%. Mixtures of the micelles with CTB were analysed with ITC 
and DLS but no interactions were observed. The limitation on carbohydrate 
inclusion and the strength of the galactose interactions were likely to be the 
deciding factors as to why no interactions were seen between the micelles and 
CTB. 
 
If detergents were modified with GM1os ligands, more success may be seen with 
binding CTB. This larger oligosaccharide may prove more of a problem when 
forming stable micelle structures but the use of tyloxapol may alleviate this problem. 
GM1os ligands have a much higher affinity for CTB and lower concentrations could 
be accessed at which the galactose based system was seen to not work. With 
these ligands CTB may be prearranged around a micelle surface before cross-
linking of the proteins. 
 
The AB5 structure of cholera toxin was used to tie the proteins together by their 
CTA2 peptide tails. Enzymatic modification of the CTA2 N-terminus with 
depsipeptides was achieved with sortase. A bpy group for metal binding was 
attached to the CTA2 peptide but was not seen to bind to Fe2+. Even after the CTA2 
sequence was almost completely altered, no binding was observed. It was thought 
that the CTA2 peptide was interacting with the bpy ligand at the point that CTA2 
penetrates into CTB. This part of the peptide sequence however, could not be 
changed without affecting the AB5 assembly. 
 
The use of a different metal ligand with a more stable binding interaction may 
overcome the problems of binding to the CTA2 peptide. A phenathroline ligand 
could be used which binds Fe2+ in a 3:1 ratio but with a stronger interaction due to 
the restricted conformation of the molecule.[176] The two nitrogens are fixed in this 
molecule, in a conformation more optimised for metal binding (Fig 6.29). 
 
 
Fig 7.2 Structure of phenanthroline, with the nitrogen atoms constrained by the ring structure. 
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A mutation was made that allowed the CTA2 peptide to be also modified by 
oxidation and then oxime formation. A biotin ligand was attached to CTA2 and 
binding of the modified AB5 protein was seen with streptavidin. A combination of 
ITC, SEC and AUC confirmed formation of a 2:1 assembly. Not all the streptavidin 
binding sites were filled due to the steric bulk of the AB5 protein preventing 
interactions with both biotin binding sites on either side of the streptavidin protein. 
The binding of two AB5 proteins resulted in two of the binding sites becoming 
inaccessible for other ligands. Less bulky biotin ligands could be used to fill these 
extra sites and build upon this structure. If a long flexible linker was used, then the 
excluded binding sites could be accessed, before attachment to another protein. 
 
There are many possibilities of using this basic protein system to build larger 
structures. The A(61)B5 proteins could bind to a GM1 coated surface. Vertical 
constructions could then be made with streptavidin binding before a second 
A(61)B5 unit or a different biotinylated protein building the structure upwards (Fig 
7.3). AFM could be used to visualise the step by step assembly. 
 
 
Fig 7.3 Surface bound construction of A(61)B5 and streptavidin. 
 
7.1.4 Further assembly 
The step wise introduction of other multivalent ligands and proteins could also be 
used to introduce another level of complexity into the system. The streptavidin 
A(61)B5 system presents the CTB proteins with five GM1os binding sites each 
pointing in opposite directions. If divalent GM1 ligands were synthesised then they 
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could potentially bind two separate CTB proteins producing a -A-B-A-C- polymeric 
system with three components (Fig 7.4 A).  
 
The W88E(54) protein could also be used in combination with A(61)B5 and 
streptavidin. Mixing of the three components would result in a closed system (Fig 
7.4 B). Again, with the introduction of divalent GM1 ligands at the right ratio, an 
oligomeric protein structure could be formed with the W88E(54) protein capping the 
construction.  
 
 
 
 
Fig 7.4 Potential (A) polymeric and (B) oligomeric assemblies of “A” A(61)B5, “B” divalent GM1os, 
“C” streptavidin and “D” W88E(54). 
 
There are other proteins with different shapes and ligand binding abilities that could 
be used to create a wider variety of structures. The trimeric mannose binding lectin 
(MBL), with three mannose binding sites, could be combined with the pentameric 
CTB in a new strategy to form VLPs. The tetrameric concanavalin A (ConA) has 
four mannose binding sites in a tetrahedral geometry and so could provide access 
to whole new range of complex protein structures.  
 
The creation of protein structures was shown with this work that expands the overall 
understanding of protein-ligand interactions. General strategies for the assembly of 
biomolecules have been investigated and can be further developed to advance the 
construction of nanoarchitecture. 
  
(A) 
 
 
 
 
 
 
 
 
 
(B) 
172 
 
 
 
 
8 How it all came about 
 
 
 
 
 
Materials, methods and experimental 
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8.1 Molecular Biology and Protein Expression 
8.1.1 Instrumentation and materials 
Media and glassware were sterilised in a Prestige Medical bench top autoclave or in 
a LTE Touchclave-R autoclave. Bacterial cultures were grown using a Kuhner 
ShakerX shaker incubator. Cultures on agar plates were grown in a Gallenkamp 
incubator. Centrifugation was performed using a Beckman Coulter™ Avanti™ J-30I 
Centrifuge or a Heraeus multifuge 3 S-R centrifuge or a Heraeus pico centrifuge. 
Protein purification was performed with a GE Pharmacia ÄKTA FPLC system. 
Spectrophotometric readings were taken in a WPA Biowave II spectrophotometer or 
a NanoDrop 2000 spectrophotometer. SDS-PAGE was performed using a Bio-Rad 
mini protean 3 apparatus and visualised on a Gel Doc system.  
 
Analytical grade reagents were supplied by Sigma-Aldrich, Fisher Scientific, Melford 
laboratories and VWR International. Pwo enzyme (DNA polymerase) (from 
Pyrococcus woesei) was made in the Turnbull lab. Restriction enzymes, T4 DNA 
ligase, DpnI and CIP were purchased from NEB. Competent cells were purchased 
from Stratagene or made in the Turnbull Lab. Primers and DNA parts for gene 
synthesis were purchased from IDT. 
 
DNA primer, gene synthesis parts and full plasmid sequences are given in the 
appendix. Protein sequences for CTB, MBP-CTA2 and mutants thereof are given in 
the appendix. 
8.1.2 Buffer solutions 
All solutions were made up to 1 L with 18 MΩ water purified using an Elga purelab 
system unless otherwise stated. Buffer solutions were adjusted to the correct pH 
using NaOH or HCl. 
 
Standard buffers 
Phosphate buffer (pH 7.0, 0.1 M): Na2HPO4.2H2O (10.27 g), NaH2PO4.2H2O (6.60 
g), 0.1 M NaCl (5.84 g). 
 
Phosphate Buffered Saline (PBS (pH 7.4)): 137 mM NaCl (8.0 g), 2.7 mM KCl (0.2 
g), 10 mM Na2HPO4.2H2O (1.78 g), 1.76 mM KH2PO4 (0.24 g). 
 
Sodium Acetate Buffer (pH 4.0, 0.1 M): NaOAc (1.26 g), acetic acid (4.84 mL). 
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HEPES buffer (pH 7.5): 50 mM HEPES (14.1 g), 150 mM NaCl (8.8 g), 5 mM CaCl2 
(0.55 g). 
 
TEAN Buffer (pH 7.0, 50 mM): 50 mM Tris (6.06 g), 200 mM NaCl (11.69 g), 3 mM 
NaN3 (0.195 g), 1 mM EDTA (0.372 g). 
 
TRIS Buffer (pH 7.4, 50 mM): 50 mM Tris (6.06 g), 200 mM NaCl (11.69 g). 
 
Citrate-phosphate buffer (pH 5.0, 2 mM): 2 mM Na2HPO4.2H2O (0.36 g), 2 mM 
NaC6H7O7 (0.43 g), 2 mM NaCl (0.12 g). 
 
Bacterial growth media 
LB growth media (LB): LB Broth (25 g premixed; 10 g Tryptone, 5 g Yeast extract, 
10 g NaCl), Ampicillin (100 mg). For high salt media; NaCl (10 g) was added. 
 
Agar Gels: agar (1.5 g) added to 100 mL of LB. 
 
Protein analysis solutions 
5 x SDS Running Buffer: 125 mM Tris (15.15 g), 960 mM glycine (72.1 g), 0.5% w/v 
SDS (5 g). 
 
SDS Loading Buffer: Tris (0.5M, pH 6.8, 1.25 mL), SDS (0.3 g), DTT (0.47 g), 
glycerol (1 mL), bromophenol blue (~5 crystals), water (7.2 mL). 
 
Coomassie stain: coomassie G250, methanol (400 mL), acetic acid (100 mL). 
 
Coomassie destain: methanol (400 mL), acetic acid (100 mL) 
 
DNA manipulation and analysis buffers 
50 x TAE Buffer: 2 M Tris (242 g), acetic acid (57.1 mL), EDTA (0.5 M, pH 8, 100 
mL). 
 
10 x PFU Buffer: 2 M Tris-HCl (pH 8.8), 1 M (NH4)2SO4, 1 M KCl, 10 mg mL
-1 BSA, 
10% (v/v) TX-100, 200 mM MgSO4. 
 
Ligase Buffer: 50mM Tris-HCl (pH 7.5), 10mM MgCl2, 1mM ATP, 10mM DTT.  
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8.1.3 Gene synthesis and mutagenesis 
Polymerase Chain Reaction (PCR) 
PCR was used for site-directed mutagenesis. The materials used are summarised 
in Table 8.1. The mixture of plasmid (~100 µg mL-1), primers (100 µM), dNTPs (25 
mM) and PWO enzyme were taken through 22 cycles of 95 °C for 30 s, 54 °C for 30 
s (or temperature adjusted to 3 °C below expected annealing temperature for 
primers used), 72 °C for 14 min before a final extension of 30 min at 72 °C. 
Following PCR, DpnI (1 µL) was added and incubated at 37 °C for 2 h to digest the 
original plasmid leaving only the new plasmid with the incorporated mutation. 
 
Table 8.1 Summary of materials used for PCR. 
 
 
 
Polymer Cycling Assembly (PCA) 
PCA was used to assemble a gene from four smaller DNA parts. The materials 
used are summarised in Table 8.2. The mixture of DNA parts (100 µM), dNTPs (25 
mM) and PWO enzyme were taken through 30 cycles of 95 °C for 30 s, 54 °C for 30 
s (3 °C below expected annealing temperature of DNA parts), 70 °C for 1 min 
before a final extension of 3 min at 70 °C. The whole cycle was repeated with the 
addition of only parts A and D (0.5 µL) to ensure amplification of the complete gene. 
 
Table 8.2 Summary of materials used for PCA. 
 
 
 
Substance Amount / µL 
H2O 42.9 
PFU buffer 10X 5.0 
dNTPs (25 mM) 0.4 
PWO enzyme 0.5 
Plasmid 0.2 
Two primers 0.5 
Substance Amount / µL 
H2O 41.4 
PFU buffer 10X 5.0 
dNTPs (25 mM) 0.4 
PWO enzyme 0.2 
Parts B and C 1.0 
Parts A and D 0.5 
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Double digests 
Analytical double digests were performed to check the inclusion of restriction sites. 
The materials used are summarised in Table 8.3. The reagents were incubated 
together for one hour at 37°C. 
 
Table 8.3 Summary of materials used for analytical double digests. 
 
substance volume / µL 
H2O 7.0 
NEB 4 buffer 10X 1.0 
plasmid 1.0 
NdeI 0.5 
XhoI 0.5 
 
Full double digests were performed to prepare DNA for ligation. For full double 
digests Table 8.4 gives the materials used. All reactants were added, except for the 
calf-intestinal phosphatase (CIP), before incubation at 37 °C for one hour. CIP was 
then added to the digested plasmid and incubated for a further 1 h at 37 °C. 
Digested DNA was then purified by gel extraction following the procedure from the 
Qiagen gel extraction kit. 
 
Table 8.4 Summary of materials used in double digests. 
 
Substance Amount / µL 
H2O 5.0 
NEB 4 buffer 10X 3.0 
Plasmid or gene 20.0 
NdeI 1.0 
XhoI 1.0 
CIP 1.0 
 
DNA ligation 
After a double digest of the plasmid and gene of interest, the two DNA fragments 
were ligated together to form one new plasmid. Plasmid (50 ng), 10X ligase buffer 
(1 µL), T4 DNA ligase (1 µL), H2O (up to 10 µL) and the gene of interest (3 
equivalents to plasmid) were mixed together and incubated at 4 °C overnight or 
incubated for 30 min at room temperature. The new plasmid was then transformed 
into E. coli XL10 competent cells. 
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Transformations 
Plasmids were transformed into suitable competent cells by adding DNA (1 µl, ~100 
µg mL-1) to the competent cells (10 µl), and incubating on ice for 10 min. The cells 
were heat shocked for 45 s at 42 °C, and then put back on ice for 10 min. LB (800 
µl) was added and the cell suspension was incubated at 37 °C for 1.5 h. An aliquot 
(100 µl) was spread on to an agar plate and incubated at 37 °C overnight. 
 
A single colony was picked to inoculate LB (5 ml) with ampicillin (100 mg L-1) 
antibiotic present and the culture was incubated overnight at 37 °C. An aliquot (0.5 
ml) of culture was mixed with 80% glycerol (0.5 ml) and frozen at -80 °C in the 
freezer as a cell stock. 
 
Plasmid preparations 
The equipment and procedure for the Qiagen Miniprep kit was followed to extract 
DNA from a cell miniculture. UV spectroscopy gave the concentration and yield of 
the DNA (Equation 8.1). 
 
 
Equation 8.1 
 
volumeionconcentratyield
gmLAAionconcentrat

 1320260 50
 
 
where 260A  and 280A  were the absorbances at 260 nm and 280 nm respectively. 
 
Agarose gels 
Agarose gels were used to assess DNA purity and confirm the size of DNA parts. 
The gels (1.2% w/v) were prepared by adding agarose (380 mg) to TAE buffer (40 
mL) and heating in a microwave for 1.5 min. After heating, the solution was allowed 
to cool before adding ethidium bromide (1 µL, 10 mg mL-1). The solution was 
poured into a mould and a comb added, removing any bubbles before the gel was 
left to set. Each DNA sample (5 µL) was mixed with loading buffer (1 µL) and then 
an aliquot (5 µL) was loaded on to the gel. Electrophoresis was performed at 100 V 
for approximately 20 min in TAE buffer. Gels were then visualised under UV light 
using the Gel Doc system. 
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8.1.4 Protein expression and purification 
CTB expression from Vibrio sp.60 
A stab from a stock of Vibrio sp.60 containing the pATA13 plasmid[134] encoding the 
CTB protein was used to inoculate a flask of high salt LB growth media (2 x 100 
mL) containing ampicillin (100 µg mL-1) and this starter culture was incubated at 30 
°C for 20 h. Starter culture (20 mL) was added to 10 x 1 L high salt LB growth 
media so the optical density at 600 nm (OD600) was 0.05. This was then incubated 
at 30 °C and after 3 h the OD600 had reached ~0.5 and IPTG (240 mg) was added to 
each flask to induce protein over-expression. The incubation was continued for 24 h 
before isolating the cells by centrifugation at 17,000 x g for 25 min. The bacterial 
pellet was discarded and the supernatant was retained and purified by one of the 
two following methods. 
 
Original precipitation method:[135] sodium hexametaphosphate (2.5 g L-1) was added 
to the supernatant and the pH was adjusted to 3.5 by addition of HCl. The solution 
was then stored at 4 °C for 3 days to allow the protein to precipitate. The 
suspension was centrifuged at 16,000 x g for 25 min, before discarding the 
supernatant and the protein pellet was resuspended in TRIS buffer (20 mL). This 
solution was centrifuged at 5,000 x g for 10 min to remove any insoluble material, 
the pellet was again resuspended in TRIS buffer and centrifuged at 100,000 x g for 
25 min. The supernatant was collected and filtered through a 0.45 µm filter 
(Sartorius Minisart) before the protein solution was purified on a lactose affinity 
column (resin from sigma) (~20/200) and eluted with TEAN buffer containing 300 
mM lactose. The protein solution was dialysed into phosphate buffer using 
SnakeSkin® pleated dialysis tubing (Thermo Scientific) with 7000 MWCO. The 
buffer solution was changed three times to ensure effective dialysis.  
 
After optimization: solid ammonium sulfate was added to the supernatant (final 
concentration 60% w/v) and stirred for 1 h. The solution was centrifuged at 17,000 x 
g for 25 min and the supernatant discarded. The protein pellet was resuspended in 
phosphate buffer and centrifuged once more at 5,000 x g for 10 min to remove any 
insoluble material. The supernatant was filtered through a 0.45 µm filter (Sartorius 
Minisart), purified on a lactose affinity column (resin from sigma) (~20/200) and 
eluted with phosphate buffer containing 300 mM lactose. 
 
The protein solution was dialysed into phosphate buffer using SnakeSkin® pleated 
dialysis tubing (Thermo Scientific) with 7000 MWCO. The purity of the protein was 
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determined by SDS-PAGE. The concentration of CTB protein was measured by UV 
spectroscopy at 280 nm.  
 
CTB mutant expression from E. coli 
A stab from a stock of E. coli C41 containing the pSAB2.2 plasmid or derivative 
(see appendix for plasmid and protein sequences) encoding the CTB protein was 
used to inoculate LB growth media (5 mL) containing ampicillin (100 µg mL-1) and 
this starter culture was incubated at 37 °C for 20 h. Starter culture (1 mL) was 
added to LB growth media (4 x 1 L) which was then incubated at 37 °C and 
monitored until the OD600 had reached ~0.5 before IPTG (240 mg) was added to 
each flask to induce protein over-expression. The incubation was continued for 24 h 
at 30 °C before isolating the cells by centrifugation at 10,000 x g for 10 min. The 
bacterial pellet was discarded and the supernatant was retained.  
 
Solid ammonium sulfate was added to the supernatant (final concentration 60% 
w/v) and stirred for 1 h. The solution was centrifuged at 17,000 x g for 25 min and 
the supernatant discarded. The protein pellet was resuspended in phosphate buffer 
and centrifuged once more at 5,000 x g for 10 min to remove any insoluble material. 
The supernatant was filtered through a 0.45 µm filter (Sartorius Minisart), purified 
on a nickel affinity column, washed with phosphate buffer containing 20 mM 
imidazole and eluted with phosphate buffer containing 500 mM imidazole. 
 
The purity of the isolated protein was determined by SDS-PAGE and the 
concentration of CTB mutant protein was measured by UV spectroscopy at 280 nm. 
 
MBP-AB5 expression from E. coli 
A stab from a stock of E. coli BL21 gold containing the pSAB2.1 plasmid or 
derivative (see appendix for plasmid and protein sequences) encoding a 
MBP-CTA2 fusion and a CTB protein was used to inoculate LB growth media (5 
mL) containing ampicillin (100 µg mL-1) and this starter culture was incubated at 
37 °C for 20 h. Starter culture (1 mL) was added to LB growth media (4 x 1 L) which 
was then incubated at 37 °C, monitored until the OD600 had reached ~0.6 before 
IPTG (120 mg) was added to each flask to induce protein over-expression. The 
incubation was continued for 24 h at 30 °C before isolating the cells by 
centrifugation at 10,000 x g for 10 min. The bacterial pellet was discarded and the 
supernatant was retained.  
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Solid ammonium sulfate was added to the supernatant (final concentration 60% 
w/v) and stirred for 1 h. The solution was centrifuged at 10,000 x g for 25 min and 
the supernatant discarded. The protein pellet was resuspended in HEPES buffer (or 
phosphate buffer for the G1S mutant) and centrifuged once more at 5,000 x g for 10 
min to remove any insoluble material. The supernatant was filtered through a 0.45 
µm filter (Sartorius Minisart), purified on a nickel affinity column, washed with 
HEPES buffer (or phosphate buffer for the G1S mutant) containing 20 mM 
imidazole and eluted with HEPES buffer (or phosphate buffer for the G1S mutant) 
containing 500 mM imidazole. The eluted protein was concentrated and further 
purified by SEC. 
 
The purity of the isolated protein was determined by SDS-PAGE and the 
concentration of MBP-AB5 was measured by UV spectroscopy at 280 nm. 
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
Protein purity and size was assessed by SDS-PAGE using BioRad tetragel 
apparatus. A resolving gel (10%) was prepared using the materials listed in Table 
8.5. The TEMED solution was added to the mixture after all the other solutions had 
been mixed and immediately before pouring the gel into the plates. 0.1% w/v SDS 
was poured on top of the resolving gel to ensure a flat surface. 
 
The stacking gel (5%) was then prepared using the materials in Table 8.5, also with 
the TEMED being left until last. The 0.1% w/v SDS was removed from the top of the 
set resolving gel, the stacking gel mixture poured on and the comb inserted. 
Samples for analysis were prepared by mixing 10 µL of protein sample mixed with 
10 µL loading buffer. After the gel had set, protein samples were loaded into the 
wells. When required, samples were heated to 95 °C prior to loading on the gel; 
these samples are described as “boiled” on the gel figures. Electrophoresis was 
performed at 180 V in SDS running buffer for approximately 45 min or until after 
sufficient time that the blue protein loading buffer had reached the bottom of the gel. 
Gels were stained with Coomassie stain overnight before incubation in Coomassie 
destain for approximately 3 hours and storage in water until the gel was imaged. Or 
the samples were stained with Instant Blue Stain (TripleRed) for 30 min before 
being imaged. 
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Table 8.5 Summary of the materials used for preparing SDS-PAGE gels. 
 
Material 10% Resolving Gel (mL) 5% Stacking Gel (mL) 
H2O 5.885 3.112 
1.5 M TRIS-HCl pH 8.8 3.800 - 
0.5 M TRIS-HCl pH 6.8 - 0.945 
10% w/v SDS 0.150 0.050 
40% Acrylamide 5.000 0.833 
15% w/v APS 0.150 0.050 
TEMED 0.015 0.010 
 
Protein concentration analysis 
Protein concentrations were measured using UV absorption at 280 nm. The 
concentration was determined using the Beer-Lambert law (Equation 8.2). 
 
Equation 8.2          
 
Where A is the absorbance, ε is the extinction coefficient in mol-1 dm3 cm-1, c is the 
concentration in mol dm-3 and l is the pathlength in cm. 
 
Theoretical extinction coefficients for the CTB, CTA2 and MBP-CTA2 proteins were 
obtained from ExPASy ProtParam (Table 8.6).[177]  
 
Table 8.6 Extinction coefficients for the proteins. 
 
Protein 
extinction coefficient / 
mol-1 dm3 cm-1 
CTB (wild-type) 11585 
CTB W88K 6085 
CTB W88K Q61E 6085 
CTB W88E 6085 
CTB I47T 11585 
CTA2 (wild-type) 2980 
CTA2 (D4N) 1490 
CTA2 (G1S) 2980 
MBP-CTA2 (wild-type) 70820 
MBP-CTA2 (D4N) 69330 
MBP-CTA2 (G1S) 70820 
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8.1.5 Protein characterisation 
8.1.5.1 Mass spectrometry (MS) 
Using a Bruker HCT ultra machine, samples were first diluted to 50-10 µM with H2O 
before analysis. Samples for analysis using a Maxis Impact electrospray were then 
also mixed 1:1 with MeOH containing 1% formic acid before analysis. Processing 
and deconvolution of multiple charge states was performed using Data Analysis 
software. 
8.1.5.2 Size exclusion chromatography (SEC) 
Proteins samples for purification or analysis (≤ 250 µL) were injected into the 
injection loop of the ÄKTA FPLC system (GE healthcare) before purification on a 
superdex™ 200 10/300 GL column. The flow rate was set at 0.4 mL min-1, fractions 
(400 µL) were collected and their UV absorbance measured at 280 nm (or 330 nm 
for dansyl group measurement or 555 nm for fluorescent streptavidin 
measurements). Samples for purification after expression (≤ 2.5 mL) were injected 
into the injection loop before purification on a superdex™ 200 HiLoad™ 26/60 
column. The flow rate was set at 1.0 mL min-1, fractions were collected (5 mL) and 
their UV absorbance at 280 nm was measured. 
8.1.5.3 Differential scanning fluorimetry (DSF) 
Protein samples (250 µM final concentration in phosphate buffer) were mixed with 
Sypro Orange dye (10 x concentrate solution, Bio-Rad) (25 µL total volume) and 
added to the wells of a 96-well polystyrene plate. The plates were heated in a Real 
Time PCR Detection System (Bio-Rad) between 25-100 °C in increments of 1 °C. 
Fluorescence changes in the wells were measured by reading the excitation at 
488 nm. 
 
The change in fluorescence per degree is plotted against the temperature, resulting 
in a curve with a peak that corresponds to the midpoint of the unfolding transition, 
the melting temperature (Tm). 
 
8.2 Chemical synthesis and protein modification 
Compounds prepared by T. R. Branson are described in this section. Other 
compounds provided by colleagues in the Turnbull lab and external collaborators 
are described in the appendix. 
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8.2.1 General methods 
Commercial reagents were used without purification, unless otherwise stated. 
Unless stated otherwise in the experimental section, analytical grade reagents were 
supplied by Sigma-Aldrich, Fisher Scientific, Melford laboratories and VWR 
International. All concentrations were performed in vacuo, unless otherwise stated. 
All reactions were carried out at room temperature unless stated otherwise. 
 
1H and 13C NMR spectra were recorded either on a Bruker Avance 500 instrument 
(at 500 MHz and 125 MHz respectively) or on a Bruker DPX300 instrument (at 300 
MHz and 75 MHz respectively) at 25 °C. 1H NMR and 13C NMR spectra were 
referenced using their residual solvent signals,[178] tetramethylsilane, and ethanol as 
internal standards. Chemical shifts are given in parts per million downfield from 
tetramethylsilane. Signals were assigned using a combination of COSY, HMQC and 
DEPT135 experiments. The following abbreviations were used to explain the signal 
multiplicities or characteristics: s, singlet; d, doublet; dd, double doublet; t, triplet; m, 
multiplet. 
 
Electrospray ionisation mass spectra were obtained on a Bruker HCT Ultra Ion Trap 
Mass Spectrometer. High resolution electrospray ionisation mass spectra were 
obtained on Bruker Daltonics MicroTOF or Maxis Impact electrospray mass 
spectrometers or a WATERS GCT Premier Mass Spectrometer. 
 
Flash chromatography was performed with silica gel 60 (Merck). 
 
Infra-red spectra were recorded on a Perkin-Elmer Spectrum One FT-IR 
spectrometer. 
 
Optical rotations were measured at the sodium D-line with an Optical Activity AA-
100 polarimeter. [α]D values are given in units of 10
-1 deg cm2 g-1. 
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8.2.2 Ligand synthesis 
 
-D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy--D-galactopyranosyl-
(1→4)-[5-acetamido-3,5-dideoxy--D-glycero-D-galacto-nonulopyranulosonyl-
(2→3)]--D-galactopyranosyl-(1→4)--D-glucopyranose (GM1 oligosaccharide; 
GM1os) 32 [141] 
 
 
 
The ceramide chain from GM1 (Avanti polar lipids Inc.) was enzymatically cleaved 
to give the GM1 oligosaccharide 32 (GM1os). Endo-glycosyl ceramidase (Takara 
Bio Inc) (EGC; 0.6 µL, 0.1 U) was added to a solution of GM1 (4.8 mg), NaOAc (10 
mM, pH 5, 10 mL) containing bovine serum albumin (0.1 mg) and triton X-100 (2 
mg). This mixture was incubated at 37 °C and after 8 days more EGC (24.4 µL, 4 
U) was added. The cleavage was monitored by TLC (CH3Cl : MeOH : H2O solvent 
system, 30 : 40 : 4) and after nine weeks the mixture was extracted twice with ether 
(500 µL) to remove the triton X-100 and the aqueous layer was applied to a C18 
column (Waters Sep-Pak® Vac 6cc). The column was washed with water (5 x 2.5 
mL) and then methanol (3 x 2.5 mL). The first water fraction contained GM1os and 
so was passed over an Amberlite IRC-50 resin and the flow-through was 
lyophilised. Analysis by LC-MS showed GM1os to be pure and the mass measured 
by ESI-MS (negative ion mode) for GM1os was 997.6 Da (calculated [M-H]- 
997.3 Da) (Fig 8.1). From the 1H NMR spectrum it was seen that GM1os was an 
equal mixture of α and β anomers. The NMR spectrum was in accord with previous 
data.[141] 
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Fig 8.1 Mass spectrum showing the purified GM1os 32 (peak 1). The mass measured by LC-MS for 
peak 1 was 997.6 Da (calculated 997.3). 
 
NMR: H (500 MHz, D2O); selected peaks: 5.15 (d, 1H, J 1.9 Hz, βDGlc H-1α), 4.60 
(d, 1H, J 8.0 Hz, βDGlc H-1β a), 4.47 (d, 1H, J 8.0 Hz, βDGal(terminal) H-1), 4.47 
(d, 1H, J 8.0 Hz, βDGal H-1), 2.60 (m, 1H, αNeu5Ac H-3eq), 1.97 (s, 3H, αNeu5Ac 
CH3), 1.94 (s, 3H, βDGalNAc CH3), 1.87 (m, 1H, αNeu5Ac H-3ax). 
 
N-methyl 2-(tert-butoxycarbonylaminooxy)acetamide 38 
 
 
MeNH2 (15 μL) was added to N-hydroxysuccinimide ester 37
[179] (25 mg) dissolved 
in methanol and stirred overnight before being concentrated. The product was 
purified by column chromatography (silica gel) and eluted with DCM/methanol 9:1. 
The pure fractions were combined and concentrated to afford the amide ligand 38. 
 
H (500 MHz, MeOD); 4.27 (s, 2H, CH2), 2.82 (s, 3H, NHCH3), 1 50 (s, 9H, 
C(CH3)3); C (75 MHz, MeOD); 83.14 (C(CH3)3), 76.55 (CH2), 28.57 (s, 3C, 
C(CH3)3), 25.95 (NHCH3); IR (vmax/cm
-1): 1724 (C=O), 1659 (C=O), 2978 (NH), 2931 
(NH). 
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Galactose peptide ligand 43  
 
 
Galactose Ligand 43 was synthesised on 2-chlorotrityl resin preloaded with glycine 
(200 mg, 0.8 mmol g-1) by solid phase peptide synthesis (SPPS). The resin was 
swelled in DCM (35 ml) for 30 min. To the resin was added Fmoc Dde-protected 
lysine 46[180] (256 mg, 0.48 mmol), HCTU (192 mg, 0.46 mmol), DMF (3.5 mL) and 
DIPEA (139 µL, 0.8 mmol) before being shaken for one hour. The resin was filtered 
and washed with DMF (3 mL, 3 x 2 min), then with piperidine/DMF (20%) (3 mL, 3 x 
2 min) to remove the Fmoc group and then again with DMF (3 mL, 3 x 2 min). 
 
Fmoc dansyl lysine 47[181] (480 mg, 0.8 mmol) was mixed with HCTU (324 mg, 0.78 
mmol), DMF (3.5 mL) and DIPEA (278 µL, 1.6 mmol) before being added to the 
resin and shaken for one hour. Again the resin was filtered and washed with DMF 
(3 mL, 3 x 2 min), then with piperidine/DMF (20%) (3 mL, 3 x 2 min) to remove the 
Fmoc group and then again with DMF (3 mL, 3 x 2 min). 
 
Succinic anhydride (80 mg, 0.8 mmol) was added with DMF (3.5 mL) and DIPEA 
(278 µL, 1.6 mmol) before being shaken for 30 min. The resin was filtered and 
washed with DMF (3 mL, 3 x 2 min). A solution of galactosylamine (Sigma Aldrich, 
91 mg, 0.5 mmol) in DMSO (3.5 mL) with HCTU (199 mg, 0.48 mmol) and DIPEA 
(41.7 µL, 0.24 mmol) was added before being shaken for one hour. Again the resin 
was filtered and washed with DMF (3 mL, 3 x 2 min), then with hydrazine/DMF (2%) 
(3 mL, 3 x 2 min) to remove the Dde protecting group and again with DMF (3 mL, 3 
x 2 min). 
 
A solution of N-hydroxysuccinimide ester 37[179] (138 mg, 0.48 mmol) in DMF (3.5 
mL) and DIPEA (139 µL, 0.8 mmol) was added before being shaken for 30 min. The 
resin was filtered and washed with DMF (3 mL, 3 x 2 min). The peptide was cleaved 
from the support by treating the resin with HFIP/DCM (30%) (3.5 mL) for 30 min; 
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this procedure was then repeated twice. The resin was subsequently washed with 
DCM (3 x 2 mL) and the combined washing solutions were combined and 
precipitated in cold ether, centrifuged and then the pellet was lyophilised from 
MeCN/water. The product was purified on an LH20 column equilibrated with 
methanol. The pure fractions were combined, concentrated and again lyophilised 
from MeCN/water to afford ligand 43 as a pale green foam. 19 mg, 12% yield. LC-
MS showed the molecule to be 92.4% pure (figure 7.4.2.2). 
 
 
Fig. 7.4.2.2. mass spectrum showing the purity of galactose ligand 43. The mass found for peak 2 by 
ESI-MS was 999.5 (calculated 999.4) and was 92.4% pure.  
 
NMR H (500 MHz, MeCN/D2O 9:1); common peaks: 9.05 (d, 1H, J 8.6 Hz, ArHa), 
8.78 (d, 1H, J 8.7 Hz, ArHb), 8.68 (dd, 1H, J 1.0 Hz, 7.3 Hz, ArHc), 8.13 (m, 2H, 
ArHd,e), 7.81 (d, 1H, J 7.5 Hz, ArHf), 3.37 (s, 6H, N(CH3)3); IR (vmax/cm
-1): 3377 (O-
H), 1719 (C=O), 1648 (C=O); HRMS: found [M+H]+ 999.4339, C43H67N8O17S 
requires 999.4292. 
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N-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-2-(tert-
butoxycarbonylaminooxy)acetamide62
 
 
 
Anhydrous THF (2.5 mL) was added to 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl 
azide[182] (100 mg, 0.27 mmol), DMAP (2 crystals), N-hydroxysuccinimide ester 
37[179] (88 mg, 0.294 mmol) and Pd/C (10 mg) before being placed under a H2 
atmosphere and left stirring overnight at room temperature. The reaction mixture 
was filtered through Celite and purified by flash column chromatography (silica gel; 
ethyl acetate/hexane 1:1). The pure fractions were concentrated to afford 
acetylated, Boc-protected ligand 62 as a colourless foam (75 mg, 54%). 
 
[α]D - 42.4 (c 0.5, CHCl3); NMR H (500 MHz, CDCl3): 5.45 (s, 1H, H-4), 5.29 (dd, 
1H, J1,2 9.3 Hz, J1,NH 9.3 Hz, H-1), 5.22 (dd, 1H, J1,2 9.3 Hz, J2,3 9.6 Hz, H-2), 5.15 
(d, 1H, J2,3 9.6 Hz, H-3), 4.38 (d, 1H, JCH2,CH2’ 16.5 Hz, CH2), 4.33 (d, 1H, JCH2,CH2’ 
16.5 Hz, CH’2) 4.15-4.03 (m, 3H, H-6, H-6’, H-5), 2.17, 2.07, 2.04, 2.00 (4 × s, 12H, 
4 × COCH3), 1.51 (s, 9H, Boc); C (75 MHz, CDCl3): 171.4, 170.4, 170.1, 169.9, 
169.6 (5 × C=O), 157.2 (C=O Boc), 77.9 (C-1), 77.2 (C(CH3)3), 75.6 (CH2), 72.4 (C-
5), 71.0 (C-2), 68.4 (C-3), 67.1 (C-4), 61.2 (C-6), 28.1 (C(CH3)3) 20.8, 20.7, 20.6, 
20.6 (C(O)(CH3)3); IR (vmax/cm
-1): 2980 (C-H), 1750 (C=O); HRMS: found [M+Na]+ 
543.1822, C21H32N2O13Na requires 543.1797. 
 
N-β-D-galactopyranosyl 2-(tert-butyloxycarbonylaminoxy)acetamide 40 
 
 
 
The acetyl protecting groups of compound 62 (25 mg) were removed by the 
addition of NaOMe (0.5 M, 77 µL) in anhydrous MeOH (240 µL) under N2 overnight. 
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The product was concentrated and lyophilised from H2O to afford ligand 40 as a 
colourless foam.  
 
NMR:H (500 MHz, CD3OD): 4.90 (m, 1H, H-1), 4.28, 4.24 (2  d, 2H, JCH2,CH2’ 16.2 
Hz, CH2ON), 3.91 (d, 1H, J3,4 3.3 Hz, H-4), 3.62-3.77 (m, 3H, H-2, H-5, H-6a, H-6b), 
3.57 (1H, (dd, 1H, J2,3 9.5 Hz J3,4 3.3 Hz, H-3), 1.46 (s, 9H, Boc). 
 
2,3,6-tri-O-acetyl-4-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-(14)-β-D-
glucopyranosyl azide 45 [183] 
 
 
 
Anhydrous DCM (25 mL) was added to acetylated lactose (3 g, 4.16 mmol) and 
trimethylsilyl azide (0.66 mL, 4.99 mmol) under N2. SnCl4 (25 mL, 1 M in DCM) was 
added and the reaction was stirred overnight at room temperature. The reaction 
mixture was washed with H2O twice and then saturated NaHCO3, dried with 
magnesium sulfate and purified by flash column chromatography (silica gel; ethyl 
acetate/hexane 5:2). The pure fractions were concentrated to afford the acetylated 
lactosyl azide 45 as a colourless foam (1.49 g, 51%). 
 
[α]D - 22.4 (c 1, CHCl3; lit. -22.0
[183]); NMR H (500 MHz, CDCl3): 5.35 (d, 1H, J3’,4’ 
3.4 Hz, H-4’), 5.21 (dd, 1H, J2,3 9.3 Hz, J 3,4 9.4 Hz, H-3), 5.11 (dd, 1H, J2’,3’ 10.4 Hz, 
J1’,2’ 8.1 Hz, H-2’), 4.96 (dd, 1H, J2’,3’ 10.4 J3’,4’ Hz 3.4 Hz, H-3’), 4.86 (dd, 1H, J1,2 8.9 
Hz J 2,3 9.3 Hz, H-2), 4.63 (d, 1H, J1,2 8.9 Hz, H-1), 4.53 (m, 1H, H-6b), 4.50 (d, 1H, 
J1’,2’ 8.1 Hz, H-1’), 4.07-4.15 (m, 3H, H-6a, H-6a’, H-6b’), 3.88 (dd, 1H, J5’,6a’ 6.8 Hz, 
J5’,6b’ 6.8 Hz, H-5’), 3.82 (dd, 1H, J3,4 9.4 Hz, J4,5 9.5 Hz, H-4), 3.71 (ddd, 1H, J4,5 9.5 
Hz, J5,6a 6.6 Hz, J5,6b 4.9 Hz, H-5), 2.15, 2.14, 2.07, 2.07, 2.05, 2.05, 1.97 (7  s, 
21H, 7 × COCH3) ; C (75 MHz, CDCl3): 170.4, 170.3, 170.1, 170.1, 169.6, 169.5, 
169.1 (7 × C=O), 101.1 (C-1’), 87.7 (C-1), 75.8 (C-4), 74.8 (C-5), 72.5 (C-3), 71.0 
(C-3’), 70.9 (C-5’), 70.7 (C-2), 69.0 (C-2’), 69.6 (C-4’), 61.7 (C-6), 60.7 (C-6’), 21.1, 
20.8, 20.7, 20.7, 20.6, 20.5 (7 × C(O)CH3)3); IR (vmax/cm
-1): 2120 (N3), 1750 (C=O); 
HRMS: found [M+Na]+ 684.1890, C26H35N3O17Na requires 684.1859. 
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N-[2,3,6-tri-O-acetyl-4-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-(14)-β-D-
glucopyranosyl] 2-(tert-butyloxycarbonylaminoxy)acetamide 63 
 
 
 
Anhydrous THF (2.5 mL) was added to acetylated lactosyl azide 45 (136 mg, 
0.21 mmol), DMAP (2 crystals), N-hydroxysuccinimide ester 37[179] (67.5 mg, 0.23 
mmol) and Pd/C (10 mg) before being placed under a H2 atmosphere and left 
stirring overnight. The reaction mixture was filtered through celite and purified by 
flash column chromatography (silica gel; ethyl acetate/hexane 3:1). The pure 
fractions were concentrated to afford acetylated, Boc protected ligand 63 as a 
colourless foam (80 mg, 48%). 
 
[α]D 21.2 (c 1, CHCl3); NMR H (500 MHz, CDCl3): 5.28 (d, 1H, J3’,4’ 3.4 Hz, H-4’), 
5.22 (dd, 1H, J2,3 9.3 Hz, J 3,4 9.2 Hz, H-3), 5.20 (d, 1H, J1,2 9.3 Hz, H-1), 5.03 (dd, 
1H, , J1’,2’ 7.9 Hz, J2’,3’ 10.4 Hz, H-2’), 4.90 (dd, 1H, J2’,3’ 10.4 Hz J3’,4’ 3.4 Hz, H-3’), 
4.90 (dd, 1H, J1,2 9.3 Hz, J2,3 9.3 Hz,H-2), 4.43 (d, 1H, J1’,2’ 7.9 Hz H-1’), 4.37 (d, 1H, 
J6a,6b 10.9 Hz, H-6b), 4.29 (d, 2H, JCH2,CH2’ 16.4 Hz, CH2), 4.24 (d, 2H, JCH2’,CH2 16.4 
Hz, CH2’), 4.10-4.00 (m, 3H, H-6a, H-6a’, H-6b’), 3.84 (dd, 1H, J5’,6a’ 6.7 Hz, J5’,6b’ 9.5 
Hz, H-5’), 3.76 (dd, 1H, J3,4 9.2 Hz, J4,5 9.8 Hz, H-4), 3.70 (m, 1H, H-5), 2.08, 2.04, 
2.00, 1.99, 1.97, 1.95, 1.89 (7  s, 21H, 7 × COCH3), 1.41 (s, 9H, Boc) ; C (75 MHz, 
CDCl3): 171.4 (C=O), 170.9, 170.6, 170.4, 170.3, 170.0, 169.8, 169.2 (C=O), 157.7 
(C=O), 101.1 (C-1’), 83.1 (C(CH3)3), 77.6 (C-1), 76.1 (C-4), 76.0 (CH2), 74.7 (C-3), 
73.0 71.2 70.8 69.2 (C-2, C-2’, C-3’, C-5, C-5’), 66.8 (C-4’), 62.3 (C-6), 61.1 (C-6’), 
28.0 (C(CH3)3) 20.9, 20.7, 20.7, 20.6, 20.5, 20.5, 20.4 (C(O)(CH3)3); IR (vmax/cm
-1): 
2981 (C-H), 1750 (C=O); HRMS: found [M+Na]+ 831.2666, C33H48N2O21Na requires 
831.2642. 
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N-[4-O-β-D-galactopyranosyl-β-(14)-D-glucopyranosyl] 2-(tert-
butyloxycarbonylaminoxy)acetamide[184] 41 
 
 
 
The acetyl protecting groups of compound 63 (50 mg) were removed by the 
addition of NaOMe (0.5 M, 173 µL) in anhydrous MeOH (300 µL) under N2 
overnight. The product was concentrated and lyophilised from H2O to afford ligand 
41 as a colourless foam.  
 
NMR:H (500 MHz, D2O): 5.02 (d, 1H, J1,2 9.2 Hz, H-1), 4.45 (dd, 1H, J1’,2’ 7.7 Hz, 
H-1’), 4.25 (m, 2H, CH2ON), 3.92-3.94 (m, 2H, H-4', H-6a), 3.64-3.83 (m, 8H, H-3, 
H-3’, H-4, H-5, H-5', H-6a', H-6b, H-6b'), 2.85 (2H, (m, 1H, H-2, H-2'), 1.36 (s, 9H, 
Boc). 
 
(4-[(tert-butoxycarbonyl)aminooxyacetamidyl]methyl)-([1,2,3]triazol-1-yl)-1-β-
D-galactopyranoside 53 [185] 
 
 
 
 
CuSO4 (9.75 µL, 0.5 M in H2O, 30 mol% final), sodium ascorbate (19.5 µL, 0.5 M in 
H2O, 60 mol% final) and galactosyl azide 50
[182] (5.0 mg, 24.4 µmol) were added to 
2-[N-(t-butoxycarbonyl)aminooxy]-N-(prop-2-ynyl)acetamide 52[185] (3.7 mg, 16.2 
µmol) with H2O (25 µL) and DMF (271 µL) in a microwave tube and the reaction 
was subjected to 150 W, 80 °C, with stirring for 20 min to afford ligand 53. The 
reaction mixture was lyophilised for direct use in protein reactions without further 
purification. ESI-MS: found [M+H]+ 434.2 C16H27N5O9 requires 434.18. 
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8.2.3 Buffer solutions 
All solutions were made up to 1 L with 18 MΩ water purified using an Elga purelab 
system unless otherwise stated. Buffer solutions were adjusted to the correct pH 
using NaOH or HCl. 
 
Standard buffers 
Phosphate buffer (pH 7.0, 0.1 M): Na2HPO4.2H2O (10.27 g), NaH2PO4.2H2O (6.60 
g), 0.1 M NaCl (5.84 g). 
 
HEPES buffer (pH 7.5): 50 mM HEPES (14.1 g), 150 mM NaCl (8.8 g), 5 mM CaCl2 
(0.55 g). 
8.2.4 N-terminal oxidation and oxime formation 
The concentrations stated for CTB refer to the monomer. AB5 concentrations are 
given for the full complex. MS results stated are for the two most prominent charge 
states observed for each modified protein. 
 
N-terminal oxidation of CTB to make CTBox 
 
General procedure: The N-terminus of the CTB protein was modified by oxidation 
according to the procedure of Chen et al.[146] Methionine (15 µL, 200 mM, 10 
equivalents, in phosphate buffer) was added to CTB (500 µL, 600 µM, in phosphate 
buffer), followed by the addition of NaIO4 (30 µL, 50 mM, 5 equivalents, in 
phosphate buffer). After 5 min at room temperature the reaction was complete, 
yielding CTBox. ESI-MS: hemihydrate found [M+11H]11+ 1057.06, [M+10H]10+ 
1162.65, C514H817N139O157S5 requires [M+11H]
11+ 1056.99, [M+10H]10+ 1162.59. 
 
Oxime ligation at the CTB N-terminus 
 
Ligands that were to be attached to the N-terminus of CTB via oxime formation 
were synthesised with a Boc-protected aminooxy group. The Boc group was then 
removed by the addition of TFA and stirring for 30 min before the TFA was 
evaporated under N2. The product was redissolved in phosphate buffer for use in 
protein modification experiments or mixed directly with the protein. As the 
unprotected aminooxy group is highly reactive, it was used immediately without 
further characterisation. Masses quoted for the compounds used in oxime formation 
with CTBox or CTA2ox refer to the mass before removal of the Boc group, for 
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simplicity. After the removal of the Boc group the compound number gains an a to 
represent the deprotected version (as shown in previous chapters). 
 
General procedure after optimisation: CTBox (500 µL, 600µM) and aniline (4.5 µL, 
to give a final concentration of 100 mM) were added to aminooxy-containing 
compound (10 equiv) in phosphate buffer and incubated at room temperature. 
Reactions were monitored by LC-MS until seen to be complete. The resulting 
modified protein was purified two times by SEC on a PD G-25 minitrap column to 
ensure complete removal of the unreacted oxyamine and aniline. 
 
Acid catalysed amide ligand 38a attachment : CTB(38) 
 
The amide ligand 38a (10 µL, 0.16 M, 15 equiv) in phosphate buffer and acetic acid 
(50 µL) were added to CTBox (520 µL, 200 µM in phosphate buffer). The reaction 
went to completion after 30 min at room temperature, yielding CTB(38). ESI-MS: 
found [M+11H]11+ 1063.23, [M+10H]10+ 1169.50, C517H821N141O157S6 requires 
[M+11H]11+ 1163.18, [M+10H]10+ 1169.39. 
 
Attachment of galactose peptide ligand 39a in the presence of a competing 
ligand: CTB(39) 
 
The galactose ligand 39a (1.07 mg, 10 equiv, in 50 µL phosphate buffer), aniline 
(1.5 µL, to give a final concentration of 100 mM) and methyl α-D-galactopyranoside 
(6.5 mg, 200 mM) as a competing ligand were added to CTBox (116.5 µL, 865 µM 
in phosphate buffer). After 90 min at room temperature the reaction went to 
completion, yielding CTB(39). ESI-MS: found [M+11H]11+ 1145.90, [M+10H]10+ 
1260.38, C556H877N149O172S6 requires [M+11H]
11+ 1145.75, [M+10H]10+ 1260.23. 
 
Oxime ligation of small galactose ligand 40a: CTB(40) 
 
Galactose ligand 40a (0.58 mg, 27 equiv) in phosphate buffer (33 µL) and aniline 
(1.2 µL, to give a final concentration of 100 mM) were added to CTBox (100 µL, at a 
final concentration of 600 µM). The reaction went to completion after 24 h at room 
temperature, yielding CTB(40). ESI-MS: found [M+11H]11+ 1076.44, [M+10H]10+ 
1183.99, C522H829N141O162S5 requires [M+11H]
11+ 1076.63, [M+10H]10+ 1184.20. 
 
194 
 
Oxime ligation of lactose ligand 41a with or without a competing ligand: 
CTB(41) 
 
Lactose ligand 41a (1.34 mg, 35 equiv) in phosphate buffer (68 µL) and aniline (1.1 
µL, to give a final concentration of 100 mM) were added to CTBox (55 µL, at a final 
concentration of 600 µM) with or without the presence of the competing ligand 
methyl α-D-galactopyranoside (4.5 mg, to a concentration of 200 mM) and these 
reactions went to completion after 3 h at room temperature, yielding CTB(41). ESI-
MS: found [M+11H]11+ 1091.20, [M+10H]10+ 1200.25, C528H839N142O167S5 requires 
[M+11H]11+ 1091.37, [M+10H]10+ 1200.40. 
 
Oxime ligation of galactose peptide ligand 42a with or without a competing 
ligand: CTB(42) 
 
Galactose ligand 42a (1.2 mg, 18 equiv) in phosphate buffer (64 µL) and aniline (1 
µL, to give a final concentration of 100 mM) were added to CTBox (43.5 µL, to give 
a final concentration of 600 µM) with and without the presence of the competing 
ligand methyl α-D-galactopyranoside (4.2 mg, to a concentration of 200 mM). 
Galactosyl ligand 42a (0.4 mg, 18 equiv) in phosphate buffer (94 µL) was also 
added with aniline (1 µL, to give a final concentration of 100 mM) to CTBox (14.6 
µL, to give a final concentration of 200 µM) with and without the presence of a 
competing ligand methyl α-D-galactopyranoside (4.2 mg, to give a concentration of 
200 mM). These reactions all went to completion after 24 h at room temperature, 
yielding CTB(42). ESI-MS: found [M+11H]11+ 1135.30, [M+10H]10+ 1248.64, 
C552H871N147O170S6 requires [M+11H]
11+ 1135.39, [M+10H]10+ 1248.82. 
 
N-terminal oxidation of CTB mutants: W88Kox and W88Eox 
 
General procedure: The N-terminus of each of the CTB mutant proteins (W88K, 
W88K Q61E and W88E) was modified by oxidation according to the procedure of 
Chen et al.[146] Methionine (15 µL, 200 mM, 10 equivalents, in phosphate buffer) 
was added to the CTB mutant (500 µL, 600 µM, in phosphate buffer), followed by 
the addition of NaIO4 (30 µL, 50 mM, 5 equivalents, in phosphate buffer). After 5 
min at room temperature the reaction was complete, yielding W88Kox and W88Eox. 
The double mutant W88K Q61E failed to oxidise.  
ESI-MS: W88Kox hemihydrate found [M+11H]11+ 1051.51, [M+10H]10+ 1156.56, 
C509H819N139O157S5 requires [M+11H]
11+ 1051.66, [M+10H]10+ 1156.73.  
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ESI-MS: W88Eox hemihydrate found [M+11H]11+ 1051.60, [M+10H]10+ 1156.68, 
C508H814N138O159S5 requires [M+11H]
11+ 1051.71, [M+10H]10+ 1156.79. 
 
Oxime ligation of galactose peptide ligand 42a to W88K: W88K(42) 
 
W88Kox (31 µL, 241 µM) and aniline (0.4 µL, to give a final concentration of 100 
mM) were added to galactose 42a (0.23 mg, 30 equiv) in phosphate buffer (6.5 µL). 
The reaction went to completion after 24 h at room temperature, yielding W88K(42). 
ESI-MS: found [M+10H]10+ 1242.75, [M+11H]11+ 1129.88, C547H873N147O170S6 
requires [M+10H]10+ 1242.96, [M+11H]11+ 1130.06. 
 
Oxime ligation of galactose peptide ligand 42a to W88E: W88E(42) 
 
W88Eox (465 µL, 216 µM) and aniline (2.2 µL, to give a final concentration of 100 
mM) were added to galactose 42a (1.0 mg, 10 equiv) in phosphate buffer and this 
reaction went to completion after 24 h at room temperature. The product was 
purified by SEC, yielding W88E(42). ESI-MS: found [M+10H]10+ 1242.84, 
[M+11H]11+ 1129.98, C546H868N146O172S6 requires [M+10H]
10+ 1243.02, [M+11H]11+ 
1130.11. 
 
Oxime ligation of galactose peptide ligand 39a to W88E: W88E(39) 
 
W88Eox (110 µL, 520 µM) and aniline (1.0 µL, to give a final concentration of 100 
mM) were added to galactose 39a (0.5 mg, 8 equiv) in phosphate buffer and this 
reaction went to completion after 20 h at room temperature. The product was 
purified by SEC, yielding W88E(39). ESI-MS: found [M+8H]8+ 1567.92, [M+9]9+ 
1393.82, C550H874N148O174S6 requires [M+8]
8+ 1567.78, [M+9H]9+ 1393.70. 
 
Oxime ligation of alkyne ligand 52a to CTB: CTB(52) 
 
CTBox (419 µL, 305 µM) and aniline (0.4 µL, to give a final concentration of 100 
mM) were added to alkyne 52a (0.30 mg, 10 equiv) in phosphate buffer and this 
reaction went to completion after 20 h at room temperature. The modified protein 
was purified using a PD G-25 minitrap column and then concentrated using an 
Amicon Ultra-15 (30,000 MWCO) to yield CTB(52). ESI-MS: found [M+11H]11+ 
1065.36, [M+10H]10+ 1171.79, C519H821N141O157S5 requires [M+11H]
11+ 1065.52, 
[M+10H]10+ 1171.96. 
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Oxime ligation of galactose triazole ligand 53a to CTB: CTB(53) 
 
CTBox (206 µL, 204 µM) and aniline (1.9 µL, to give a final concentration of 100 
mM) were added to ligand 53a (3.25 µmol, 76 equiv) in phosphate buffer and this 
reaction went to completion after 20h at room temperature. The resultant 
modification was purified by a PD G-25 minitrap column to yield CTB(53). ESI-MS: 
found [M+11H]11+ 1084.26, [M+10H]10+ 1192.52, C525H832N144O162S5 requires 
[M+11H]11+ 1084.00, [M+10H]10+ 1192.30. 
 
Oxime ligation of GM1 ligand 54a to W88E: W88E(54) 
 
Oxidised W88E protein (100 µL, 400 µM) and aniline (0.9 µL, to give a final 
concentration of 100 mM) were added to GM1 ligand 54a (0.64 mg, 11 equiv) in 
phosphate buffer. After 20 h at room temperature, the modified protein was purified 
by a PD G-25 minitrap column, yielding W88E(54). ESI-MS: found [M+10H]10+ 
1285.46, [M+9H]9+ 1428.17, C561H901N145O188S5 requires [M+10H]
10+ 1285.34, 
[M+9H]9+ 1428.05. 
 
N-terminal oxidation of CTA2 (G1S): CTA2ox 
 
The N-terminus of CTA2 (G1S) was modified in a similar way to CTB by oxidation 
according to the procedure of Chen et al.[146] Methionine (1.42 µL, 200 mM, 10 
equivalents, in phosphate buffer) was added to AB5 (810 µL, 35 µM, in phosphate 
buffer), followed by the addition of NaIO4 (2.84 µL, 50 mM, 5 equivalents, in 
phosphate buffer). After 5 min at room temperature the reaction was complete, 
yielding CTA2ox. ESI-MS: CTA2ox hemiacetal found [M+7H]7+ 727.64, [M+6H]6+ 
848.74, C237H371N67O80S1 requires [M+7H]
7+ 727.57, [M+6]6+ 848.66. CTB found 
[M+10H]10+ 1162.21, [M+9H]9+ 1291.23, C515H820N140O155S5 requires [M+10H]
10+ 
1162.19, [M+9H]9+ 1291.21. 
 
Oxime ligation of biotin 61 to CTA2 (G1S): A(61)B5 
 
CTA2ox as part of the AB5 complex (814 µL, 35 µM) and aniline (7.4 µL, to give a 
final concentration of 100 mM) were added to biotin ligand 61 (3.0 mg, 240 equiv) in 
phosphate buffer and this reaction proceeded overnight before purification two 
times by PD-10 G-25 minitrap column, yielding A(61)B5. ESI-MS: found [M+6H]
6+ 
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912.79, [M+5H]5+ 1095.15, C551H878N146O174S5 requires [M+6H]
6+ 912.77, [M+5H]5+ 
1095.13. 
8.2.5 Protein CuAAC 
 
Copper-catalysed azide-alkyne cycloaddition (CuAAC) between CTB(52) and 
lactosyl azide 51 in the presence of TBTA 
 
Alkyne-modified CTB, CTB(52), (142 µL, 305 µM, 80 µM final concentration) was 
mixed with CuSO4 (5 µL, 100 mM, 2 mM final concentration), TCEP (12.5 µL, 100 
mM, 5 mM final concentration) and lactosyl azide 51 (0.375 mg, 78 µL, 2.8 mM final 
concentration) all in phosphate buffer (at pH 8). TBTA was added to the solution 
(12.5 µL, 100 mM, 2 mM final concentration) in DMSO and the mixture was 
vortexed at room temperature for 48 h.[159] After centrifugation at 13 krpm for 1 min, 
the supernatant was purified using a PD G-25 minitrap column. ESI-MS showed an 
incomplete reaction with most of the product being the desired lactose modification 
but also a significant amount of alkyne starting material (Fig 8.2). Other products 
identified included CTB modified with a galactosyl ligand, indicating partial cleavage 
of the lactose moiety, and another product with only the aglycone chain attached 
suggesting some full cleavage of the carbohydrate section.  
 
Fig 8.2 Mass spectrum of CuAAC reaction showing incomplete conversion. 
 
CuAAC between CTB(52) and lactosyl azide 51 in the presence of BPSA 
 
Alkyne CTB(52) (37 µL, 540 µM, 100 µM final concentration) was mixed with 
CuSO4 (4 µL, 100 mM, 2 mM final concentration), TCEP (8 µL, 100 mM, 4 mM final 
concentration) and BPSA (8 µL, 100 mM, 4 mM final concentration) all in phosphate 
buffer (pH 8). Lactose azide 51 (0.1 mg, 143 µL, 5 mM final concentration) was 
added to the solution and the mixture was vortexed at room temperature for 48 
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h.[162] ESI-MS showed no reaction had taken place and all the protein was still the 
alkyne derivative. 
 
CuAAC between CTB(52) and galactosyl azide 50 in the presence of either 
BPSA or TBTA 
 
Alkyne CTB(52) (46.3 µL, 540 µM, 100 µM final concentration) was mixed with 
CuSO4 (5 µL, 100 mM, 2 mM final concentration), TCEP (5 µL, 100 mM, 5 mM final 
concentration) and galactosyl azide 50 (32 mM, 39 µL, 5 mM final concentration) all 
in phosphate buffer (pH 8). BPSA or TBTA (12.5 µL, 40 mM, 2 mM final 
concentration) was added to the solution, in phosphate buffer or DMSO 
respectively, with extra phosphate buffer (142.2 µL, pH 8) and the mixture was 
vortexed at room temperature for 24 h.[159] Analysis by ESI-MS showed that no 
reaction had taken place with BPSA and an incomplete reaction had taken place 
with TBTA (Fig 8.3). The mass spectrum also showed an incomplete alkyne 
addition as some CTBox was still present, but this did not affect the progress of the 
CuAAC reaction. 
 
 
Fig 8.3 Mass spectrum of CuAAC reaction showing incomplete conversion. 
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8.2.6 Enzymatic cleavage and ligations 
 
Cleavage of MBP-AB5 using Tobacco Etch Virus (TEV) protease 
 
General procedure: TEV protease (30 µL, 63 µM, 5 mol%) was added to MBP-AB5 
(750 µL, 50 µM) in HEPES buffer and incubated at room temperature for 90 min. 
The cleaved AB5 protein was purified by Ni affinity chromatography, eluting with 
500 mM imidazole in HEPES buffer. 
ESI-MS: CTA2 (wild-type) found [M+7H]7+ 723.48, [M+6H]6+ 843.73, C219H342N64O74 
requires [M+7H]7+ 723.22, [M+6H]6+ 843.59. Found for CTB [M+11H]11+ 1059.33, 
[M+10H]10+ 1165.14, C516H822N140O156S5 requires [M+11H]
11+ 1059.45, [M+10H]10+ 
1165.29. 
ESI-MS: CTA2 (D4N) found [M+6H]6+ 621.56, [M+5H]5+ 745.67, C155H248N52O55 
requires [M+6H]6+ 620.99, [M+5H]5+ 744.98. Found for CTB [M+11H]11+ 1059.75, 
[M+10H]10+ 1165.51, C516H822N140O156S5 requires [M+11H]
11+ 1059.45, [M+10H]10+ 
1165.29. 
ESI-MS: CTA2 (G1S) found [M+7H]7+ 727.37, [M+6H]6+ 848.43 C220H344N64O75 
requires [M+7H]7+ 727.50, [M+6H]6+ 848.58. Found for CTB (T1A) [M+10H]10+ 
1162.21, [M+9H]9+ 1291.34, C515H820N140O155S5 requires [M+10H]
10+ 1162.19, 
[M+9H]9+ 1291.21. 
  
Sortase ligation of bpy depsipeptide 60 and CTA2 (wild-type): A(60)B5 
 
AB5 (wild-type) (120 µL, 225 µM) was mixed with sortase (7.1 µL, 380 µM, 10 
mol%) and bpy depsipeptide 60 (27 µL, 5 mM, 5 equiv). The reaction was incubated 
at 37 °C for 3 h before purification by SEC to yield A(60)B5. ESI-MS: found 
[M+8H]8+ 749.11, [M+7H]7+ 855.91, C265H399N73O86 requires [M+8H]
8+ 748.87 
[M+7H]7+ 855.70. 
 
Attempted sortase ligation of Fe(bpy 60)3 to CTA2 (wild-type)  
 
FeCl2 (3.4 µL, 2 mM) and bpy depsipeptide 60 (10.2 µL, 2 mM) in HEPES buffer 
were mixed together resulting in a red solution. AB5 (wild-type) (85 µL, 218 µM) was 
mixed with sortase (9.8 µL, 380 µM, 20 mol%) and added to the Fe(bpy 60)3 
complex (1 equiv bpy 60 to AB5). After incubation at 37 °C for 1 h the red colour 
was no longer present and after 4 h analysis by ESI-MS showed no ligation reaction 
had taken place. 
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Sortase ligation of bpy depsipeptide 60 and CTA2 (D4N): A(60)B5 (D4N) 
 
AB5 (D4N) (280 µL, 193 µM) was mixed with sortase (18 µL, 600 µM, 20 mol%) and 
bpy depsipeptide 60 (54 µL, 10 mM, 10 equiv). The reaction was incubated at 37 °C 
for 4 h before purification by Ni affinity chromatography to yield A(60)B5 (D4N). ESI-
MS: found [M+7H]7+ 665.85, [M+6H]6+ 776.65, C201H305N61O67 requires [M+7H]
7+ 
664.90, [M+6H]6+ 775.55. 
 
8.3 Biophysical analysis of binding interactions 
8.3.1 Atomic force microscopy (AFM) 
AFM experiments were carried out using a Nanoscope III Multimode AFM and 
Veeco NP-S cantilevers (spring constant ~0.3 N m-1). Experiments were conducted 
in buffers listed below using a fluid cell and images were acquired in tapping mode 
at a frequency of ~9 kHz. Images reported here are raw, unfiltered data and in 
height mode were collected with 512 × 512 points at a scanning rate of 1-2 Hz. 
 
A mica disk was freshly cleaved with tape before samples of protein solution 
(20-80 µL, 10-7 M) were added to the mica surface and incubated for 15-60 min 
before diluting with 0-2 x 30 µL of 2 mM citrate-phosphate buffer pH 5 before being 
imaged. 
 
For three component bilayers 5 mM stock solutions of DOPC, cholesterol and 
sphingomyelin were prepared in CHCl3. A 1 mg ml
-1 1:1:1 lipid solution was created 
by adding each component (125 µL). The CHCl3 was evaporated under N2, placed 
in a desiccator overnight and the lipids redissolved in H2O to give a cloudy solution 
as multilamellar vesicles (MLVs) are formed. After sonication for 30 min, the 
solution became clear indicating that the lipids had been broken up into small 
unilamellar vesicles (SUVs). Lipid solution (100 µL) was applied to a freshly cleaved 
mica surface and incubated for 30 min. The mica was then rinsed with H2O and left 
for a further hour before being imaged in contact mode. 
 
DOPC lipid bilayers were prepared as above but were dissolved in PBS buffer. 
GM1 was incorporated into the lipid solution at 1 mg ml-1 after sonication and 
incubated overnight at 4 °C. CTB (40 µL, 10-7 M) was added after the bilayers were 
applied to a mica surface and incubated for 30 min before imaging in tapping mode. 
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8.3.2 Analytical ultracentrifugation (AUC) 
Samples (0.41 mL) were centrifuged in 1.2 cm pathlength 2-sector aluminium 
centrepiece cells (sample in right hand sector, reference buffer in left hand sector) 
built with sapphire windows in an 8-place An50Ti or 6-place An60Ti analytical rotor 
running in an Optima XL-I analytical ultracentrifuge (Beckman Instruments, Inc., 
Palo Alto, California 94304) at 35 krpm (unless otherwise stated) and at a 
temperature of 20 °C. Changes in solute concentration were detected by 150 
absorbance scans measured at 280 nm (or other appropriate wavelength) over a 
period of 5-15 hours.  
 
Analysis and fitting of the data was performed using the software SedFit.[137] A 
continuous c (s) distribution model was fitted to the data, taking every 2nd scan. 
The resolution was set at 200 over a sedimentation coefficient range of 0.1-15.0 S. 
Parameters were set for the partial specific volume as 0.73654, the buffer density of 
1.04910 and the buffer viscosity at 0.01410. The frictional coefficient, the baseline 
and the raw data noise were floated in the fitting. The meniscus and bottom of the 
cell path were also floated after initial estimations from the raw data.  
8.3.3 Dynamic light scattering (DLS) 
Disposable polystyrene cuvettes were used for light scattering experiments 
performed using a Zetasizer Nano ZS (Malvern) at 20 °C measuring the scattering 
at an angle of 173° and using a laser wavelength of 633 nm. Protein samples 
(50-200 µL, 50-500 µM) and detergent samples (200 µL, 1-2 mM) in the appropriate 
buffer (either phosphate buffer or HEPES buffer) were filtered through a 0.8 µm 
filter (Millipore membrane filters) prior to analysis to ensure no dust particles were 
present which would skew the experiment. Readings of 10 scans over 10 seconds 
each were taken in triplicate with the average calculated. Measurement data was 
analysed using volume % which accounts for the volume of the objects when 
calculating relative quantities with a certain diameter. This measurement causes the 
data to not become skewed by the high scattering of larger particles. 
8.3.4 Enzyme-linked Lectin assay (ELLA) 
96-well polystyrene plates (NUNC Maxisorp) were prepared for the simultaneous 
testing of multiple samples. Ganglioside GM1 (100 µL, 1.3 µM in ethanol) was 
coated onto each well of a 96-well microtitre plate and the solvent was left to 
evaporate. The plate was washed with PBS (3 × 200 µL) to remove any unattached 
GM1 and any remaining free binding sites in the wells were blocked with BSA by 
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incubating with a PBS solution containing 1% (w/v) BSA (100 µL) for 30 min at 
37 °C. The wells were then washed again with PBS (3 × 200 µL). A series of 
inhibitor samples spanning a range of concentrations were prepared in PBS 
containing 0.1% BSA and 0.05% Tween 20. Each sample was mixed with CTB-
HRP in the same buffer to give a final CTB-HRP concentration of 25 ng mL-1. These 
mixtures of inhibitor and toxin were incubated at room temperature for 2 h before 
200 µL was transferred to each GM1 coated well. The limits of detection were 
determined by control samples containing only the CTB-HRP component and no 
inhibitor, which gave the highest response, and a blank sample of only buffer which 
gave the lower limit. These two measurements were used to find the maximum and 
minimum optical density values for CTB-HRP binding to the GM1-coated wells. The 
inhibitor-toxin mixtures were incubated at room temperature for 30 min before the 
plate was washed with PBS, 0.1% BSA, 0.05% Tween 20 (3 × 200 µL), to remove 
the unbound CTB-HRP-inhibitor complexes. An OPD solution was freshly prepared 
(25 mg OPD.2HCL, 7.5 mL 0.1 M citric acid, 7.5 mL 0.1 M sodium citrate and 6 µL 
of a 30% H2O2 solution, pH 6.0) and added to each well (100 µL). The solution was 
allowed to react in the dark, at room temperature, for 25 min before the oxidation 
reaction was quenched by the addition of 1 M H2SO4 (50 µL). The absorbance at 
490 nm was measured within 5 min. 
 
The samples were analysed in triplicate, initially over a large concentration range 
using a 10-fold dilution. A more accurate 2-fold dilution was then performed around 
the expected IC50 values. Anomalous data points were removed in a few cases 
leaving duplicate results. The error of each sample was calculated as the standard 
error (Equation 8.3). 
 
Equation 8.3 
               
  
   
        
 
   
  
 
 
where N is the size of the sample, xi is the observed value of each sample and   is the mean value of 
the sample. 
 
The absorbance of each sample was converted to percentage binding by 
comparison with the maximum absorbance and minimum absorbance obtained 
from the control samples. These values were then plotted against the concentration 
of inhibitor for each sample and curve fitting was performed using the standard 
dose-response model in Origin (Equation 8.4). Fitting was performed with weighted 
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data points according to the standard error. Concentration values were converted to 
log(concentration) before curve fitting. 
 
Equation 8.4 
     
     
              
 
 
Where A1 is y-value for the bottom plateau, A2 is the y-value for the top plateau, x0 is the IC50 value, x 
is log(inhibitor concentration) and p is the Hill slope parameter. 
 
8.3.5 Isothermal titration calorimetry (ITC) 
ITC titrations were performed using a Microcal ITC200 calorimeter (GE healthcare) 
with a cell volume of 0.2028 mL and data processed and fitted using Origin with the 
one site model.[186] Protein samples were dialysed into phosphate buffer 
(SnakeSkin® pleated dialysis tubing, Thermo Scientific, with 7000 MWCO) prior to 
analysis. The ligands were then dissolved in the dialysis buffer to ensure an exact 
match for the buffers during the titration. The reference cell was filled with water and 
the analysis cell was filled with the protein solution and both were allowed to reach 
thermal equilibrium at 25 °C before titrations were performed. Titrations typically 
comprised 20 injections of 2 µL at 2 minute intervals. Separate titrations of the 
ligand into buffer were used to subtract the heat of dilution from the integrated data 
prior to curve fitting. The binding stoichiometry (n) was fixed at 1.0 for low c-value 
titrations as described by Turnbull and Daranas.[141] 
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9 Appendix 
 
 
 
 
 
Protein and DNA sequences,  
and yet more synthetic data 
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9.1 Protein sequences 
Introduced mutations in the amino acid sequences are marked in red and 
underlined. Differences from the wild-type El Tor biotype of CTB in the CTB 
classical biotype and in LTB are marked in green. The TEV cleavage site in the 
MBP-CTA2 sequence is marked in blue. The sequence for CTA2 begins at G399 in 
the MBP-CTA2 sequence 
 
CTB  
  1          11         21         31              
wt (El Tor) TPQNITDLCA EYHNTQIYTL NDKIFSYTES LAGKREMAII  
W88K  TPQNITDLCA EYHNTQIYTL NDKIFSYTES LAGKREMAII 
W88K T1A APQNITDLCA EYHNTQIYTL NDKIFSYTES LAGKREMAII 
W88K Q61E  TPQNITDLCA EYHNTQIYTL NDKIFSYTES LAGKREMAII 
W88E TPQNITDLCA EYHNTQIYTL NDKIFSYTES LAGKREMAII 
T1A APQNITDLCA EYHNTQIYTL NDKIFSYTES LAGKREMAII 
I47T TPQNITDLCA EYHNTQIYTL NDKIFSYTES LAGKREMAII 
CTB classical TPQNITDLCA EYHNTQIHTL NDKIFSYTES LAGKREMAII 
LTB APQSITELCS EYHNTQIYTI NDKILSYTES MAGKREMVII 
 
  41         51         61         71    
wt (El Tor) TFKNGAIFQV EVPGSQHIDS QKKAIERMKD TLRIAYLTEA 
W88K   TFKNGAIFQV EVPGSQHIDS QKKAIERMKD TLRIAYLTEA 
W88K T1A TFKNGAIFQV EVPGSQHIDS QKKAIERMKD TLRIAYLTEA 
W88K Q61E  TFKNGAIFQV EVPGSQHIDS EKKAIERMKD TLRIAYLTEA 
W88E  TFKNGAIFQV EVPGSQHIDS QKKAIERMKD TLRIAYLTEA 
T1A   TFKNGAIFQV EVPGSQHIDS QKKAIERMKD TLRIAYLTEA 
I47T   TFKNGATFQV EVPGSQHIDS QKKAIERMKD TLRIAYLTEA 
CTB classical TFKNGATFQV EVPGSQHIDS QKKAIERMKD TLRIAYLTEA 
LTB  TFKSGATFQV EVPGSQHIDS QKKAIERMKD TLRITYLTET 
 
        81         91         101 
wt (El Tor) KVEKLCVWNN KTPHAIAAIS MAN 
W88K  KVEKLCVKNN KTPHAIAAIS MAN 
W88K T1A KVEKLCVKNN KTPHAIAAIS MAN 
W88K Q61E  KVEKLCVKNN KTPHAIAAIS MAN 
W88E  KVEKLCVENN KTPHAIAAIS MAN 
T1A  KVEKLCVWNN KTPHAIAAIS MAN 
I47T  KVEKLCVWNN KTPHAIAAIS MAN 
CTB classical KVEKLCVWNN KTPHAIAAIS MAN 
LTB  KVEKLCVWNN KTPNSIAAIS MEN 
 
 
 
MBP-CTA2 
  1          11         21         31              
wild-type KIEEGKLVIW INGDKGYNGL AEVGKKFEKD TGIKVTVEHP 
D4N  KIEEGKLVIW INGDKGYNGL AEVGKKFEKD TGIKVTVEHP 
G1S   KIEEGKLVIW INGDKGYNGL AEVGKKFEKD TGIKVTVEHP 
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  41         51         61         71    
wild-type DKLEEKFPQV AATGDGPDII FWAHDRFGGY AQSGLLAEIT 
D4N  DKLEEKFPQV AATGDGPDII FWAHDRFGGY AQSGLLAEIT 
G1S   DKLEEKFPQV AATGDGPDII FWAHDRFGGY AQSGLLAEIT 
 
  81         91         101        111              
wild-type PDKAFQDKLY PFTWDAVRYN GKLIAYPIAV EALSLIYNKD 
D4N PDKAFQDKLY PFTWDAVRYN GKLIAYPIAV EALSLIYNKD 
G1S  PDKAFQDKLY PFTWDAVRYN GKLIAYPIAV EALSLIYNKD 
 
  121        131        141        151    
wild-type LLPNPPKTWE EIPALDKELK AKGKSALMFN LQEPYFTWPL 
D4N  LLPNPPKTWE EIPALDKELK AKGKSALMFN LQEPYFTWPL 
G1S   LLPNPPKTWE EIPALDKELK AKGKSALMFN LQEPYFTWPL 
 
  161        171        181        191              
wild-type IAADGGYAFK YENGKYDIKD KYDIKDVGVD NAGAKAGLTF 
D4N IAADGGYAFK YENGKYDIKD VGVDNAGAKA GLTFLVDLIK 
G1S  IAADGGYAFK YENGKYDIKD VGVDNAGAKA GLTFLVDLIK 
 
  201        211        221        231    
wild-type NKHMNADTDY SIAEAAFNKG ETAMTINGPW AWSNIDTSKV 
D4N  NKHMNADTDY SIAEAAFNKG ETAMTINGPW AWSNIDTSKV 
G1S   NKHMNADTDY SIAEAAFNKG ETAMTINGPW AWSNIDTSKV 
 
  241        251        261        271              
wild-type NYGVTVLPTF KGQPSKPFVG VLSAGINAAS PNKELAKEFL 
D4N NYGVTVLPTF KGQPSKPFVG VLSAGINAAS PNKELAKEFL  
G1S  NYGVTVLPTF KGQPSKPFVG VLSAGINAAS PNKELAKEFL 
 
  281        291        301        311    
wild-type ENYLLTDEGL EAVNKDKPLG AVALKSYEEE LVKDPRIAAT 
D4N  ENYLLTDEGL EAVNKDKPLG AVALKSYEEE LVKDPRIAAT 
G1S  ENYLLTDEGL EAVNKDKPLG AVALKSYEEE LVKDPRIAAT 
 
  321        331        341        351              
wild-type MENAQKGEIM PNIPQMSAFW YAVRTAVINA ASGRQTVDEA 
D4N MENAQKGEIM PNIPQMSAFW YAVRTAVINA ASGRQTVDEA 
G1S  MENAQKGEIM PNIPQMSAFW YAVRTAVINA ASGRQTVDEA 
 
  361        371        381        391    
wild-type LKDAQTNSSS NNNNNNNNNN LGIEGRISHM GSENLYFQGG 
D4N  LKDAQTNSSS NNNNNNNNNN LGIEGRISHM GSENLYFQGG 
G1S  LKDAQTNSSS NNNNNNNNNN LGIEGRISHM GSENLYFQSG 
 
  401        411        421        431              
wild-type GDEKTQSHGV KFLDEYQSKV KRQIFSGYQS DIDTHNRIKD 
D4N GNNNNN---- -------SKV KRQIFSGYQS DIDTHNRIKD  
G1S  GDEKTQSHGV KFLDEYQSKV KRQIFSGYQS DIDTHNRIKD 
 
  441         
wild-type EL 
D4N  EL 
G1S   EL  
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9.2 DNA plasmid sequences 
The genes encoding the proteins CTB, MBP and CTA2 are highlighted in red, blue 
and green respectively. 
9.2.1 pATA13 
 
Fig 9.1 Plasmid map for pATA13 
 
The CTB plasmid for expression in Vibrio sp.60 is pATA13 (Fig 9.1).[187] It is derived 
from pTRH64[188], which in turn is derived from pMMB68[189], which originates from 
plasmid PMMB66EH.[190] 
 
Full sequence: 
 
AGCTTGGCTGTTTTGGCGGATGAGAGAAGATTTTCAGCCTGATACAGATTAAATCAGAACGCAGAAGC
GGTCTGATAAAACAGAATTTGCCTGGCGGCAGTAGCGCGGTGGTCCCACCTGACCCCATGCCGAACTC
AGAAGTGAAACGCCGTAGCGCCGATGGTAGTGTGGGGTCTCCCCATGCGAGAGTAGGGAACTGCCAGG
CATCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGGTGAA
CGCTCTCCTGAGTAGGACAAATCCGCCGGGAGCGGATTTGAACGTTGCGAAGCAACGGCCCGGAGGGT
GGCGGGCAGGACGCCCGCCATAAACTGCCAGGCATCAAATTAAGCAGAAGGCCATCCTGACGGATGGC
CTTTTTGCGTTTCTACAAACTCTTTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGA
GACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGT
GTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAA
AGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTA
AGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGT
GGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAA
TGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTAT
GCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCG
AAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGA
GCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGC
GCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCG
GATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG
AGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCG
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TAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGT
GCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTCTG
AAAGCGACCAGGTGCTCGGCGTGGCAAGACTCGCAGCGAACCCGTAGAAAGCCATGCTCCAGCCGCCC
GCATTGGAGAAATTCTTCAAATTCCCGTTGCACATAGCCCGGCAATTCCTTTCCCTGCTCTGCCATAA
GCGCAGCGAATGCCGGGTAATACTCGTCAACGATCTGATAGAGAAGGGTTTGCTCGGGTCGGTGGCTC
TGGTAACGACCAGTATCCCGATCCCGGCTGGCCGTCCTGGCCGCCACATGAGGCATGTTCCGCGTCCT
TGCAATACTGTGTTTACATACAGTCTATCGCTTAGCGGAAAGTTCTTTTACCCTCAGCCGAAATGCCT
GCCGTTGCTAGACATTGCCAGCCAGTGCCCGTCACTCCCGTACTAACTGTCACGAACCCCTGCAATAA
CTGTCACGCCCCCCTGCAATAACTGTCACGAACCCCTGCAATAACTGTCACGCCCCCAAACCTGCAAA
CCCAGCAGGGGCGGGGGCTGGCGGGGTGTTGGAAAAATCCATCCATGATTATCTAAGAATAATCCACT
AGGCGCGGTTATCAGCGCCCTTGTGGGGCGCTGCTGCCCTTGCCCAATATGCCCGGCCAGAGGCCGGA
TAGCTGGTCTATTCGCTGCGCTAGGCTACACACCGCCCCACCGCTGCGCGGCAGGGGGAAAGGCGGGC
AAAGCCCGCTAAACCCCACACCAAACCCCGCAGAAATACGCTGGAGCGCTTTTAGCCGCTTTAGCGGC
CTTTCCCCCTACCCGAAGGGTGGGGGCGCGTGTGCAGCCCCGCAGGGCCTGTCTCGGTCGATCATTCA
GCCCGGCTCATCCTTCTGGCGTGGCGGCAGACCGAACAAGGCGCGGTCGTGGTCGCGTTCAAGGTACG
CATCCATTGCCGCCATGAGCCGATCCTCCGGCCACTCGCTGCTGTTCACCTTGGCCAAAATCATGGCC
CCCACCAGCACCTTGCGCCTTGTTTCGTTCTTGCGCTCTTGCTGCTGTTCCCTTGCCCGCTCCCGCTG
AATTTCGGCATTGATTCGCGCTCGTTGTTCTTCGAGCTTGGCCAGCCGATCCGCCGCCTTGTTGCTCC
CCTTAACCATCTTGACACCCCATTGTTAATGTGCTGTCTCGTAGGCTATCATGGAGGCACAGCGGCGG
CAATCCCGACCCTACTTTGTAGGGGAGGGCGCACTTACCGGTTTCTCTTCGAGAAACTGGCCTAACGG
CCACCCTTCGGGCGGTGCGCTCTCCGAGGGCCATTGCATGGAGCCGAAAAGCAAAAGCAACAGCGAGG
CAGCATGGCGATTTATCACCTTACGGCGAAAACCGGCAGCAGGTCGGGCGGCCAATCGGCCAGGGCCA
AGGCCGACTACATCCAGCGCGAAGGCAAGTATGCCCGCGACATGGATGAAGTCTTGCACGCCGAATCC
GGGCACATGCCGGAGTTCGTCGAGCGGCCCGCCGACTACTGGGATGCTGCCGACCTGTATGAACGCGC
CAATGGGCGGCTGTTCAAGGAGGTCGAATTTGCCCTGCCGGTCGAGCTGACCCTCGACCAGCAGAAGG
CGCTGGCGTCCGAGTTCGCCCAGCACCTGACCGGTGCCGAGCGCCTGCCGTATACGCTGGCCATCCAT
GCCGGTGGCGGCGAGAACCCGCACTGCCACCTGATGATCTCCGAGCGGATCAATGACGGCATCGAGCG
GCCCGCCGCTCAGTGGTTCAAGCGGTACAACGGCAAGACCCCGGAGAAGGGCGGGGCACAGAAGACCG
AAGCGCTCAAGCCCAAGGCATGGCTTGAGCAGACCCGCGAGGCATGGGCCGACCATGCCAACCGGGCA
TTAGAGCGGGCTGGCCACGACGCCCGCATTGACCACAGAACACTTGAGGCGCAGGGCATCGAGCGCCT
GCCCGGTGTTCACCTGGGGCCGAACGTGGTGGAGATGGAAGGCCGGGGCATCCGCACCGACCGGGCAG
ACGTGGCCCTGAACATCGACACCGCCAACGCCCAGATCATCGACTTACAGGAATACCGGGAGGCAATA
GACCATGAACGCAATCGACAGAGTGAAGAAATCCAGAGGCATCAACGAGTTAGCGGAGCAGATCGAAC
CGCTGGCCCAGAGCATGGCGACACTGGCCGACGAAGCCCGGCAGGTCATGAGCCAGACCAAGCAGGCC
AGCGAGGCGCAGGCGGCGGAGTGGCTGAAAGCCCAGCGCCAGACAGGGGCGGCATGGGTGGAGCTGGC
CAAAGAGTTGCGGGAGGTAGCCGCCGAGGTGAGCAGCGCCGCGCAGAGCGCCCGGAGCGCGTCGCGGG
GGTGGCACTGGAAGCTATGGCTAACCGTGATGCTGGCTTCCATGATGCCTACGGTGGTGCTGCTGATC
GCATCGTTGCTCTTGCTCGACCTGACGCCACTGACAACCGAGGACGGCTCGATCTGGCTGCGCTTGGT
GGCCCGATGAAGAACGACAGGACTTTGCAGGCCATAGGCCGACAGCTCAAGGCCATGGGCTGTGAGCG
CTTCGATATCGGCGTCAGGGACGCACCCACCGGCCAGATGATGAACCGGGAATGGTCAGCCGCCGAAG
TGCTCCAGAACACGCCATGGCTCAAGCGGATGAATGCCCAGGGCAATGACGTGTATATCAGGCCCGCC
GAGCAGGAGCGGCATGGTCTGGTGCTGGTGGACGACCTCAGCGAGTTTGACCTGGATGACATGAAAGC
CGAGGGCCGGGAGCCTGCCCTGGTAGTGGAAACCAGCCCGAAGAACTATCAGGCATGGGTCAAGGTGG
CCGACGCCGCAGGCGGTGAACTTCGGGGGCAGATTGCCCGGACGCTGGCCAGCGAGTACGACGCCGAC
CCGGCCAGCGCCGACAGCCGCCACTATGGCCGCTTGGCGGGCTTCACCAACCGCAAGGACAAGCACAC
CACCCGCGCCGGTTATCAGCCGTGGGTGCTGCTGCGTGAATCCAAGGGCAAGACCGCCACCGCTGGCC
CGGCGCTGGTGCAGCAGGCTGGCCAGCAGATCGAGCAGGCCCAGCGGCAGCAGGAGAAGGCCCGCAGG
CTGGCCAGCCTCGAACTGCCCGAGCGGCAGCTTAGCCGCCACCGGCGCACGGCGCTGGACGAGTACCG
CAGCGAGATGGCCGGGCTGGTCAAGCGCTTCGGTCATGACCTCAGCAAGTGCGACTTTATCGCCGCGC
AGAAGCTGGCCAGCCGGGGCCGCAGTGCCGAGGAAATCGGCAAGGCCATGGCCGAGGCCAGCCCAGCG
CTGGCAGAGCGCAAGCCCGGCCACGAAGCGGATTACATCGAGCGCACCGTCAGCAAGGTCATGGGTCT
GCCCAGCGTCCAGCTTGCGCGGGCCGAGCTGGCACGGGCACCGGCACCCCGCCAGCGAGGCATGGACA
GGGGCGGGCCAGATTTCAGCATGTAGTGCTTGCGTTGGTACTCACGCCTGTTATACTATGAGTACTCA
CGCACAGAAGGGGGTTTTATGGAATACGAAAAAAGCGCTTCAGGGTCGGTCTACCTGATCAAAAGTGA
CAAGGGCTATTGGTTGCCCGGTGGCTTTGGTTATACGTCAAACAAGGCCGAGGCTGGCCGCTTTTCAG
TCGCTGATATGGCCAGCCTTAACCTTGACGGCTGCACCTTGTCCTTGTTCCGCGAAGACAAGCCTTTC
GGCCCCGGCAAGTTTCTCGGTGACTGATATGAAAGACCAAAAGGACAAGCAGACCGGCGACCTGCTGG
CCAGCCCTGACGCTGTACGCCAAGCGCGATATGCCGAGCGCATGAAGGCCAAAGGGATGCGTCAGCGC
AAGTTCTGGCTGACCGACGACGAATACGAGGCGCTGCGCGAGTGCCTGGAAGAACTCAGAGCGGCGCA
GGGCGGGGGTAGTGACCCCGCCAGCGCCTAACCACCAACTGCCTGCAAAGGAGGCAATCAATGGCTAC
CCATAAGCCTATCAATATTCTGGAGGCGTTCGCAGCAGCGCCGCCACCGCTGGACTACGTTTTGCCCA
ACATGGTGGCCGGTACGGTCGGGGCGCTGGTGTCGCCCGGTGGTGCCGGTAAATCCATGCTGGCCCTG
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CAACTGGCCGCACAGATTGCAGGCGGGCCGGATCTGCTGGAGGTGGGCGAACTGCCCACCGGCCCGGT
GATCTACCTGCCCGCCGAAGACCCGCCCACCGCCATTCATCACCGCCTGCACGCCCTTGGGGCGCACC
TCAGCGCCGAGGAACGGCAAGCCGTGGCTGACGGCCTGCTGATCCAGCCGCTGATCGGCAGCCTGCCC
AACATCATGGCCCCGGAGTGGTTCGACGGCCTCAAGCGCGCCGCCGAGGGCCGCCGCCTGATGGTGCT
GGACACGCTGCGCCGGTTCCACATCGAGGAAGAAAACGCCAGCGGCCCCATGGCCCAGGTCATCGGTC
GCATGGAGGCCATCGCCGCCGATACCGGGTGCTCTATCGTGTTCCTGCACCATGCCAGCAAGGGCGCG
GCCATGATGGGCGCAGGCGACCAGCAGCAGGCCAGCCGGGGCAGCTCGGTACTGGTCGATAACATCCG
CTGGCAGTCCTACCTGTCGAGCATGACCAGCGCCGAGGCCGAGGAATGGGGTGTGGACGACGACCAGC
GCCGGTTCTTCGTCCGCTTCGGTGTGAGCAAGGCCAACTATGGCGCACCGTTCGCTGATCGGTGGTTC
AGGCGGCATGACGGCGGGGTGCTCAAGCCCGCCGTGCTGGAGAGGCAGCGCAAGAGCAAGGGGGTGCC
CCGTGGTGAAGCCTAAGAACAAGCACAGCCTCAGCCACGTCCGGCACGACCCGGCGCACTGTCTGGCC
CCCGGCCTGTTCCGTGCCCTCAAGCGGGGCGAGCGCAAGCGCAGCAAGCTGGACGTGACGTATGACTA
CGGCGACGGCAAGCGGATCGAGTTCAGCGGCCCGGAGCCGCTGGGCGCTGATGATCTGCGCATCCTGC
AAGGGCTGGTGGCCATGGCTGGGCCTAATGGCCTAGTGCTTGGCCCGGAACCCAAGACCGAAGGCGGA
CGGCAGCTCCGGCTGTTCCTGGAACCCAAGTGGGAGGCCGTCACCGCTGAATGCCATGTGGTCAAAGG
TAGCTATCGGGCGCTGGCAAAGGAAATCGGGGCAGAGGTCGATAGTGGTGGGGCGCTCAAGCACATAC
AGGACTGCATCGAGCGCCTTTGGAAGGTATCCATCATCGCCCAGAATGGCCGCAAGCGGCAGGGGTTT
CGGCTGCTGTCGGAGTACGCCAGCGACGAGGCGGACGGGCGCCTGTACGTGGCCCTGAACCCCTTGAT
CGCGCAGGCCGTCATGGGTGGCGGCCAGCATGTGCGCATCAGCATGGACGAGGTGCGGGCGCTGGACA
GCGAAACCGCCCGCCTGCTGCACCAGCGGCTGTGTGGCTGGATCGACCCCGGCAAAACCGGCAAGGCT
TCCATAGATACCTTGTGCGGCTATGTCTGGCCGTCAGAGGCCAGTGGTTCGACCATGCGCAAGCGCCG
CAAGCGGGTGCGCGAGGCGTTGCCGGAGCTGGTCGCGCTGGGCTGGACGGTAACCGAGTTCGCGGCGG
GCAAGTACGACATCACCCGGCCCAAGGCGGCAGGCTGACCCCCCCCACTCTATTGTAAACAAGACATT
TTTATCTTTTATATTCAATGGCTTATTTTCCTGCTAATTGGTAATACCATGAAAAATACCATGCTCAG
AAAAGGCTTAACAATATTTTGAAAAATTGCCTACTGAGCGCTGCCGCACAGCTCCATAGGCCGCTTTC
CTGGCTTTGCTTCCAGATGTATGCTCTTCTGCTCCCGAACGCCAGCAAGACGTAGCCCAGCGCGTCGG
CCAGCTTGCAATTCGCGCTAACTTACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGTCGGGAAA
CCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCC
AGGGTGGTTTTTCTTTTCACCAGTGAGACGGGCAACAGCTGATTGCCCTTCACCGCCTGGCCCTGAGA
GAGTTGCAGCAAGCGGTCCACGTGGTTTGCCCCAGCAGGCGAAAATCCTGTTTGATGGTGGTTAACGG
CGGGATATAACATGAGCTGTCTTCGGTATCGTCGTATCCCACTACCGAGATATCCGCACCAACGCGCA
GCCCGGACTCGGTAATGGCGCGCATTGCGCCCAGCGCCATCTGATCGTTGGCAACCAGCATCGCAGTG
GGAACGATGCCCTCATTCAGCATTTGCATGGTTTGTTGAAAACCGGACATGGCACTCCAGTCGCCTTC
CCGTTCCGCTATCGGCTGAATTTGATTGCGAGTGAGATATTTATGCCAGCCAGCCAGACGCAGACGCG
CCGAGACAGAACTTAATGGGCCCGCTAACAGCGCGATTTGCTGGTGACCCAATGCGACCAGATGCTCC
ACGCCCAGTCGCGTACCGTCTTCATGGGAGAAAATAATACTGTTGATGGGTGTCTGGTCAGAGACATC
AAGAAATAACGCCGGAACATTAGTGCAGGCAGCTTCCACAGCAATGGCATCCTGGTCATCCAGCGGAT
AGTTAATGATCAGCCCACTGACGCGTTGCGCGAGAAGATTGTGCACCGCCGCTTTACAGGCTTCGACG
CCGCTTCGTTCTACCATCGACACCACCACGCTGGCACCCAGTTGATCGGCGCGAGATTTAATCGCCGC
GACAATTTGCGACGGCGCGTGCAGGGCCAGACTGGAGGTGGCAACGCCAATCAGCAACGACTGTTTGC
CCGCCAGTTGTTGTGCCACGCGGTTGGGAATGTAATTCAGCTCCGCCATCGCCGCTTCCACTTTTTCC
CGCGTTTTCGCAGAAACGTGGCTGGCCTGGTTCACCACGCGGGAAACGGTCTGATAAGAGACACCGGC
ATACTCTGCGACATCGTATAACGTTACTGGTTTCACATTCACCACCCTGAATTGACTCTCTTCCGGGC
GCTATCATGCCATACCGCGAAAGGTTTTGCACCATTCGATGGTGTCAACGTAAATGCCGCTTCGCCTT
CGCGCGCGAATTGCAAGCTGATCCGGGCTTATCGACTGCACGGTGCACCAATGCTTCTGGCGTCAGGC
AGCCATCGGAAGCTGTGGTATGGCTGTGCAGGTCGTAAATCACTGCATAATTCGTGTCGCTCAAGGCG
CACTCCCGTTCTGGATAATGTTTTTTGCGCCGACATCATAACGGTTCTGGCAAATATTCTGAAATGAG
CTGTTGACAATTAATCATCGGCTCGTATAATGTGTGGAATTGTGAGCGGATACAATTTCACACAGGAA
ACAGAATTCGGCCCCCATAAAAAGTAAATTAAAATTTGGTGTTTTTTTTACAGTTTTACTATCTTCAG
CATATGCACATGGAACACCTCAAAATATTACTGATTTGTGTGCAGAATACCACAACACACAAATATAT
ACGCTAAATGATAAGATATTTTCGTATACAGAATCTCTAGCTGGAAAAAGAGAGATGGCTATCATTAC
TTTTAAGAATGGTGCAATTTTTCAAGTAGAAGTACCAGGTAGTCAACATATAGATTCACAAAAAAAAG
CGATTGAAAGGATGAAGGATACCCTGAGGATTGCATATCTTACTGAAGCTAAAGTCGAAAAGTTATGT
GTATGGAATAATAAAACGCCTCATGCGATTGCCGCAATTAGTATGGCAAACTAGTTTGCTTTAAAAGC
ATGTCTAATGCTAGGAACCTATATAACAACTACTGTACTTATACTAATGAGCCTTATGCTGCATTTGA
AAAGGCGGTAGAGGATGCAATACCGATCCTTAAACTGTAACACTATAACAGCTTCCACTACAGGGAGC
TGTTATAGCAAACAGAAAAAACTAAGCTAGGCTGGGGGGGCA 
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9.2.2 pSAB2.1A 
 
Fig 9.2 Plasmid map for pSAB2.1A 
 
 
The MBP-AB5 plasmid for expression in E.coli is pSAB2.1A (Fig 9.2). It is derived 
from pMAL-p5X obtained from Genscript. An MBP-CTA2 fusion was introduced 
along with the gene for CTB (1A), with the LTIIB efficient periplasmic targeting 
leader sequence. This resulted in plasmid pSAB2.1A (preparation of the plasmid 
performed by Mr James Ross).  
 
Derivatives of plasmid pSAB2.1A include:  
pSAB2.1T, pTRBAB5-D4N and pTRBAB5-G1S 
 
Full sequence: 
 
CCGACACCATCGAATGGTGCAAAACCTTTCGCGGTATGGCATGATAGCGCCCGGAAGAGAGTCAATTC
AGGGTGGTGAATGTGAAACCAGTAACGTTATACGATGTCGCAGAGTATGCCGGTGTCTCTTATCAGAC
CGTTTCCCGCGTGGTGAACCAGGCCAGCCACGTTTCTGCGAAAACGCGGGAAAAAGTGGAAGCGGCGA
TGGCGGAGCTGAATTACATTCCCAACCGCGTGGCACAACAACTGGCGGGCAAACAGTCGTTGCTGATT
GGCGTTGCCACCTCCAGTCTGGCCCTGCACGCGCCGTCGCAAATTGTCGCGGCGATTAAATCTCGCGC
CGATCAACTGGGTGCCAGCGTGGTGGTGTCGATGGTAGAACGAAGCGGCGTCGAAGCCTGTAAAGCGG
CGGTGCACAATCTTCTCGCGCAACGCGTCAGTGGGCTGATCATTAACTATCCGCTGGATGACCAGGAT
GCCATTGCTGTGGAAGCTGCCTGCACTAATGTTCCGGCGTTATTTCTTGATGTCTCTGACCAGACACC
CATCAACAGTATTATTTTCTCCCATGAAGACGGTACGCGACTGGGCGTGGAGCATCTGGTCGCATTGG
GTCACCAGCAAATCGCGCTGTTAGCGGGCCCATTAAGTTCTGTCTCGGCGCGTCTGCGTCTGGCTGGC
TGGCATAAATATCTCACTCGCAATCAAATTCAGCCGATAGCGGAACGGGAAGGCGACTGGAGTGCCAT
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GTCCGGTTTTCAACAAACCATGCAAATGCTGAATGAGGGCATCGTTCCCACTGCGATGCTGGTTGCCA
ACGATCAGATGGCGCTGGGCGCAATGCGCGCCATTACCGAGTCCGGGCTGCGCGTTGGTGCGGATATT
TCGGTAGTGGGATACGACGATACCGAAGACAGCTCATGTTATATCCCGCCGTTAACCACCATCAAACA
GGATTTTCGCCTGCTGGGGCAAACCAGCGTGGACCGCTTGCTGCAACTCTCTCAGGGCCAGGCGGTGA
AGGGCAATCAGCTGTTGCCCGTCTCACTGGTGAAAAGAAAAACCACCCTGGCGCCCAATACGCAAACC
GCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGG
GCAGTGAGCGCAACGCAATTAATGTAAGTTAGCTCACTCATTAGGCACAATTCTCATGTTTGACAGCT
TATCATCGACTGCACGGTGCACCAATGCTTCTGGCGTCAGGCAGCCATCGGAAGCTGTGGTATGGCTG
TGCAGGTCGTAAATCACTGCATAATTCGTGTCGCTCAAGGCGCACTCCCGTTCTGGATAATGTTTTTT
GCGCCGACATCATAACGGTTCTGGCAAATATTCTGAAATGAGCTGTTGACAATTAATCATCGGCTCGT
ATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCCAGTCCGTTTAGGTGTTTTC
ACGAGCAATTGACCAACAAGGACCATAGATTATGAAAATAAAAACAGGTGCACGCATCCTCGCATTAT
CCGCATTAACGACGATGATGTTTTCCGCCTCGGCTCTCGCCAAAATCGAAGAAGGTAAACTGGTAATC
TGGATTAACGGCGATAAAGGCTATAACGGTCTCGCTGAAGTCGGTAAGAAATTCGAGAAAGATACCGG
AATTAAAGTCACCGTTGAGCATCCGGATAAACTGGAAGAGAAATTCCCACAGGTTGCGGCAACTGGCG
ATGGCCCTGACATTATCTTCTGGGCACACGACCGCTTTGGTGGCTACGCTCAATCTGGCCTGTTGGCT
GAAATCACCCCGGACAAAGCGTTCCAGGACAAGCTGTATCCGTTTACCTGGGATGCCGTACGTTACAA
CGGCAAGCTGATTGCTTACCCGATCGCTGTTGAAGCGTTATCGCTGATTTATAACAAAGATCTGCTGC
CGAACCCGCCAAAAACCTGGGAAGAGATCCCGGCGCTGGATAAAGAACTGAAAGCGAAAGGTAAGAGC
GCGCTGATGTTCAACCTGCAAGAACCGTACTTCACCTGGCCGCTGATTGCTGCTGACGGGGGTTATGC
GTTCAAGTATGAAAACGGCAAGTACGACATTAAAGACGTGGGCGTGGATAACGCTGGCGCGAAAGCGG
GTCTGACCTTCCTGGTTGACCTGATTAAAAACAAACACATGAATGCAGACACCGATTACTCCATCGCA
GAAGCTGCCTTTAATAAAGGCGAAACAGCGATGACCATCAACGGCCCGTGGGCATGGTCCAACATCGA
CACCAGCAAAGTGAATTATGGTGTAACGGTACTGCCGACCTTCAAGGGTCAACCATCCAAACCGTTCG
TTGGCGTGCTGAGCGCAGGTATTAACGCCGCCAGTCCGAACAAAGAGCTGGCAAAAGAGTTCCTCGAA
AACTATCTGCTGACTGATGAAGGTCTGGAAGCGGTTAATAAAGACAAACCGCTGGGTGCCGTAGCGCT
GAAGTCTTACGAGGAAGAGTTGGTGAAAGATCCGCGTATTGCCGCCACTATGGAAAACGCCCAGAAAG
GTGAAATCATGCCGAACATCCCGCAGATGTCCGCTTTCTGGTATGCCGTGCGTACTGCGGTGATCAAC
GCCGCCAGCGGTCGTCAGACTGTCGATGAAGCCCTGAAAGACGCGCAGACTAATTCGAGCTCGAACAA
CAACAACAATAACAATAACAACAACCTCGGGATCGAGGGAAGGATTTCACATATGGGATCCGAAAACC
TGTACTTTCAGGGTGGCGGTGATGAAAAAACCCAAAGTCATGGTGTAAAATTCCTTGACGAATACCAA
TCTAAAGTTAAAAGACAAATATTTTCAGGCTATCAATCTGATATTGATACACATAATAGAATTAAGGA
TGAATTATGACCTCGAGGTGAATTCACGAGCAATTGACCAACAAGGACCATAGATTATGAGCTTTAAG
AAAATTATCAAGGCATTTGTTATCATGGCTGCTTTGGTATCTGTTCAGGCGCATGCAGCTCCTCAAAA
TATTACTGATTTGTGCGCAGAATACCACAACACACAAATATATACGCTAAATGATAAGATCTTTTCGT
ATACAGAATCGCTAGCGGGAAAAAGAGAGATGGCTATCATTACTTTTAAGAATGGTGCAATTTTTCAA
GTAGAGGTACCAGGTAGTCAACATATAGATTCACAAAAAAAAGCGATTGAAAGGATGAAGGATACCCT
GAGGATTGCATATCTTACTGAAGCTAAAGTCGAAAAGTTATGTGTATGGAATAATAAAACGCCTCATG
CGATCGCCGCAATTAGTATGGCAAACTAAGTTTTCCCTGCAGGTAATTAAATAAGCTTCAAATAAAAC
GAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGGTGAACGCTCTCCTGAGT
AGGACAAATCCGCCGGGAGCGGATTTGAACGTTGCGAAGCAACGGCCCGGAGGGTGGCGGGCAGGACG
CCCGCCATAAACTGCCAGGCATCAAATTAAGCAGAAGGCCATCCTGACGGATGGCCTTTTTGCGTTTC
TACAAACTCTTTCGGTCCGTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAA
TAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGC
CCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAA
AAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATC
CTTGAGAGTTTTCGCCCCGAAGAACGTTTCCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGC
GGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACT
TGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGT
GCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGA
GCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGA
ATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAA
CTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAA
AGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCG
GTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTT
ATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTC
ACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTCCTTAGGA
CTGAGCGTCAACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTG
CTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTC
TTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAG
TTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGT
GGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGG
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CGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAA
CTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTA
TCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATC
TTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGG
CGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGC
TCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTG
ATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTG
ATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATATAAGGTGCACTGTGACTGGG
TCATGGCTGCGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCA
TCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACC
GAAACGCGCGAGGCAGCTGCGGTAAAGCTCATCAGCGTGGTCGTGCAGCGATTCACAGATGTCTGCCT
GTTCATCCGCGTCCAGCTCGTTGAGTTTCTCCAGAAGCGTTAATGTCTGGCTTCTGATAAAGCGGGCC
ATGTTAAGGGCGGTTTTTTCCTGTTTGGTCACTGATGCCTCCGTGTAAGGGGGATTTCTGTTCATGGG
GGTAATGATACCGATGAAACGAGAGAGGATGCTCACGATACGGGTTACTGATGATGAACATGCCCGGT
TACTGGAACGTTGTGAGGGTAAACAACTGGCGGTATGGATGCGGCGGGACCAGAGAAAAATCACTCAG
GGTCAATGCCAGCGCTTCGTTAATACAGATGTAGGTGTTCCACAGGGTAGCCAGCAGCATCCTGCGAT
GCAGATCCGGAACATAATGGTGCAGGGCGCTGACTTCCGCGTTTCCAGACTTTACGAAACACGGAAAC
CGAAGACCATTCATGTTGTTGCTCAGGTCGCAGACGTTTTGCAGCAGCAGTCGCTTCACGTTCGCTCG
CGTATCGGTGATTCATTCTGCTAACCAGTAAGGCAACCCCGCCAGCCTAGCCGGGTCCTCAACGACAG
GAGCACGATCATGCGCACCCGTGGCCAGGACCCAACGCTGCCCGAAATT 
 
9.2.3 pSAB2.2A 
 
 
Fig 9.3 Plasmid map for pSAB2.2A 
 
The CTB plasmid for expression in E.coli is pSAB2.2A (Fig 9.3). It is derived from 
pMAL-p5X obtained from Genscript. An MBP-CTA2 fusion was introduced along 
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with the gene for CTB (1A), with the LTIIB efficient periplasmic targeting leader 
sequence. This resulted in plasmid pSAB2.1A. The MBP-CTA2 gene was then 
removed to produce plasmid pSAB2.2A containing only the CTB gene (preparation 
of the plasmid performed by Mr James Ross).  
 
Derivatives of plasmid pSAB2.2A include: 
pSAB2.2T, pTRB-I47T, pSAB2.2-T1AW88K, pTRB-W88K, pTRB-W88E and 
pTRB-W88KQ61E 
 
Full sequence: 
 
CCGACACCATCGAATGGTGCAAAACCTTTCGCGGTATGGCATGATAGCGCCCGGAAGAGAGTCAATTC
AGGGTGGTGAATGTGAAACCAGTAACGTTATACGATGTCGCAGAGTATGCCGGTGTCTCTTATCAGAC
CGTTTCCCGCGTGGTGAACCAGGCCAGCCACGTTTCTGCGAAAACGCGGGAAAAAGTGGAAGCGGCGA
TGGCGGAGCTGAATTACATTCCCAACCGCGTGGCACAACAACTGGCGGGCAAACAGTCGTTGCTGATT
GGCGTTGCCACCTCCAGTCTGGCCCTGCACGCGCCGTCGCAAATTGTCGCGGCGATTAAATCTCGCGC
CGATCAACTGGGTGCCAGCGTGGTGGTGTCGATGGTAGAACGAAGCGGCGTCGAAGCCTGTAAAGCGG
CGGTGCACAATCTTCTCGCGCAACGCGTCAGTGGGCTGATCATTAACTATCCGCTGGATGACCAGGAT
GCCATTGCTGTGGAAGCTGCCTGCACTAATGTTCCGGCGTTATTTCTTGATGTCTCTGACCAGACACC
CATCAACAGTATTATTTTCTCCCATGAAGACGGTACGCGACTGGGCGTGGAGCATCTGGTCGCATTGG
GTCACCAGCAAATCGCGCTGTTAGCGGGCCCATTAAGTTCTGTCTCGGCGCGTCTGCGTCTGGCTGGC
TGGCATAAATATCTCACTCGCAATCAAATTCAGCCGATAGCGGAACGGGAAGGCGACTGGAGTGCCAT
GTCCGGTTTTCAACAAACCATGCAAATGCTGAATGAGGGCATCGTTCCCACTGCGATGCTGGTTGCCA
ACGATCAGATGGCGCTGGGCGCAATGCGCGCCATTACCGAGTCCGGGCTGCGCGTTGGTGCGGATATT
TCGGTAGTGGGATACGACGATACCGAAGACAGCTCATGTTATATCCCGCCGTTAACCACCATCAAACA
GGATTTTCGCCTGCTGGGGCAAACCAGCGTGGACCGCTTGCTGCAACTCTCTCAGGGCCAGGCGGTGA
AGGGCAATCAGCTGTTGCCCGTCTCACTGGTGAAAAGAAAAACCACCCTGGCGCCCAATACGCAAACC
GCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGG
GCAGTGAGCGCAACGCAATTAATGTAAGTTAGCTCACTCATTAGGCACAATTCTCATGTTTGACAGCT
TATCATCGACTGCACGGTGCACCAATGCTTCTGGCGTCAGGCAGCCATCGGAAGCTGTGGTATGGCTG
TGCAGGTCGTAAATCACTGCATAATTCGTGTCGCTCAAGGCGCACTCCCGTTCTGGATAATGTTTTTT
GCGCCGACATCATAACGGTTCTGGCAAATATTCTGAAATGAGCTGTTGACAATTAATCATCGGCTCGT
ATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCCAGTCCGTTTAGGTGTTTTC
ACGAGCAATTGACCAACAAGGACCATAGATTATGAGCTTTAAGAAAATTATCAAGGCATTTGTTATCA
TGGCTGCTTTGGTATCTGTTCAGGCGCATGCAGCTCCTCAAAATATTACTGATTTGTGCGCAGAATAC
CACAACACACAAATATATACGCTAAATGATAAGATCTTTTCGTATACAGAATCGCTAGCGGGAAAAAG
AGAGATGGCTATCATTACTTTTAAGAATGGTGCAATTTTTCAAGTAGAGGTACCAGGTAGTCAACATA
TAGATTCACAAAAAAAAGCGATTGAAAGGATGAAGGATACCCTGAGGATTGCATATCTTACTGAAGCT
AAAGTCGAAAAGTTATGTGTATGGAATAATAAAACGCCTCATGCGATCGCCGCAATTAGTATGGCAAA
CTAAGTTTTCCCTGCAGGTAATTAAATAAGCTTCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGC
CTTTCGTTTTATCTGTTGTTTGTCGGTGAACGCTCTCCTGAGTAGGACAAATCCGCCGGGAGCGGATT
TGAACGTTGCGAAGCAACGGCCCGGAGGGTGGCGGGCAGGACGCCCGCCATAAACTGCCAGGCATCAA
ATTAAGCAGAAGGCCATCCTGACGGATGGCCTTTTTGCGTTTCTACAAACTCTTTCGGTCCGTTGTTT
ATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAAT
ATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTT
TGCCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGC
ACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAAC
GTTTCCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGG
CAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGA
AAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACA
CTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATG
GGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCG
TGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTC
TAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCG
GCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCAT
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TGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAA
CTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCA
GACCAAGTTTACTCATATATACTTTAGATTGATTTCCTTAGGACTGAGCGTCAACCCCGTAGAAAAGA
TCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCG
CTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAG
CAGAGCGCAGATACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTG
TAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCG
TGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGG
TTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTAT
GAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACA
GGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCA
CCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCA
ACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCC
CCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGCCGCAGCCGAACGAC
CGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTGATGCGGTATTTTCTCCTTACGCATC
TGTGCGGTATTTCACACCGCATATAAGGTGCACTGTGACTGGGTCATGGCTGCGCCCCGACACCCGCC
AACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCG
TCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGGCAGCTGCGGTAA
AGCTCATCAGCGTGGTCGTGCAGCGATTCACAGATGTCTGCCTGTTCATCCGCGTCCAGCTCGTTGAG
TTTCTCCAGAAGCGTTAATGTCTGGCTTCTGATAAAGCGGGCCATGTTAAGGGCGGTTTTTTCCTGTT
TGGTCACTGATGCCTCCGTGTAAGGGGGATTTCTGTTCATGGGGGTAATGATACCGATGAAACGAGAG
AGGATGCTCACGATACGGGTTACTGATGATGAACATGCCCGGTTACTGGAACGTTGTGAGGGTAAACA
ACTGGCGGTATGGATGCGGCGGGACCAGAGAAAAATCACTCAGGGTCAATGCCAGCGCTTCGTTAATA
CAGATGTAGGTGTTCCACAGGGTAGCCAGCAGCATCCTGCGATGCAGATCCGGAACATAATGGTGCAG
GGCGCTGACTTCCGCGTTTCCAGACTTTACGAAACACGGAAACCGAAGACCATTCATGTTGTTGCTCA
GGTCGCAGACGTTTTGCAGCAGCAGTCGCTTCACGTTCGCTCGCGTATCGGTGATTCATTCTGCTAAC
CAGTAAGGCAACCCCGCCAGCCTAGCCGGGTCCTCAACGACAGGAGCACGATCATGCGCACCCGTGGC
CAGGACCCAACGCTGCCCGAAATT 
 
9.3 DNA primers and parts 
9.3.1 Primers for site-directed mutagenesis 
Mutations are highlighted in red. 
 
 
CTB mutation I47T  
 
5’ CTT TTA AGA ATG GTG CAA CTT TTC AAG TAG AGG TAC C  3’ 
3’ GAA AAT TCT TAC CAC GTT GAA AAG GGC ATC TCC ATG G  5’ 
 
Predicted Tm = 62.2 °C 
 
 
CTB mutation A1T  
 
5’ GTT CAG GCG CAT GCA ACT CCT CAA AAT ATT ACT G  3’ 
3’ CAA GTC CGC GTA CGT TGA GGA GTT TTA TAA TGA C  5’ 
 
Predicted Tm = 62.2 °C 
 
 
CTB mutation K88E 
 
5’ CGA AAA GTT ATG TGT AGA GAA TAA TAA AAC GCC  3’ 
3’ GCT TTT CAA TAC ACA TCT CTT ATT ATT TTG CGG  5’ 
 
Predicted Tm = 56.5 °C 
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CTB mutation Q61E 
 
5’ GTC AAC ATA TAG ATT CAG AAA AAA AAG CGA TTG AAA GG  3’ 
3’ CAG TTG TAT ATC TAA GTC TTT TTT TTC GCT AAC TTT CC  5’ 
 
Predicted Tm = 58.5 °C 
 
 
CTA2 mutation G1S 
 
5’ CCT GTA CTT TCA GAG TGG CGG TGA TG  3’ 
3’ GGA CAT GAA AGT CTC ACC GCC ACT AC  5’ 
 
Predicted Tm = 61.0 °C 
 
 
9.3.2 DNA parts for gene synthesis 
The sequences for the four DNA parts (Parts A, B, C and D) for the synthesis of the 
new CTA2 gene, containing five asparagine residues, are shown below. The NdeI 
restriction site is marked in blue and the XhoI restriction site is marked in purple. 
 
 
A & C: 5’  GAT TTC ACA TAT GGG ATC CGA AAA CCT GTA CTT TCA AGG TGG  
B & D: 3’                                               GT TCC ACC  
 
A & C:     TGG CAA CAA C               CTC TAA GGT GAA GCG TCA GAT  
B & D:     ACC GTT GTT GTT ATT GTT GAG ATT CCA CTT CGC AGT C                       
 
A & C:     ATT TTC AGG CTA TCA ATC TGA TAT TGA TAC CCA CAA CC 
B & D:                           G ACT ATA ACT ATG GGT GTT GGC ATA  
 
A & C:                                               3’ 
B & D:     GTT CCT ACT TAA TAC TGG AGC TCC ACT TAA   5’ 
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9.4 Other compounds used in the project  
The following compounds which were used in the project were provided by 
colleagues in the Turnbull group or external collaborators. All literature compounds 
had analytical properties in agreement with those reported previously. 
 
meta-nitrophenyl α-D-galactopyranoside (MNPG) 5 
 
 
 
Synthesised by Dr Ed Hayes.[191] 
 
3-(Methyloxycarbonylamino)propyl -L-fucopyranosyl-(1→2)--D-
galactopyranosyl-(1→4)-[-L-fucopyranosyl-(1→3)]-2-acetamido-2-deoxy--D-
glucopyranoside 35 
 
 
 
Synthesised by Dr Pintu Mandal[88] 
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3-(Methyloxycarbonylamino)propyl ) α-D-galactopyranosyl-(1→3)-[-L-
fucopyranosyl-(1→2)]--D-galactopyranosyl-(1→4)-[-L-fucopyranosyl-(1→3)]-
2-acetamido-2-deoxy--D-glucopyranoside 36 
 
 
 
Synthesised by Dr Pintu Mandal.[88] 
 
Galactose peptide ligand 39 
 
 
 
Synthesised by Dr Martin Fascione using SPPS. 
HRMS: Found [M-H]- 1111.4659, C47H71N10O19S requires 1111.4623. 
HPLC: 
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Galactose peptide ligand 42 
 
 
 
Synthesised by Dr Martin Fascione using SPPS. 
[α]D
25
 -4.2 (c 0.12, MeOH); HRMS: Found [M+H]
+ 999.4328, C43H67N8O17S1 
requires 999.4339; IR (vmax/cm
-1) 3368 (OH), 2912 (C=C), 1650 (C=O). 
HPLC: 
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Fmoc-Lys(Dde)-OH 46[192] 
 
 
Synthesised by Dr Martin Fascione. 
NMR: H (300 MHz, CDCl3): Dde: 8.56 (1H, d, 8.5 Hz, Ar-H), 8.37 (1H, d, 8.5 Hz, 
Ar-H), 8.21 (1H, d, 6.8 Hz, Ar-H), 7.58-7.54 (2H, m, Ar-H), 7.24 (d, 7.7 Hz, Ar-H), 
2.87 (6H, s, N(CH3)2) Fmoc: 7.80-7.77 (2H, m, Ar-H), 7.68 (1H, d, 7.7 Hz, Ar-H), 
7.66 (1H, d, 7.7 Hz, Ar-H), 7.40-7.36 (2H, m, Ar-H), 7.32 (1H, d, 7.7 Hz, Ar-H), 7.29 
(1H, d, 7.7 Hz, Ar-H), 4.38 (2H, dd, 6.8 Hz, 1.7 Hz, CH2-CH), 4.3 (1H, dd, 6.8 Hz, 
6.8 Hz, CH2-CH) Lys: 3.98-3.95 (1H, m, H), 1.64-1.20 (6H, m, H2/3, H2/3, H2/3), 
2.85-2.82 (2H, m, H1/2);
 13C NMR (75 MHz, CDCl3)  198.27, 174.81, 174.07, 
156.20, 143.88, 141.26, 129.04, 128.23, 127.72, 127.06, 125.16, 120.00, 107.87, 
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67.04, 53.56, 52.44, 47.12, 43.29, 31.96, 30.16, 28.33, 22.44, 21.49, 18.21; 
ESI-MS: found [M+Na+] 555.2 C31H36N2O6Na requires 555.25. 
 
Fmoc-Lys(dansyl)-OH 47[181] 
 
Synthesised by Dr Martin Fascione. 
NMR: H (500 MHz, CD3OD): Dansyl: 8.56 (1H, d, 8.5 Hz, Ar-H), 8.37 (1H, d, 8.5 
Hz, Ar-H), 8.21 (1H, d, 6.8 Hz, Ar-H), 7.58-7.54 (2H, m, Ar-H), 7.24 (d, 7.7 Hz, Ar-
H), 2.87 (6H, s, N(CH3)2) Fmoc: 7.80-7.77 (2H, m, Ar-H), 7.68 (1H, d, 7.7 Hz, Ar-H), 
7.66 (1H, d, 7.7 Hz, Ar-H), 7.40-7.36 (2H, m, Ar-H), 7.32 (1H, d, 7.7 Hz, Ar-H), 7.29 
(1H, d, 7.7 Hz, Ar-H), 4.38 (2H, dd, 6.8 Hz, 1.7 Hz, CH2-CH), 4.3 (1H, dd, 6.8 Hz, 
6.8 Hz, CH2-CH) Lys: 3.98-3.95 (1H, m, H), 1.64-1.20 (6H, m, H2/3, H2/3, H2/3), 
2.85-2.82 (2H, m, H1/2); ESI-MS: found [M+H
+] 602.2 C33H36N3O6S requires 602.23. 
 
11-azidoundecyl -D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy--D-
galactopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy--D-glycero-D-galacto-
nonulopyranulosonyl-(2→3)]--D-galactopyranosyl-(1→4)--D-
glucopyranoside 49 
 
 
Provided by the Zuilhof lab.[193] 
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-D-galactopyranosyl azide 50 
 
 
 
Synthesised by Mr Dan Williamson.[182] 
 
11-azidoundecyl -D-galactopyranosyl-(1→4)--D-glucopyranoside 51 
 
 
 
Provided by the Zuilhof lab.[193] 
 
2-[N-(t-butoxycarbonyl)aminooxy]-N-(prop-2-ynyl)acetamide[185] 52 
 
 
 
Synthesised by Dr Tom McAllister. 
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4-{N-[2-(tert-butoxycarbonylaminooxy)acetamidyl]-methyl}-1-{11-[-D-
galactopyranosyl-(1→3)-2-acetamido-2-deoxy--D-galactopyranosyl-(1→4)-[5-
acetamido-3,5-dideoxy--D-glycero-D-galacto-nonulopyranulosonyl-(2→3)]--
D-galactopyranosyl-(1→4)--D-glucopyranosyloxy]undecyl}-[1,2,3]triazole 54 
 
 
Synthesised by Dr Tom McAllister. 
11-azidoundecyl -D-galactopyranosyl-(1→3)-2-acetamido-2-deoxy--D-
galactopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy--D-glycero-D-galacto-
nonulopyranulosonyl-(2→3)]--D-galactopyranosyl-(1→4)--D-glucopyranoside 49 
(5.2 mg, 4.4 mol) was dissolved in H2O (100 L) in a 1.5 mL Eppendorf tube. A 
solution of TBTA in THF (10 mg/mL, 70 L, 0.7 mg, 1 mol) was added to 2-[N-(t-
butoxycarbonyl)aminooxy]-N-(prop-2-ynyl)acetamide 52 (2.0 mg, 9 mol) and the 
resultant solution added to the Eppendorf. The vessels were rinsed with THF (2 × 
115L) and the washes also added to the Eppendorf. CuSO4 (1 mg/mL in H2O, 100 
L, 0.1 mg, 0.6 mol) and sodium-ascorbate (10 mg/mL in H2O, 40 L, 0.4 mg, 2 
mol) were added, followed by H2O (60 L), and the mixture was stirred at rt for 16 
h. At this point, analysis of the reaction mixture by TLC and LCMS showed no 
product formation so further portions of CuSO4 (10 mg/mL in H2O, 5 L, 0.5 mg, 3.1 
mol) and sodium-ascorbate (100 mg/mL in H2O, 10 L, 1 mg, 5 mol) were added 
and stirring continued. After a further 16 h, analysis by LCMS suggested complete 
conversion to the expected product. The reaction was diluted with H2O to a total 
volume of 12 mL and passed down a sep-pak column (pre-washed with dioxane 
and then equilibrated with H2O). The column was then eluted with a step-wise 
gradient of aqueous dioxane (0-100% in 10% steps, 1.1 mL per wash). The column 
flow-through and 0-40% fractions were identified as containing the product by 
LCMS and TLC though the 30% and 40% fractions also contained TBTA. The flow-
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through, 0, 10 and 20% fractions were combined and lyophilised to leave triazole 54 
as a colourless amorphous solid (3.15 mg, 2.2 mol, 50%) 
NMR: H (500 MHz, D2O); selected peaks: 7.4-7.9 (m, 1H, triazole H-5), 4.48 (d, 
1H, J 7.6 Hz, GalNAc-C H-1), 4.46 (d, 1H, J 7.3 Hz, Gal-D H-1), 4.41 (d, 1H, J 8.0 
Hz, Gal-B H-1), 4.33-4.35 (m, 2H, Glc-A H-1, Gal-B H-4), 2.60 (m, 1H, αNeu5Ac H-
3eq), 1.97 (s, 3H, Neu5Ac CH3), 1.94 (s, 3H, GalNAc-C CH3), 1.87 (m, 1H, 
αNeu5Ac H-3ax); 1.34 (s, 9H, Boc); HRMS: found [M+Na]+ 1444.6143, 
C58H99N7NaO33 requires 1444.6176. 
HPLC: 
 
 
 
No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
  min   mAU mAU*min % 
1   0.58       n.a. 314.805  23.766  8.88     
2   0.68       n.a. 38.331  2.145  0.80     
3   1.39       n.a. 23.906  1.546  0.58     
4   2.49       n.a. 241.931  8.012  2.99     
5   2.55       n.a. 2454.481  219.092  81.83     
6   2.85       n.a. 161.202  13.188  4.93     
Total:     3234.656  267.749  100.00     
 
 
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224 
 
-D-galactopyranosyl Triton X-100 57 
 
 
 
Synthesised by Dr Martin Fascione 
Trimethylsilyl trifluoromethanesulfonic anhydride (33 μL, 1.788 mmol) was added to 
a solution of TX-100 55 (174 μL, 0.298 mmol), acetylated α-galactosyl 
trichloroacetimidate (440 mg, 0.896 mmol) and 4 Å MS (440 mg) in 
dichloromethane (2 mL) at −78 °C. The reaction mixture was warmed to r.t. over 30 
min, and stirred for 1 h before quenching with aq. NaHCO3 (2 mL), diluted with 
dichloromethane (10 mL) and washed with further aq. NaHCO3 (10 mL) and aq. 
NaCl (10 mL), before being concentrated. The resulting crude residue was 
dissolved in methanol (5 mL) and sodium methoxide (39 mg, 0.716 mmol) was 
added, the reaction mixture was stirred for 1 h 30 min and then neutralised with 
Amberlite IRC 50 H+ resin, filtered and concentrated. The crude product was 
purified by gel filtration (Sephadex LH-20 in methanol, flow rate 0.37 mL/min, 12 
min fractions) and fractions 30-40 combined and concentrated to afford 57 (120 mg, 
51% recovery, ~80-85% galactosylated). 
Selected peaks for TX-100 55: 
NMR: H (500 MHz, CDCl3) 7.25 (d, J = 8.7 Hz, 2H, ArH), 6.82 (d, J = 8.7 Hz, 2H, 
ArH), 4.11 (t, J = 5.0 Hz, 2H), 3.84 (t, J = 5.0 Hz, 2H), 3.72 (m, 5H), 1.33 (s, 6H, 
CH3), 0.71 (s, 9H, CH3). 
Selected new peaks for 57: 
NMR: H (500 MHz, CDCl3) δ 4.29 (d, J1,2 = 7.4 Hz, 1H (80-85%, measured against 
tert-butyl peaks at 0.71), 4.06 – 3.96 (m, 2H), 3.52 (m, 1H); 
 
 
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-D-galactopyranosyl-(1→4)--D-glucopyranosyl Triton X-100 58 
 
 
 
Synthesised by Dr Martin Fascione. 
Trimethylsilyl trifluoromethanesulfonic anhydride (33 μL, 1.788 mmol) was added to 
a solution of TX-100 55 (174 μL, 0.298 mmol), acetylated α-lactosyl 
trichloroacetimidate (660 mg, 0.890 mmol) and 4 Å MS (400 mg) in 
dichloromethane (2 mL) at −78 °C. The reaction mixture was warmed to r.t. over 30 
min before quenching with aq. NaHCO3 (2 mL), diluted with dichloromethane (10 
mL) and washed with further aq. NaHCO3 (10 mL) and aq. NaCl (10 mL), before 
being concentrated. The resulting crude residue was dissolved in 2:1:1 methanol-
tetrahydrofuran-water (8 mL) and sodium methoxide (100 mg, 1.84 mmol) was 
added, the reaction mixture was stirred for 15 h and then neutralised with Amberlite 
IRC 50H+ resin, filtered and concentrated. The crude product was purified by gel 
filtration (Sephadex LH-20 in water, flow rate 0.35 mL/min, 12 min fractions) and 
fractions 56-70 combined and lyophilized to afford 58 (100 mg, 35% recovery, ~60-
65% lactosylated, ~17% orthosester);  
Selected peaks for 58: 
NMR: H (500 MHz, MeOD) 5.16 (d, J = 3.3 Hz, H-1α orthoester (17% of 1H)), 4.52 
(d, J = 7.8 Hz, H-1β orthoester (17% of 1H)), 4.45 (d, J = 7.6 Hz, H-1β lactoside 
(60-65% of 1H)). 
 

 
226 
 
-D-galactopyranosyl Tyloxapol 59 
 
 
 
Synthesised by Dr Martin Fascione. 
Trimethylsilyl trifluoromethanesulfonic anhydride (15 μL, 0.815 mmol) was added to 
a solution of Tyloxapol 56 (288 μL, 0.068 mmol, based on average m.w.),[167] 
acetylated α-galactosyl trichloroacetimidate (200 mg, 0.407 mmol) and 4 Å MS (200 
mg) in dichloromethane (1 mL) at −78 °C. The reaction mixture was warmed to r.t. 
over 40 min before quenching with aq. NaHCO3 (1 mL), diluted with 
dichloromethane (10 mL) and washed with further aq. NaHCO3 (10 mL) and aq. 
NaCl (10 mL), before being concentrated. The resulting crude residue was 
dissolved in methanol (2 mL) and sodium methoxide (19.5 mg, 0.358 mmol) was 
added, the reaction mixture was stirred for 3 h and then neutralised with Amberlite 
IRC 50H+ resin, filtered and concentrated. The crude product was purified by gel 
filtration (Sephadex LH-20 in methanol, flow rate 0.4 mL/min, 12 min fractions) and 
fractions 18-24 combined and concentrated to afford 59 (298 mg, 94% recovery, 
~78% galactosylated) as a colourless syrup; Selected anomeric peak for 59: 
NMR: H (500 MHz, CDCl3) 4.31 (m, H-1β (78% of 1H)). 
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Bpy depsipeptide 60 
 
 
 
Synthesised by Miss Fiona Ng. 
Synthesised by SPPS. A colourless lyophilisate yielded 60 (44 mg, 38%).  
HRMS: Found [M+Cu2+-H+] 1122.3714, C50H63CuN10O16 requires 1122.3711. 
HPLC: 
 
 
No.  Ret.Time  Peak Name  Height  Area  Rel.Area  
  min   mAU mAU*min % 
1   0.74       n.a. 45.774  5.924  27.72     
2   1.69       n.a. 67.764  1.689  7.90     
3   1.92       n.a. 74.887  1.621  7.59     
4   2.06       n.a. 60.962  1.006  4.71     
5   2.09       n.a. 458.796  11.129  52.08     
Total:     708.184  21.370  100.00     
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